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CHAPTER I 
 
INTRODUCTION 
 
An essential step in the pathogenesis of many viruses is systemic dissemination to 
target organs where secondary replication can occur. Viral replication at targeted sites of 
secondary replication is often manifested as the clinical symptoms associated with viral 
infection. The bloodstream is a common route used by many viral pathogens to ensure 
widespread dissemination in infected hosts. Although viremia is a well-established 
prerequisite to spread of the virus to sites of secondary replication, mechanisms used by 
viruses to gain entry into or exit from the bloodstream are not well understood.  
 Mammalian orthoreoviruses (reoviruses) are nonenveloped, double-stranded (ds) 
RNA viruses that are transmitted primarily by the fecal-oral route. Systemic 
dissemination of reoviruses occurs via bloodstream and neural routes, and the patterns of 
spread and pathogenesis differ based on viral serotype. While reoviruses infect virtually 
all mammals, disease manifestations of reovirus infection are seen only in the very 
young. Reovirus infection of newborn mice results in various disease phenotypes 
including biliary atresia, myocarditis, hydrocephalus, and encephalitis. A robust neonatal 
mouse model and a facile reverse genetics system has allowed for the use of reovirus to 
be used as a model to dissect mechanisms of viral hematogenous dissemination.   
 When this work was initiated, a proteinaceous receptor for reovirus, junctional 
adhesion molecule A (JAM-A), had been found to mediate hematogenous dissemination 
of reovirus in vivo. However, the precise mechanism by which JAM-A promotes 
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bloodstream spread was unknown. I hypothesized that expression of JAM-A in 
endothelial cells is required for reovirus entry into and egress from the bloodstream and 
subsequent dissemination to targeted sites of secondary replication. In Chapter II, I report 
that endothelial but not hematopoietic JAM-A is required for bloodstream dissemination 
using mice with tissue-specific alterations in JAM-A expression. In Chapter III, I present 
data demonstrating the requirement of sialic acid and JAM-A in reovirus infection of 
polarized endothelial cells in culture. In Chapter IV, I show that reovirus egress from 
polarized endothelial cells is directional and occurs noncytolytically. Together, these 
findings indicate that the endothelium is an essential mediator of reovirus pathogenesis. 
Furthermore, my work demonstrates that the precise expression of a viral receptor is 
critical for bloodstream dissemination.  
 
Reoviruses 
 
 Viruses of the Reoviridae family infect a wide range of host organisms, including 
mammals, birds, insects, and plants (1). The Reoviridae includes rotaviruses, the most 
common diarrheal pathogen among children (2), orbiviruses, which are economically 
important pathogens of sheep, cattle, and horses (3), and reoviruses. Three reovirus 
serotypes (T1, T2, and T3) currently circulate in humans and other mammals. The 
serotypes are distinguished on the basis of antibody-mediated neutralization of infectivity 
and inhibition of hemagglutination. Each serotype is represented by a prototype strain 
isolated from a human host: type 1 Lang (T1L), type 2 Jones (T2J), and type 3 Dearing 
(T3D). These strains differ dramatically in host cell tropism, mechanisms of cell killing, 
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modes of dissemination, and central nervous system (CNS) disease. In particular, studies 
of T1 and T3 reoviruses have generated foundational knowledge about strategies used by 
viruses to replicate and cause neural injury. Development of a plasmid-based reverse 
genetics system allows introduction of mutations into the viral genome to test specific 
hypotheses about the structure and function of viral proteins and RNAs (4, 5). In concert 
with an experimentally facile mouse model of infection (6, 7), reovirus is an ideal 
experimental platform for studies of virus-host interactions. 
 Reoviruses are nonenveloped, icosahedral viruses that contain a genome 
consisting of 10 segments of dsRNA (Figure I-1) (1). There are three large (L1, L2, L3), 
three medium (M1, M2, M3), and four small (S1, S2, S3, S4) dsRNA segments that are 
packaged in an equimolar stoichiometric relationship with one copy of each per virion. 
With the exception of the M3 and S1 gene segments, each of the reovirus gene segments 
is monocistronic. Reovirus virions are composed of two concentric protein shells, the 
outer capsid and core (Figure I-1) (8). The outer capsid consists of heterohexameric 
complexes of the µ1 (encoded by M2) and σ3 (encoded by S4) proteins. At each of the 
icosahedral five-fold symmetry axes, the attachment protein σ1 (encoded by S1) extends 
from turret-like structures formed by pentamers of λ2 (encoded by L2) protein. The inner 
core shell is formed by parallel asymmetric dimers of λ1 (encoded by L3) protein that are 
stabilized by σ2 (encoded by S2) protein. The λ3 (encoded by L1) and µ2 (encoded by 
M1) proteins are anchored to the inner surface of the core via interactions with λ1. Lastly, 
the M3 gene segment encodes nonstructural proteins µNS and µNSC, the S3 gene 
segment encodes nonstructural protein σNS, and the S1 gene segment encodes 
nonstructural protein σ1s.  
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Figure I-1. The reovirus virion. (A) Cryo-electron micrograph image reconstruction 
of a reovirus virion. Outer-capsid protein σ3 (blue), is the initial target for virion 
disassembly in infected cells. Pentameric λ2 protein (yellow) forms an insertion 
pedestal for σ1, which is the viral attachment protein. From Nason et al. (2001). (B) 
Schematic of a reovirus virion. Reovirus particles are formed from two concentric 
protein shells, the outer capsid and core. The core contains the viral genome, which 
consists of ten dsRNA segments. Reovirus also encodes nonstructural proteins, σNS, 
µNS, µNSC, and σ1s. 
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Reovirus Attachment and Entry 
 
 Viral attachment protein σ1 is a long filamentous molecule with head-and-tail 
morphology (Figure I-2A) (9-12). The σ1 protein is comprised of three distinct structural 
domains: an N-terminal α-helical coiled-coil tail, a central β-spiral body, and a C-
terminal globular head (9, 11). Short regions of undefined structure separate each domain 
and are hypothesized to permit molecular flexibility required to engage cellular receptors 
during viral entry (Figure I-2A) (9-11, 13). Attachment of the σ1 protein to cell-surface 
receptors initiates reovirus infection of susceptible host cells (14, 15). The σ1 protein 
targets two different receptors, α-linked sialic acid (SA) (16-21) and JAM-A (22-24). 
Residues in the T1 σ1 head domain (21) and T3 σ1 β-spiral body domain bind SA (11, 
25); sequences in the head domain of both T1 and T3 σ1 engage JAM-A (22, 26). 
 Residues in the T3 σ1 protein that interact with SA have been identified using 
structure-guided point-mutant viruses. The T3 σ1 residues Asn198, Arg202, Leu203, 
Pro204, and Gly205 are required for hemagglutination and infection of murine 
erythroleukemia (MEL) cells, which are dependent on SA engagement for productive T3 
reovirus infection (Figure I-3) (11). Residues in the T1 σ1 protein that engage SA also 
have been identified using studies of structure-guided point mutant viruses. The T1 σ1 
residues Val354, Ser370, and Gln371 are required for hemagglutination and infection of 
murine embryonic fibroblasts (MEFs), which are dependent on SA engagement for T1 
reovirus infection (21). A glycan array was performed and identified ganglioside GM2 as 
the glycan engaged by T1 reovirus (21).  
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 JAM-A is used as a receptor by all reovirus serotypes (23, 24). Each σ1 trimer is 
capable of binding three independent JAM-A monomers (24). Structural and biochemical 
studies identified residues in the D-E loop of the σ1 head that mediate interactions with 
JAM-A. Residues Thr380, Gly381, and Asp 382 engage JAM-A via polar interactions 
(Figure I-4) (26). Mutations of these residues in the reovirus σ1 protein diminishes JAM-
A engagement (26).  
 After receptor binding, reovirus virions are internalized into endosomes via a 
process dependent on β1 integrin (27) and distributed to organelles marked by Rab7 and 
Rab9 where viral disassembly takes place (28). During viral disassembly, outer-capsid 
protein σ3 is degraded by cathepsin proteases, attachment protein σ1 undergoes a 
conformational change, and outer-capsid protein µ1 is cleaved to form infectious 
subvirion particles (ISVPs) (29). The µ1 cleavage fragments undergo conformational 
rearrangement to facilitate endosome penetration and delivery of transcriptionally active 
core particles into the cytoplasm (30, 31). Primary transcription occurs within the viral 
core, and nascent RNAs are translated or encapsidated into new viral cores, where they 
serve as templates for negative-strand synthesis. Within new viral cores, secondary 
rounds of transcription occur. Outer-capsid proteins are added to nascent cores, which 
silences viral transcription and yields progeny viral particles. 
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Figure I-2. Structure of σ1 and JAM-A. (A) Full-length model of attachment protein 
σ1 bound to JAM-A. A model of full-length σ1 extending from the virion is shown as 
a ribbon drawing, with the known structure of the C-terminus in tricolor and the 
predicted structure of the N-terminus in grey. Arrows indicate predicted regions of 
flexibility. A model of full-length JAM-A is shown in green as a ribbon drawing of the 
known structure of the extracellular domain and a schematic representation of the 
transmembrane and intracellular domains. For clarity, only two JAM-A monomers are 
shown bound to σ1. Adapted from Kirchner et al. (2008). (B) Structure of human 
JAM-A D1 and D2 domains. Ribbon drawings of a JAM-A homodimer, with one 
monomer shown in yellow and the other in green. Two orthogonal views are 
displayed. Adapted from Prota et al. (2003).  
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Figure I-3. Critical contacts of T3D σ1 and SA. (A) Ribbon drawing of the T3D σ1 
body and head domains in complex with α-2,3-sialyllactose. The σ1 monomers are 
shown in red, blue, and yellow. The body domain consists of seven triple β-spiral 
repeats (β1–β7) and an α-helical coiled-coil domain (cc) that is inserted between β-
spiral repeats β4 and β5. The bound α-2,3-sialyllactose is shown in stick 
representation and colored in orange. The black box indicates the enlarged region 
depicted in (B). (B) Detailed interactions between σ1 and the terminal SA of α-2,3-
sialyllactose. Residues in the binding region are drawn in ball and stick representation, 
while the rest of the protein is shown as a ribbon drawing. The σ1 residues forming 
hydrogen bonds or salt bridges with the ligand are shown in green, and residues 
forming van der Waals contacts are shown in cyan. The side chain of Asn189 (colored 
dark blue) is contributed by a neighboring σ1 monomer. SA is shown in ball-and-stick 
representation, with carbons colored orange, oxygens colored red, and nitrogens 
colored blue. Bridging waters are shown as orange spheres. Hydrogen bonds and salt 
bridges are represented with broken lines. Adapted from Reiter et al. (2011). 
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JAM-A D1 
σ1 Head A B 
Figure I-4. Critical contacts at the σ1 head-JAM-A D1 interface. (A) Overview 
displaying the location of residues in the σ1 head-JAM-A D1 complex shown in (B). 
D1 and σ1 head are colored green and orange, respectively. The black box indicates 
the enlarged region depicted in (B). (B) Carbon atoms are shown in green (D1) or 
orange (σ1H), oxygen atoms in red, and nitrogen atoms in blue. Dotted lines represent 
hydrogen bonds and salt bridges. For clarity, only interacting residues are shown. 
Amino acids are labeled in single-letter code. (B) Interactions between D1 and 
residues in the 310 helix in the D–E loop of σ1H. The 310 helix is depicted 
transparently so that the main chain interactions are visible. Adapted from Kirchner et 
al. (2008). 
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Reovirus Assembly and Egress 
 
Assembly of reovirus particles is thought to occur in cytoplasmic viral inclusions, 
which contain viral proteins, double-stranded RNA, and virion particles at various stages 
of maturation. Empty cores and fully-assembled particles are evident in electron 
micrographs of viral inclusions (32). The synthesis of genomic dsRNA and viral core 
assembly likely occur simultaneously, and assembly of the outer capsid occurs 
subsequent to formation of the complete core particle (1). The addition of reovirus 
attachment protein σ1 to the outer capsid requires host chaperone proteins Hsc70 and 
Hsp90 (33, 34). Reovirus release from host cells is hypothesized to occur via a lytic 
mechanism, but the egress pathway is not understood (1). Reovirus induces apoptosis 
(35-38), which may contribute to viral release from some cell types. 
 
JAM-A 
 
JAM-A is the only known proteinaceous receptor for reovirus. It mediates entry of 
prototype and field-isolate strains of all three reovirus serotypes (22, 23). JAM-A is a 
member of the immunoglobulin (Ig) superfamily of proteins that functions in cell-cell 
adhesion (39). It is expressed on the surface of endothelial and epithelial cells as a 
component of tight junctions (TJs) that maintain the integrity of barriers formed between 
polarized cells (40, 41). JAM-A also is expressed on hematopoietic cells, where it 
mediates leukocyte extravasation (42, 43), and on platelets, where it functions in platelet 
activation during blood clot formation (39, 44). JAM-A contains three distinct structural 
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domains: an N-terminal ectodomain, a single-span transmembrane anchor, and a C-
terminal cytoplasmic tail (Figure I-2) (24). The ectodomain consists of two Ig-like 
domains, a membrane-distal D1 domain and a membrane-proximal D2 domain (Figure I-
2B). The cytoplasmic tail terminates in a post-synaptic density protein (PSD95), 
Drosophila disc large tumor suppressor (Dig1), zona occludens 1 (ZO-1) (PDZ)-binding 
domain that interacts with intracellular TJ components (45, 46). JAM-A participates in 
homotypic interactions between D1 domains on opposing monomers (24). An interaction 
between two JAM-A monomers on adjacent cells promotes cell adhesion (47-49). 
 The σ1 protein interacts with the JAM-A D1 domain to adhere reovirus virions to 
the surface of target cells (26). JAM-A residues Ar59, Glu61, Lys63, Leu72, Tyr75, and 
Asn76 are required for σ1 binding and reovirus infectivity (50). Interestingly, the σ1-
JAM-A interaction is substantially stronger (approximately 1000-fold) than the 
interaction between JAM-A monomers (26). Consequently, σ1 binding to JAM-A likely 
disrupts JAM-A homodimers. Studies using JAM-A knock-out (KO) mice indicate that 
JAM-A is required for the establishment of viremia, which is essential for dissemination 
and disease in newborn mice following peroral inoculation of reovirus (51). JAM-A is 
not required for reovirus replication in the murine CNS or development of encephalitis 
(51). These findings suggest that reovirus utilizes other cell-surface receptors to mediate 
entry into specific cell types.  
JAM-A is localized to the apical junctional complex that link epithelial and 
endothelial cells together. Endothelial cells are specialized cells that line blood vessels, 
and are responsible for separating the vascular compartment from surrounding tissue. 
Endothelial cells are linked together via the interactions of several cell-surface proteins 
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(52). Tight junctions are comprised of occludins, claudins, coxsackie and adenovirus 
receptor (CAR), JAM-A, and endothelial cell-selective adhesion molecule (ESAM), and 
nectin (52). Adherens junctions include vascular endothelial cadherin (VE-cadherin) and 
vascular endothelial protein tyrosine phosphatase (VE-PTP) (52).  Adjacent endothelial 
cells also are linked by platelet endothelial cell adhesion molecule (PECAM) and neural 
cadherin (N-cadherin) (52). Several TJ proteins act as viral receptors or facilitators of 
viral entry. Occludin is used by coxsackie B virus for internalization (53) and along with 
claudin-1 is required for hepatitis C virus infection of liver cells (54). CAR is used by 
both adenovirus and coxsackievirus infection (55) and JAM-A also serves as a receptor 
for feline calicivirus (56). The pathogenesis of these viruses requires traversal of 
polarized epithelial cell barriers, making TJ proteins logical targets for viral entry. In 
addition, Helicobacter pylori interacts with JAM-A to induce epithelial barrier 
dysfunction (57). Understanding how JAM-A facilitates infection of polarized cells may 
shed light on how other viruses and pathogens utilize TJ proteins as receptors or entry 
mediators.  
 
Reovirus Pathogenesis 
 
 Reoviruses have been isolated from the stools of healthy (58, 59) and ill (60) 
children as well as a variety of animals (60). These findings suggest that reovirus is 
ingested into and shed from the gastrointestinal tract. The dynamics of reovirus infection 
in vivo have largely been elucidated using experimental mouse and rat model systems. 
Following entry into the gastrointestinal tract, intestinal proteases rapidly convert 
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reovirus virions to ISVPs, suggesting that the form of the reovirus particle that initiates 
infection in the intestine is the ISVP (61-63). In newborn mice, cells at the tips of 
microvilli are readily infected (Figure I-5), whereas cells in the intestinal crypts are 
spared (51, 64). In contrast, intestinal crypt cells are infected in adult mice, and cells at 
the villus tips are uninfected (65). Infectious reovirus can be recovered following peroral 
inoculation from the duodenum, jejunum, ileum, and colon (65, 66). However, the vast 
majority of virus is produced in the ileum. This differential production of virus may be 
due to the capacity of reovirus to infect Peyer patches. Reoviruses are thought to 
penetrate the intestinal barrier via transport across microfold (M) cells (Figure I-5), which 
are specialized cells of the follicle-associated epithelium (FAE) that overlay the Peyer 
patches (67-70). M cells transfer antigens from the intestinal lumen to lymphoid cells of 
the gut-associated lymphoid tissue (GALT) (71) and serve to monitor luminal contents by 
exposing Peyer patch lymphoid cells to food antigens, the intestinal microbiota, and 
intestinal microbial pathogens. This process is essential for induction of oral tolerance 
and activation of immune responses to pathogenic microorganisms (71). The preferential 
targeting of crypt cells observed in adult mice is hypothesized to result from transcytosis 
of virus across M cells and subsequent infection of crypt cells via the basolateral surface 
(72). However, M cells also take up reovirus in neonatal mice (51, 64, 67), suggesting 
that viral transcytosis across M cells is unlikely to explain the difference in intestinal cell 
tropism observed in adult and newborn mice. It is possible that the proliferative status of 
stem cells in the crypts of adult mice may recapitulate the cellular environment of 
neonatal intestinal cells, thereby facilitating reovirus infection of intestinal crypt cells. 
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 Systemic reovirus infection is thought to originate from infected lymphoid cells in 
the Peyer patch (Figure I-5). From the Peyer patch, reovirus transits intestinal lymphatics 
to the mesenteric lymph node (MLN) and ultimately enters the bloodstream via the 
thoracic duct (51, 64, 67). Many pathogens that cause systemic disease, including 
poliovirus (73, 74) and Salmonella (75-77), initiate extraintestinal infection and access 
the bloodstream via this route. It is possible that in addition to this route reovirus also 
contacts endothelial cells within the intestine that allow entry into the bloodstream to 
allow for systemic dissemination.  
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Figure I-5. Model of reovirus dissemination from the intestine. A schematic 
depicting where reovirus antigen is detected in the intestine following peroral 
infection. Reovirus antigen is detectable in the tips of microvilli, M cells, and FAE. 
Infected dendritic cells traffic reovirus out of the intestine via the lymphatic system. 
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 Reovirus reaches the Peyer patches early after infection; viral antigen is detected 
in Peyer patches within 24 hours after peroral inoculation (51, 64, 67, 69, 70, 78). 
However, the mechanism by which reovirus infects Peyer patch cells is not known. It is 
possible that dendritic cells in the Peyer patches take up reovirus virions immediately 
following viral transcytosis across M cells. This is the most direct route from the 
intestinal lumen to the Peyer patch and the primary pathway used for processing of 
intestinal antigens for immune surveillance. A second possibility is that progeny virions 
released from the basolateral surface of infected FAE cells are taken up by lymphoid cells 
in Peyer patches. Both viral structural and nonstructural proteins are detected in FAE 
cells (79), indicating that active viral replication occurs in these cells. However, it is not 
known whether FAE cells produce virus. A third possibility is that dendritic cells in 
Peyer patches take up apoptotic fragments from infected FAE cells, which undergo 
apoptosis following reovirus infection (79). Dendritic cells in the underlying Peyer 
patches immediately adjacent to apoptotic FAE cells contain both active caspase-3 and 
reovirus structural proteins (79). These observations suggest that Peyer patch dendritic 
cells take up apoptotic bodies from infected FAE cells. Additionally, apoptosis induction 
in the FAE may signal Peyer patch cells to phagocytose the apoptotic remnants, along 
with reovirus particles. 
 Regardless of the mechanism by which reovirus accesses Peyer patches, reovirus 
antigen is detected in the MLN 24 hours after peroral inoculation. Little is known about 
the cell types that support reovirus growth within the intestine and dissemination to the 
MLN. In adult mice, CD11c+ dendritic cells harbor reovirus antigen, but these cells are 
not thought to be actively infected (79). Viral nonstructural proteins are not present in 
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these cells (79), suggesting that active replication does not occur. CD11c+ dendritic cells 
are present in neonatal animals (80), but it is not known whether these cells internalize 
reovirus following peroral inoculation of newborn mice.  
 From Peyer patches, reovirus is hypothesized to traffic via afferent lymphatics to 
the MLN, then through efferent lymphatics to the blood. It is possible that infected 
lymphoid cells or lymphoid cells harboring virus mediate transport from the Peyer 
patches to the bloodstream. However, migrating dendritic cells rarely exit lymph nodes 
once they enter and present antigen to B and T cells (81). Thus, the cells responsible for 
transport of reovirus from the Peyer patch are likely retained in the MLN. Reovirus titers 
in the MLN increase rapidly after peroral inoculation (51, 64), suggesting that active viral 
replication occurs in the MLN. However, it also is possible that the increase in viral load 
in the MLN represents migration of infected lymphoid cells from the Peyer patches. 
Dissemination from the MLN to the bloodstream may occur as free virus or within 
another lymphoid cell subset. 
 An alternative mechanism for accessing the blood is direct uptake of viral 
particles from the gut. CD18+ phagocytes extend cellular processes between enterocytes 
to directly sample luminal contents. Dendritic cells also extend processes through the 
epithelial monolayer while maintaining barrier integrity to sample gut pathogens (82). A 
number of pathogens, including Salmonella (83) and Yersinia (84), use macrophages or 
dendritic cells to invade the bloodstream and cause extraintestinal infection. Following 
uptake of luminal pathogens, CD18+ phagocytes traffic across the lamina propria and 
directly into the blood allowing for rapid entry of the pathogen into the bloodstream.  
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Reoviruses are highly virulent in newborn mice and cause injury to a variety of 
host organs, including the CNS, heart, and liver (1). T1 and T3 reovirus strains invade the 
CNS but use different routes and produce distinct pathologic consequences following 
peroral or intramuscular inoculation. T1 reoviruses spread by hematogenous routes and 
infect ependymal cells, causing nonlethal hydrocephalus (85-87). T3 reoviruses spread to 
the CNS by both hematogenous and neural routes and infect neurons (51, 87, 88). In the 
brain, T3 reoviruses induce neuronal apoptosis, which results in fatal encephalitis (85-87, 
89). Studies using T1L × T3D reassortant viruses mapped the major determinant of CNS 
pathology to the viral S1 gene (90, 91), which encodes attachment protein σ1 and 
nonstructural protein σ1s (14, 92). Because of its role in viral attachment and entry, these 
serotype-specific differences in dissemination and disease have largely been ascribed to 
the σ1 protein. However, σ1s plays a critical role in promoting reovirus spread by the 
bloodstream (64, 88). 
 
Reovirus Viremia 
 
Reovirus viremia serves to spread virions to sites of secondary replication that are 
distant from the initial portal of entry. Other Reoviridae family members, including 
bluetongue virus (BTV) and Colorado tick fever virus, produce cell-associated viremia 
during infection. BTV infects and replicates in mononuclear cells, lymphocytes, and 
endothelial cells (93-97). Colorado tick fever virus is detected in mature erythrocytes (98). 
However, arthropod vectors transmit BTV and Colorado tick fever virus, making viremia 
a necessary part of the viral infectious cycle in nature. Mammalian reoviruses are not 
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transmitted by arthropod vectors and may produce a distinctly different type of viremia. 
Studies in which oncolytic reovirus was delivered intravenously to persons with cancer 
revealed that virus is largely found in hematopoietic cells, specifically mononuclear cells, 
granulocytes, and platelets (99). Each of these cell types express JAM-A (40, 100, 101), 
suggesting that reovirus associates with or infects blood cells to disseminate through the 
blood to target organs. However, in these studies, virus was delivered directly into the 
bloodstream by intravenous inoculation. It is not known how reovirus spreads 
systemically following infection from a natural portal, such as the intestine or lung. 
 
Role of Reovirus Receptors in Pathogenesis 
 
Interactions between viral attachment proteins and host cell receptors play a 
pivotal role in viral pathogenesis. Receptor engagement is a primary mechanism by 
which viruses target specific cell types. Therefore, patterns of receptor expression are a 
key determinant of viral disease. Reoviruses engage two types of cellular receptors: cell-
surface carbohydrate (16) and JAM-A (16, 22, 23). Both T1 and T3 reoviruses bind cell-
surface SA (16-20). However, the domains of σ1 that engage glycans differ between the 
serotypes (19, 21), as do the specific glycans bound (21). 
SA engagement enhances reovirus infection through an adhesion-strengthening 
mechanism in which viral particles are tethered to the cell surface via a low-affinity 
interaction with the carbohydrate (102). This interaction maintains the virus on the cell 
surface and increases the opportunity to engage JAM-A. SA-binding reovirus strains have 
an increased capacity to infect cells compared with non-SA-binding viruses; pre-
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treatment of cells with neuraminidase to remove cell-surface SA eliminates this 
advantage (102). SA engagement also enhances reovirus tropism for bile duct epithelial 
cells in mice following peroral inoculation (103). The resulting disease closely mimics 
biliary atresia in human infants (103), an illness epidemiologically associated with 
reovirus (104, 105).  
 Reovirus strains circulating in nature vary in the capacity to bind SA (19, 106). 
This finding suggests that SA binding comes with a fitness cost. Accordingly, SA binding 
appears to inhibit the capacity of reovirus to establish infection at mucosal portals of 
entry. Non-SA-binding viruses infect primary human airway epithelial cells substantially 
more efficiently than SA-binding strains (107). Moreover, infection of primary human 
airway epithelial cells by SA-binding viruses is enhanced by removal of cell-surface SA 
with neuraminidase. Mucosal surfaces are covered with a glycocalyx consisting of 
polysaccharides and glycoproteins that are rich in SA (107). SA-binding viruses may be 
trapped by SA within the glycocalyx and incapable of reaching the underlying epithelium 
(107). However, once infection is established, SA binding may enhance the capacity of 
reovirus to cause disease. In addition to the capacity to target bile duct epithelium, SA-
binding strains are more neurovirulent than non-SA-binding viruses following 
intracranial inoculation (103). This increase in virulence is likely due to more efficient 
infection of neurons, which results in neuronal apoptosis and encephalitis. The function 
of SA binding in reovirus hematogenous spread remains to be determined. 
Although all reoviruses bind JAM-A, T1 and T3 reoviruses infect distinct cells 
and cause serotype-specific patterns of pathologic injury within the CNS. These 
observations suggest that JAM-A binding does not influence serotype-specific 
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differences in reovirus neural tropism and CNS disease. Following peroral inoculation, 
reovirus produces similar titers in the intestine of wild-type and JAM-AKO mice (Figure 
I-6) (51), suggesting that JAM-A is not required for reovirus replication in the mouse 
gastrointestinal tract. In sharp contrast, viral titers at all sites of secondary replication are 
significantly lower in JAM-AKO animals compared with wild-type controls (Figure I-6) 
(51). Viral loads are comparable within the brains of wild-type and JAM-AKO animals 
after intracranial inoculation, suggesting that JAM-A is not required for viral replication 
at this site of secondary replication (51). These results suggest that JAM-A is required for 
dissemination of the virus from the intestine to replication sites in target organs.  
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Figure I-6. Reovirus T3SA- is attenuated following peroral inoculation of JAM-A 
KO mice. Newborn JAM-A+/+ and JAM-A−/− mice were inoculated perorally with 104 
PFU T3SA-. At days 4, 8, and 12 after inoculation, mice were euthanized, organs were 
resected, and viral titers were determined by plaque assay. Results are expressed as 
mean viral titers for 6–13 animals for each time point. Error bars indicate SD. *, P < 
0.05 by Student’s t test. Adapted from Antar et al. (2009).  
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Reovirus Neural Spread 
 
In addition to bloodborne spread, T3 reoviruses use neural circuits to disseminate 
to the CNS (87, 88). Spread via neural routes is a fundamental mechanism of reovirus 
pathogenesis that is essential for development of reovirus-induced encephalitis (87, 88). 
Direct infection of neurons at peripheral sites provides the virus with access to the spinal 
cord and serves as a conduit to the brain. Although the importance of neural spread to 
reovirus pathogenesis is well-appreciated, the cellular and molecular mechanisms that 
underlie neuronal reovirus trafficking are not well understood.  
In contrast to hematogenous spread, JAM-A is dispensable for neural 
dissemination. Although JAM-A is expressed in the brain, the cell types on which it is 
present have not been defined. JAM-A is found on NG2-glia cells, which are a subset of 
stem cells that give rise to oligodendrocytes (108). It is unclear whether JAM-A is 
expressed on peripheral or CNS neurons. Viral titers in the brains of wild-type and JAM-
AKO mice are comparable after intracranial inoculation (51). Viral tropism in the brain 
for hippocampal, thalamic, and cortical regions also does not differ between wild-type 
and JAM-AKO mice. Concordantly, primary cortical neurons isolated from wild-type and 
JAM-AKO mice are equally susceptible to reovirus infection and produce equivalent 
yields of viral progeny (51). Together, these data indicate JAM-A is not required for 
reovirus infection of neural tissue and suggest that JAM-A is dispensable for reovirus 
spread by neural routes. These findings further suggest that a cellular receptor distinct 
from JAM-A mediates reovirus infection of neurons. 
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Some evidence exists about the means by which reovirus traverses neural circuits. 
Treatment of animals with colchicine to inhibit fast axonal transport impairs reovirus 
spread to the spinal cord following hindlimb inoculation (87, 109). However, treatment 
with β-β′-iminodipropronitrile to inhibit slow axonal transport does not affect reovirus 
dissemination to the spinal cord (87, 110). These findings suggest that reovirus traffics in 
neurons along fast axonal transport pathways. However, these inhibitors may act non-
specifically to impair other aspects of viral replication. Much work is required to fully 
elucidate how reoviruses replicate and traffic in neurons. 
 
Reovirus Oncolytics 
 
Reoviruses are superb candidates for oncolytic therapeutics due to their preference 
for transformed cells and capacity to induce apoptosis (1). It is not well understood why 
reoviruses preferentially infect transformed cells. Cells with expression of epidermal 
growth factor receptor and activated Ras signaling pathways have increased susceptibility 
to reovirus infection (111, 112). In addition, transformed cells often do not have normal 
interferon responses, have increased receptor availability, more effective infectious 
particle generation, and increased virus release (1). Currently, reovirus strain T3D is 
being administered to a variety of cancer patients in Phase I-III clinical trials 
intravenously due to its poor infectivity within the intestine (1). Spread of reovirus by the 
bloodstream route enables the virus to target even the smallest foci of tumor cells (99, 
113).  
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Significance of the Research 
 
Viremia is often a key step in viral pathogenesis. The circulatory system ensures 
systemic spread throughout an infected host. Although this critical process is prerequisite 
to seeding virus to targeted sites of secondary replication, little is known about how 
viruses gain access to, replicate within, and egress from the bloodstream. It is possible 
that pathways into and out of the bloodstream may be conserved amongst viruses that 
establish viremia during an infectious cycle.  
The overarching goal of this dissertation was to determine mechanisms by which 
reovirus disseminates hematogenously. The central hypothesis was that JAM-A 
expression on endothelial cells facilitates bloodstream spread of reovirus. In the work 
presented here, I demonstrate that endothelial JAM-A facilitates reovirus bloodstream 
entry, viremia, and egress from the circulation using in vivo and in vitro studies. Future 
studies will focus on examining the means of reovirus bloodstream transport, egress of 
reovirus from infected endothelial cells, and reovirus exit from the circulatory system. 
Understanding mechanisms that govern the spread of reovirus by the bloodstream may 
shed light on how to inhibit this critical process during viral pathogenesis and also allow 
manipulation of reovirus to be a more effective oncolytic. 
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CHAPTER II 
 
ENDOTHELIAL JAM-A FACILITATES REOVIRUS 
VIREMIA AND BLOODSTREAM SPREAD 
 
Clinical manifestations of viral infection are often dictated by tropism of the virus 
for a particular cell type or organ. In the case of neurotropic viruses, infection of neurons 
can lead to encephalitis or other neurologic impairment. However, for many viruses to 
cause disease, they must first reach target tissues from a site of entry into the host and 
commonly use lymphatic, hematogenous, or neural pathways to traffic systemically. 
Infection of cells that facilitate access to these pathways can influence whether viral 
infection results in symptomatic disease. For example, a neurotropic virus may infect 
endothelial cells to promote viral entry into the bloodstream and delivery to the CNS. 
Knowledge gained from studies to determine precisely how viruses disseminate can be 
used to block this key step in viral pathogenesis and improve vector targeting for clinical 
purposes. 
To determine whether endothelial or hematopoietic JAM-A facilitates reovirus 
bloodstream dissemination, mice with decreased endothelial cell-specific expression of 
JAM-A (EndoJAM-AKD) were generated and infected by peroral and intravascular 
routes. Because EndoJAM-AKD mice also lack JAM-A expression in hematopoietic 
cells, mice lacking or expressing JAM-A solely in the hematopoietic cell compartment 
(HematoJAM-AKO and HematoJAM-A, respectively) also were generated to determine 
whether hematopoietic JAM-A facilitates reovirus bloodstream spread. Viral titers in 
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blood and at sites of secondary replication were lower in EndoJAM-AKD mice than 
those in wild-type mice following either peroral or intravascular reovirus inoculation. In 
contrast, viral titers in blood and at sites of secondary replication in HematoJAM-AKO 
mice were similar to those in wild-type mice following both peroral and intravascular 
inoculation. Levels of viremia and viral replication at sites of secondary replication in 
HematoJAM-A mice were lower than those in wild-type mice following both peroral and 
intravascular inoculation. Together, these data suggest that endothelial and not 
hematopoietic JAM-A is required for bloodstream dissemination of reovirus. 
 
Characterization of mice with targeted disruption of JAM-A expression. To 
determine the role of endothelial JAM-A in reovirus infection, I generated mice lacking 
JAM-A exclusively in the endothelial cell compartment (Figure II-1). Genotypes of the 
different mouse strains were confirmed by PCR using primers specific for the Tek-Cre 
(Cre recombinase) transgene and floxed JAM-A (Table 1, Figure II-1). I assessed cell-
surface expression of JAM-A on hematopoietic and endothelial cells of EndoJAM-AKD 
mice. Surprisingly, I found that cell-surface JAM-A was decreased on endothelial cells 
and absent on hematopoietic cells in EndoJAM-AKD mice (Figures II-2, II-6, II-7). 
Compared to JAM-A expression on endothelial cells in wild-type mice, JAM-A 
expression on endothelial cells in EndoJAM-AKD mice was diminished approximately 
two-fold as determined by the mean fluorescence intensity (MFI) (Figure II-3).  
To determine the role of hematopoietic JAM-A in reovirus infection, I generated 
mice that either lack or express JAM-A solely in the hematopoietic compartment (Figure 
II-4). Genotypes of the different mouse strains were confirmed by PCR using primers 
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specific for the Vav-cre transgene and floxed JAM-A (for HematoJAM-AKO mice) or 
Vav-JAM transgene and JAM-AKO allele (for HematoJAM-A mice) (Table 1, Figure II-
4). I assessed cell-surface JAM-A expression on endothelial and hematopoietic cells of 
HematoJAM-AKO and HematoJAM-A mice. As expected, JAM-A expression on lung 
endothelial cells of HematoJAM-AKO mice mirrored that seen in lung endothelial cells 
of wild-type mice (Figure II-5). In contrast, lung endothelial cells from HematoJAM-A 
mice, which lack all native JAM-A but express a hematopoietic-specific JAM-A 
transgene (Figure II-4), had levels of JAM-A expression similar to JAM-AKO mouse 
lung endothelial cells (Figure II-5). Levels of JAM-A expression on hematopoietic cells 
collected from HematoJAM-AKO mice were undetectable, but hematopoietic JAM-A 
expression in HematoJAM-A mice was identical to that seen in wild-type mice (Figures 
II-5, II-6, II-7). The JAM-A expression phenotypes of the mouse strains used in this 
study are shown in Table 2. 
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TABLE 1. Primer sequences used to genotype mice with altered JAM-A expression. 
 
Mouse Region Forward Primer Reverse Primer 
JAM-A 
f/f 
(WT) 
JAM-A 
Exon 1 
TCT TTT CAC CAA TCG GAA 
CG 
AAA AAC TCT AGG AAC TCA 
CCC AGG A 
JAM-
AKO 
(KO) 
JAM-A 
Exon 1 
TCT TCT TCA GAC GCC 
GAA CCT 
CCT CTC TTT TCA CCA ATC 
GGA 
Tek-Cre 
(EKO) 
Tek P 
to Cre 
CCC TGT GCT CAG ACA 
GAA ATG AGA  
CGC ATA ACC AGT GAA 
ACA GCA TTG C 
Vav-Cre 
(HKO) 
Vav P 
to Cre 
GAA GGA ACG AGG GTG 
CAC 
TGC CTG TCC CTG AAC ATG 
TC 
Vav-Cre 
(HKO) 
Cre to 
Vav E 
ATG CAG GCT GGT GGC 
TGG 
GGC TCG CGA GGT TTT ACT 
TGC 
Vav-
JAM 
(HJ) 
Vav P 
to 
JAM-A 
GAA GGA ACG AGG GTG 
CAC 
GTG CAG GTC AAT  TTG ATG 
GAC TCG  
Vav-
JAM 
(HJ) 
JAM-A 
to Vav 
E 
CAG CTG TCC TGG TAA 
CAC TGA TTC  
GGC TCG CGA GGT TTT ACT 
TGC 
aIn cases in which two sets of primers for a particular mouse strain are shown, only one 
was used at any time to determine the genotype. 
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Figure II-1. Generation of EndoJAM-AKD mice. A schematic depicting the 
generation of EndoJAM-AKD mice used in infection experiments. Exon 1 of JAM-A 
is flanked by loxP sites in JAM-A f/f mice. Cre recombinase expression in 
endothelial-specific Cre tg mice is driven by Tek promoter and enhancer sequences 
from an inserted transgene. Crosses between JAM-A f/f and tissue-specific Cre mice 
generate mice in which exon 1 of JAM-A is excised in tissues where Cre is expressed. 
Arrows indicate primer binding sites for JAM-A primers (J1, J2), JAM-A f/f primers 
(F1, F2), and Tek-Cre primers (TC1, TC2). Tek = Tek promoter, CRE = Cre 
recombinase, E = Tek enhancer. 
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Figure II-2. Characterization of EndoJAM-AKD mice. JAM-A expression was 
assessed in 6- to 8-week-old mice by genomic DNA PCR and flow cytometry. 
Hematopoietic cells were collected from blood and spleens, and endothelial cells were 
cultured from lungs. JAM-A expression was quantified using flow cytometry. (A) 
Agarose gels displaying bands corresponding to regions of genomic DNA amplified in 
genotyping PCR reactions. Bands from the following reactions are shown for each 
mouse strain: JAM-A f/f, Tek-Cre, Vav-Cre, Vav-JAM, JAM-AKO. (B) Flow 
cytometric profiles of endothelial and hematopoietic cells (peripheral blood 
granulocytes and macrophages) from each mouse strain. US = Unstained, WT = Wild-
type (JAM-A f/f), KO = JAM-AKO, EKD = EndoJAM-AKD.  	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Figure II-3. Quantification of JAM-A expression in primary lung endothelial 
cells. Endothelial cells were cultured from lungs excised from 6- to 8-week-old mice. 
Cells were stained with JAM-A-specific antibody and cell-surface JAM-A expression 
was quantified using flow cytometry. JAM-A expression is displayed as MFI values 
that were normalized by subtracting MFI of unstained controls. WT = Wild-type 
(JAM-A f/f), KO = JAM-AKO, EKD = EndoJAM-AKD. 
EKD HJ HKO KO WT 
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Figure II-4. Generation of HematoJAM-AKO and HematoJAM-A mice. (A) A 
schematic depicting the generation of HematoJAM-AKO mice used in infection 
experiments. Cre recombinase expression in hematopoietic-specific Cre tg mice is 
driven by Vav promoter and enhancer sequences from an inserted transgene. Arrows 
indicate primer binding sites for JAM-A primers (J1, J2), JAM-A f/f primers (F1, F2), 
and Vav-cre primers (TC1, TC2). Vav = Vav promoter, CRE = Cre recombinase, E = 
Vav enhancer. (B) Mice that express JAM-A only within the hematopoietic cell 
compartment (HematoJAM-A mice) were obtained by generating tg mice expressing a 
transgene in which JAM-A expression is driven by Vav1 promoter and enhancer 
sequences. JAM-A expression was abolished by breeding the tg mice with JAM-AKO 
mice. Arrows indicate primer binding sites for Vav-JAM primers (VJ1, VJ2). Vav = 
Vav promoter, JAM = JAM-A cDNA, E = Vav enhancer.  
A 
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Figure II-5. Characterization of HematoJAM-AKO and HematoJAM-A mice. 
JAM-A expression was assessed in 6- to 8-week-old mice by genomic DNA PCR and 
flow cytometry. Hematopoietic cells were collected from blood and spleens, and 
endothelial cells were cultured from lungs. JAM-A expression was quantified using 
flow cytometry. (A) Agarose gels displaying bands corresponding to regions of 
genomic DNA amplified in genotyping PCR reactions. Bands from the following 
reactions are shown for each mouse strain: JAM-A f/f, Tek-Cre, Vav-Cre, Vav-JAM, 
JAM-AKO. (B) Flow cytometric profiles of endothelial and hematopoietic cells 
(granulocytes and macrophages) from each mouse strain. US = Unstained, WT = 
Wild-type (JAM-A f/f), KO = JAM-AKO, HKO = HematoJAM-AKO, HJ = 
HematoJAM-A. 
A 
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Figure II-6. JAM-A expression in circulating hematopoietic cells. Blood was 
collected retroorbitally from 6- to 8-week-old mice, and JAM-A expression on 
leukocytes was quantified using flow cytometry. B and T lymphocytes were defined as 
the populations that were B220+ and TCR-β+, respectively. Each set of histograms 
includes data from unstained, WT, and JAM-AKO cells along with the indicated 
genotype. WT = Wild-type (JAM-A f/f), KO = JAM-AKO, EKD = EndoJAM-AKD, 
HKO = HematoJAM-AKO, HJ = HematoJAM-A. 
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Figure II-7. JAM-A expression in splenocytes. Spleens were excised from 6- to 8-
week-old mice, and splenocytes were stained for various hematopoietic cell markers. 
Granulocytes, macrophages, dendritic cells, B lymphocytes, and T lymphocytes were 
defined as the populations that were Gr-1+, CD11b+, Cd11c+, B220+, and TCR-β+, 
respectively. Each set of histograms includes data from unstained, WT, and JAM-AKO 
cells along with the indicated genotype. WT = Wild-type (JAM-A f/f), KO = JAM-
AKO, EKD = EndoJAM-AKD, HKO = HematoJAM-AKO, HJ = HematoJAM-A. 
HKO HJAM EKD 
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TABLE 2. JAM-A expression in mouse strains used in studies of reovirus 
bloodstream spread. 
 
Mouse strain 
JAM-A Expression 
Endothelial Cells Hematopoietic 
Cells 
Wild-type (JAM-A f/f) +
a + 
JAM-AKO -
b - 
EndoJAM-AKD ↓
c       - 
HematoJAM-AKO + - 
Hemato-JAM-A - + 
aWild-type expression; bAbsent expression;  
cExpression decreased approximately 50% 
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Endothelial JAM-A promotes bloodstream dissemination of reovirus. To determine 
whether endothelial or hematopoietic JAM-A is required for bloodstream spread of 
reovirus, wild-type, JAM-AKO, EndoJAM-AKD, HematoJAM-AKO, and HematoJAM-
A mice were inoculated perorally with reovirus strain T1L. Following peroral inoculation 
of newborn mice, T1L infects the intestine, disseminates hematogenously, and reaches 
high titers in most visceral organs (51, 64). Reovirus dissemination was assessed by 
determining viral titers in organ homogenates and blood of infected mice 4, 8, and 12 d 
post-inoculation. As anticipated, wild-type, JAM-AKO, and the tissue-specific JAM-A-
expressing mice had equivalent viral titers in the intestine (Figure II-8), as replication at 
this site is not JAM-A-dependent (51). Viral titers were minimally detectable in the brain, 
heart, and blood of JAM-AKO mice and significantly lower in the spleen and liver 
compared with those in wild-type animals (Figures II-8, II-9). After peroral reovirus 
inoculation, HematoJAM-AKO mice, which lack JAM-A only in hematopoietic cells, 
phenocopied wild-type mice. Viral titers in the heart, spleen, liver, brain, and blood of 
infected HematoJAM-AKO mice were equivalent to those in infected wild-type mice 
(Figures II-8, II-9). Viral titers in the brain, heart, spleen, liver, and blood of 
HematoJAM-A mice, which express JAM-A solely in hematopoietic cells, were similar 
to those seen in JAM-AKO mice (Figures II-8, II-9). These data suggest that 
hematopoietic JAM-A is dispensable for reovirus hematogenous dissemination.Viral 
titers in the spleen, liver, heart, brain, and blood of EndoJAM-AKD mice were 
significantly lower than those observed in wild-type mice (Figures II-8, II-9). Titers of 
virus in these animals were similar to those observed in JAM-AKO and HematoJAM-A 
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mice, suggesting that reovirus hematogenous dissemination is dependent on endothelial 
but not hematopoietic JAM-A.  
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Figure II-8. Endothelial JAM-A is required for reovirus bloodstream spread. 
Newborn (2-3 d) mice were inoculated perorally with reovirus strain T1L at 1000 
plaque forming units (PFU) per mouse. At 4, 8, and 12 d post-inoculation, intestine, 
heart, and brain were excised and blood was collected into an equal volume of 
Alsever’s solution for determination of viral titer by plaque assay. Results are 
presented as mean viral titer. Error bars indicate standard deviation. For each time 
point and mouse strain, two to twenty-two mice were used. WT = Wild-type (JAM-A 
f/f), KO = JAM-AKO, EKO = EndoJAM-AKO, HKO = HematoJAM-AKO, HJ = 
HematoJAM-A. *, P < 0.05, **, P < 0.005, ***, P < 0.001 by Student’s t test. 
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Figure II-9. Reovirus dissemination to the liver and spleen requires endothelial 
JAM-A. Newborn (2-3 d) mice were inoculated perorally with reovirus strain T1L at 
1000 PFU per mouse. At 4, 8, and 12 d post-inoculation, spleen and liver were excised 
for determination of viral titer by plaque assay. Results are presented as mean viral 
titer. Error bars indicate standard deviation. For each time point and mouse strain, two 
to twenty-two mice were used. WT = Wild-type (JAM-A f/f), KO = JAM-AKO, EKO 
= EndoJAM-AKO, HKO = HematoJAM-AKO, HJ = HematoJAM-A. *, P < 0.05, **, 
P < 0.005, ***, P < 0.001 by Student’s t test. 
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Endothelial JAM-A is required for reovirus egress from the bloodstream. Because 
the requirement for bloodstream entry may differ from the requirement for bloodstream 
egress, I used an intravenous inoculation protocol to directly assess the role of JAM-A in 
reovirus bloodstream egress. Wild-type and JAM-AKO mice were inoculated 
intravenously with reovirus strain T1L, and viral titers in organ homogenates were 
determined by plaque assay 8 d post-inoculation (Figure II-10). Viral titers in wild-type 
mice inoculated intravenously were similar to those in perorally-inoculated wild-type 
mice (Figures II-8, II-9, II-10). In intravenously-inoculated mice, reovirus disseminated 
to the intestine, spleen, liver, heart, and brain (Figure II-10). Viral titers in JAM-AKO 
mice were significantly lower in all organs tested compared with those in wild-type mice, 
suggesting that reovirus egress from the bloodstream is dependent on JAM-A expression 
(Figure II-10).  
To determine whether endothelial or hematopoietic JAM-A facilitates reovirus 
egress from the bloodstream, EndoJAM-AKD, HematoJAM-AKO, and HematoJAM-A 
mice were inoculated intravenously, and viral titers were determined in organ 
homogenates 8 d post-inoculation. Reovirus titers in HematoJAM-AKO were comparable 
to those observed in wild-type mice (Figure II-10), suggesting that dissemination to these 
sites does not require hematopoietic JAM-A. Viral titers in the liver and heart of 
HematoJAMKO mice were significantly lower than those seen in wild-type mice (Figure 
II-10). However, the magnitude of this decrease in viral titers is modest. Viral titers in the 
intestine, spleen, liver, heart, and brain of HematoJAM mice were similar to those 
observed in JAM-AKO mice, suggesting that hematopoietic JAM-A is not sufficient for 
reovirus exit from the circulation and infection of these organs (Figure II-10). Viral titers 
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in EndoJAM-AKD mice were significantly lower in the blood and intestine, spleen, liver, 
heart, and brain compared with those observed in wild-type mice (Figure II-10). Taken 
together, these data suggest that reovirus egress from the bloodstream requires 
endothelial but not hematopoietic JAM-A.   
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Figure II-10. Reovirus uses endothelial JAM-A to egress from the circulation. 
Newborn (2-3 d) mice were inoculated perorally with reovirus strain T1L at 1000 PFU 
per mouse. At 8 d post-inoculation, intestine, spleen, liver, heart, and brain were 
excised and blood was collected into an equal volume of Alsever’s solution for 
determination of viral titer by plaque assay. Results are presented as the mean viral 
titer. Error bars indicate standard deviation. For each time point and mouse strain, five 
to eighteen mice were used. WT = Wild-type (JAM-A f/f), KO = JAM-AKO, EKO = 
EndoJAM-AKO, HKO = HematoJAM-AKO, HJ = HematoJAM-A. *, P < 0.05, **, P 
< 0.005, ***, P < 0.001 by Student’s t test. 
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Primary endothelial cells are permissive for reovirus infection. Polarized endothelial 
cells are permissive for reovirus infection in vitro (51, 114). Because reovirus spread was 
limited in EndoJAM-AKD mice, I wondered whether this defect in viral replication is 
due to a replication defect in the endothelial cell compartment. Primary lung endothelial 
cells were cultured from lungs excised from wild-type, JAM-AKO, EndoJAM-AKD, 
HematoJAM-AKO, and HematoJAM-A mice and infected with reovirus strain T1L at a 
multiplicity of infection (MOI) of 100 PFU per cell. After one replication cycle, cells 
were collected and stained for reovirus antigen using Alexa Fluor-conjugated reovirus-
specific antiserum. The percentage of infected cells for each genotype (Figure II-11) 
correlated with the level of JAM-A expression in endothelial cells (Figure II-3). These 
data suggest that reovirus replication in endothelial cells seeds the bloodstream with 
virus.  
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Figure II-11. Reovirus infectivity is diminished in EndoJAM-AKO lung 
endothelial cells. Endothelial cells were cultured from lungs excised from 6- to 8-
week-old mice. Cells were adsorbed with virus strain T1L at an MOI of 100 PFU per 
cell. After incubation at 37⁰C for 24 h, cells were harvested and stained for reovirus 
antigen using Alexa Fluor-conjugated reovirus-specific antiserum. The percentage of 
infected cells was determined using flow cytometry.  
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Discussion 
 
Reoviruses are neurotropic viruses that disseminate by hematogenous and neural routes. 
These viruses are useful experimental models to dissect mechanisms by which viruses 
gain access to these systemic transport pathways. In this study, I assessed hematogenous 
reovirus spread in mice with tissue-specific alterations in JAM-A expression. I 
hypothesized that systemic bloodstream spread of reovirus depends on expression of 
JAM-A in the endothelium and on hematopoietic cells. The key finding in this chapter is 
that endothelial but not hematopoietic JAM-A is required for reovirus bloodstream 
spread.  
To generate mice with altered JAM-A expression in the endothelial compartment, 
I chose to use animals that express Cre driven by the Tek promoter. Tek is a tyrosine 
kinase that is specific for endothelial cells, but it also is expressed in hematopoietic stem 
cells (115). Tek-dependent Cre recombinase expression in hematopoietic stem cells likely 
accounts for the absence of JAM-A expression in all hematopoietic cell types in 
EndoJAM-AKD mice (Figures II-2B, II-6, II-7). To exclude the possibility that the 
absence of hematopoietic JAM-A might confound the effects seen in EndoJAM-AKD 
mice, I generated HematoJAM-AKO and HematoJAM-A mice.   
Dissemination by the bloodstream route requires that a virus surmount several 
physiological obstacles. Reoviruses initially replicate in the small intestine in a JAM-A-
independent manner (51), enter into the bloodstream, and target the CNS where 
replication is again JAM-A-independent (51). Mice lacking JAM-A are protected from 
reovirus-induced encephalitis because the virus cannot enter the bloodstream (51). 
	   50 
Accordingly, reovirus infection of polarized endothelial cells is dependent on JAM-A 
(114). When infected from the basolateral (or tissue) surface, polarized endothelial cells 
route the virus to the luminal (or blood) surface of the polarized monolayer (114). These 
data suggest that reovirus uses JAM-A to infect endothelial cells to gain access to the 
bloodstream. EndoJAM-AKD mice, which display diminished JAM-A expression in 
endothelial cells, have significantly lower levels of viremia after peroral and intravenous 
inoculation compared with those in wild-type mice (Figures II-8D, H, L and II-10F), 
suggesting that endothelial JAM-A facilitates reovirus entry into and exit from the 
bloodstream. Subsequent spread to sites of secondary replication (e.g., brain and heart) 
after peroral inoculation is significantly diminished in EndoJAM-AKD mice (Figure II-
8), suggesting that efficient spread to those sites requires a threshold level of viremia. 
Although viral titers in organ homogenates prepared from EndoJAMKD mice are 
significantly lower than those observed in wild-type mice, there is detectable virus at 
these sites. This finding might be attributable to residual JAM-A expression in the 
endothelium of EndoJAM-AKD mice or the presence of another host component that 
facilitates systemic trafficking of reovirus. Nonetheless, my findings provide strong 
evidence that endothelial JAM-A promotes bloodstream entry during systemic infection.  
Many viruses use hematopoietic cells to traffic in an infected host. For example, 
HIV-1 adheres to dendritic cells prior to contact with their primary target, CD4+ T 
lymphocytes (116, 117). Because JAM-A is expressed on circulating hematopoietic cells, 
I hypothesized that reovirus uses leukocytes to traffic within the circulation. Surprisingly, 
I found that viral titers in the blood and at sites of secondary replication of 
HematoJAMKO mice, which lack JAM-A in the hematopoietic compartment, are 
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equivalent to those seen in wild-type mice after peroral and intravenous inoculation 
(Figures II-8, II-9, II-10). Viral titers in HematoJAM mice, which express JAM-A only in 
hematopoietic cells, mirrored those seen in JAM-AKO mice (Figures II-8, II-9, II-10), 
further confirming that hematopoietic JAM-A does not facilitate reovirus spread through 
the bloodstream. Since reoviruses have been reported to associate with dendritic cells in 
vivo (99), it is possible that reoviruses bind to or infect leukocytes using a molecule 
distinct from JAM-A. In clinical trials using reovirus strain T3D as an oncolytic agent, 
the virus was observed to bind human immune cells in the blood (99). Therefore, reovirus 
strains may differ in the capacity to infect leukocytes in vivo.  
Development of viremia may occur as a consequence of viral replication in 
endothelial cells. Flaviviruses like dengue virus (DENV) are capable of infecting 
endothelial cells and replicate to high titers, lysing the cells to increase viremia (118). In 
the case of DENV infection, high-titer viremia is required for vectoral transmission of the 
virus to a naïve host (119). Reovirus viremia is not required for transmission of the virus 
since reovirus host-to-host spread occurs primarily by the fecal-oral route. Instead, 
viremia serves to spread reovirus systemically to sites of secondary replication. Viral 
titers in the blood of JAM-AKO mice are significantly lower than those observed in wild-
type mice (Figure II-8D, H, L) (51), suggesting that JAM-A promotes establishment of 
viremia. Infection of polarized endothelial cells with reovirus requires JAM-A and may 
serve as a means to amplify reovirus within the bloodstream (114). Apical (or luminal) 
infection of polarized endothelial cells is efficient, and infected cells release virus 
noncytolytically from the apical surface (114). Lower viral titers in the blood of 
EndoJAM-AKD mice and wild-type viral titers in the blood of HematoJAM-AKO mice 
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after peroral and intravenous inoculation (Figures II-8, II-10) suggest that endothelial and 
not hematopoietic JAM-A is required for development of viremia.  
Reoviruses are superb candidates for oncolytic therapeutics due to their 
preference for transformed cells and capacity to induce apoptosis (1). Currently, reovirus 
strain T3D is being administered to a variety of cancer patients in Phase I-III clinical 
trials intravenously due to its poor infectivity within the intestine (1). Spread of reovirus 
by the bloodstream route enables the virus to target even the smallest foci of tumor cells 
(99). By understanding how reovirus interacts with JAM-A on the endothelium, it may be 
possible to design new reovirus vectors to reach target tumors more efficiently. For 
example, reoviruses with higher affinity for JAM-A may enter and exit the circulation 
more readily, allowing for more efficient targeting of tumor cells. On the other hand, 
generating reoviruses that bind JAM-A with lower affinity may decrease the 
pathogenicity of the virus by inhibiting viremia. Thus, understanding mechanisms that 
govern the spread of reovirus by the bloodstream sheds light on how pathogens 
systemically disseminate and may enhance systemic vector targeting for a host of 
therapeutic applications.  
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CHAPTER III 
 
JAM-A FACILITATES REOVIRUS INFECTION OF POLARIZED  
HUMAN BRAIN MICROVASCULAR ENDOTHELIAL CELLS 
 
Bloodstream dissemination within an infected host is required for the 
pathogenesis of many viruses. In particular, many neurotropic viruses use the circulation 
to invade the CNS from a distant site of primary replication. Regardless of the site of 
entry into the host, viruses that disseminate hematogenously must first traverse an 
endothelial barrier and egress from the circulation. Although viremia is a well-established 
dissemination process, precise mechanisms of viral entry into the bloodstream are not 
well understood. 
In this study, I examined reovirus infection of polarized human brain 
microvascular endothelial cells (HBMECs) to better understand mechanisms of viral 
entry into the bloodstream. I found that reovirus productively infects polarized 
endothelial cells from both apical and basolateral routes of adsorption. Regardless of the 
route of adsorption, reovirus infection of polarized endothelial cells is dependent on 
engagement of receptors SA and JAM-A. Reovirus infection by the apical route of 
infection is more efficient than infection by the basolateral route, likely because of 
increased expression of JAM-A on the apical surface of polarized endothelial cells. These 
studies provide a new understanding of how viruses infect polarized endothelial cells and 
identify the endothelium as an important mediator of viral pathogenesis. 
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Generation of a polarized endothelial cell system for studies of reovirus infection. To 
investigate how reoviruses might use a polarized endothelium to enter the bloodstream, a 
polarized endothelial cell system was generated by culturing HBMECs on Transwell 
inserts. To confirm that the conditions used to cultivate HBMECs on Transwell inserts 
lead to formation of polarized cultures, transendothelial electrical resistance (TEER) and 
permeability of the monolayers to diffusion of dextrans was determined. The TEER of 
HBMECs increased over time in comparison to L929 fibroblast cells, which do not 
polarize, suggesting the formation of TJs and establishment of polarized cultures (Figure 
III-1A). The permeability to FITC-labeled dextrans across cultured HBMEC monolayers 
decreased over time in parallel with increased TEER, with dextran diffusion barely 
detectable 7 d post-seeding (Figure III-1B). As a control, ethylenediaminetetraacetic acid 
(EDTA) treatment, which chelates divalent cations required for TJ maintenance, 
enhanced permeability across the HBMEC monolayer (Figure III-1B). Furthermore, TJ 
protein markers are present in confocal micrographs of HBMECs cultured on Transwells 
for 7 d (Figure III-1C, white asterisks). These data suggest that HBMECs cultivated on 
Transwell inserts form TJs and become polarized 7 d post-seeding.  
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Figure III-1. Barrier properties of polarized HBMECs. (A) HBMECs (solid line) 
and L929 cells (dashed line) cultivated on Transwells were monitored for TEER daily 
for 12 d. The data are presented as unit area resistance, where normalized TEER is 
multiplied by the area of the Transwell insert (Ω·cm2). A representative experiment of 
two performed is shown, with each experiment conducted in duplicate. Error bars 
indicate range of data for the duplicates. (B) FITC-labeled dextrans were added to the 
apical compartment of HBMECs cultivated on Transwell inserts at 1, 4, or 7 d post-
seeding. Prior to the addition of dextrans, TEER (Ω·cm2) was determined and is 
presented in parentheses above each bar. The percent permeability was determined 
using the following equation: Permeability (%) = [FITC-dextran]basolateral/([FITC-
dextran]basolateral + [FITC-dextran]apical) x 100. On day 7, 2.5 mM EDTA was added to 
the apical and basolateral compartments as a control to disrupt TJs. A representative 
experiment of three performed is shown, with each experiment conducted in duplicate. 
Error bars indicate range of data for the duplicates. (C) HBMECs cultured on 
Transwells for 7 d were stained for TJ proteins claudin-1 (red) and JAM-A (green) and 
nuclei (blue). At the bottom of the merged image, blue staining shows the Transwell 
membrane. Representative images of the cell monolayer in the xz plane are shown. 
White asterisks indicate colocalization of TJ proteins. Cell images were captured using 
a Zeiss LSM 510 Meta laser-scanning confocal microscope using a 63×/1.40 Plan-
Apochromat objective lens. 
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Reovirus infection of polarized endothelial cells is more efficient from the apical 
surface. To determine whether reovirus productively infects polarized endothelial cells, I 
adsorbed either the apical or basolateral surface of polarized HBMECs with strain 
T3SA+, a virus that efficiently binds sialic acid and JAM-A (22, 102). Viral titer in cell 
lysates increased over time regardless of the route of adsorption (Figure III-2A). 
Following apical adsorption, viral titer peaked at 24 h post- infection, with the yield 
reaching approximately 1000-fold over input (Figure III-2A). In contrast, following 
basolateral adsorption, viral replication was delayed with yields of 5-fold at 24 h and 
100-fold at 48 h post-infection (Figure III-2A). I observed a similar trend with polarized 
HBMECs infected with reovirus strain T1L (Figure III-3A). These data indicate that 
reovirus infection of polarized HBMECs is productive following either apical or 
basolateral entry routes, but apical adsorption results in more efficient replication and 
increased viral yields.  
Because I observed higher peak titers in polarized HBMECs after apical 
adsorption, I sought to determine whether initiation of reovirus infection is more efficient 
when cells are infected apically versus basolaterally. Polarized HBMECs were adsorbed 
with virus by the apical or basolateral route, and the percentage of reovirus antigen-
positive cells was quantified using flow cytometry. Apical adsorption resulted in 
approximately ten-fold more infected cells compared with that following basolateral 
adsorption (Figure III-2B). Apical infection of polarized HBMECs by reovirus strain T1L 
also yielded significantly more infected cells than that observed after basolateral infection 
(Figure III-3B). As a control, apical or basolateral adsorption of nonpolarized L929 
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fibroblast cells cultivated on Transwell inserts yielded equivalent numbers of infected 
cells (Figure III-2B).  
To determine whether differences in infectivity are attributable to differences in 
virus binding, I assessed virus attachment to polarized HBMECs following apical or 
basolateral adsorption. In concordance with the infectivity data, approximately 10-fold 
more virus was bound to HBMECs following apical adsorption compared with that 
following basolateral adsorption (Figure III-2C). As anticipated, virus bound equivalently 
to L929 fibroblasts following adsorption either apically or basolaterally (Figure III-2C). 
Together, these data suggest that reovirus binds more efficiently to the apical surface of 
polarized HBMECs, which results in increased infectivity and replication. 
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Figure III-2. Reovirus infection of polarized HBMECs is more efficient following 
adsorption from the apical surface. Polarized HBMECs were adsorbed either 
apically (white bars) or basolaterally (black bars) with reovirus T3SA+ at an MOI of 
10 PFU per cell. (A) Transwell inserts were excised at 0, 24, and 48 h post-infection, 
and viral titers in cell lysates were determined by plaque assay. A representative 
experiment of three performed is shown, with each experiment conducted in duplicate. 
Error bars indicate range of data for the duplicates. (B) HBMECs were incubated for 
20-24 h and harvested by trypsinization. Cells were permeabilized and stained with 
Alexa Fluor-conjugated reovirus-specific antiserum. The percentage of infected cells 
was determined using flow cytometry. A representative experiment of three performed 
is shown, with each experiment conducted in duplicate.    Error bars indicate range of 
data for the duplicates. (C) HBMECs were removed immediately after adsorption and 
stained with Alexa Fluor-conjugated reovirus-specific antiserum. MFI was determined 
using flow cytometry. A representative experiment of three performed is shown, with 
each experiment conducted in duplicate. Error bars indicate range of data for the 
duplicates.**, P < 0.005, n.s., not significant. 
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Figure III-3. T1L infection of polarized HBMECs is more efficient by the apical 
route. Polarized HBMECs were adsorbed either apically or basolaterally with reovirus 
T1L at an MOI of 10 PFU per cell. After adsorption with virus, cells were incubated 
for various intervals. (A) Transwell inserts were excised at 0, 24, and 48 h post-
infection, and viral titers in cell lysates were determined by plaque assay. A 
representative experiment of two performed is shown, with each experiment 
conducted in duplicate. Error bars indicate range of data for the duplicates. (B) 
HBMECs were incubated for 20-24 h and harvested by trypsinization. Cells were 
permeabilized, stained with Alexa Fluor-conjugated reovirus-specific antiserum, and 
the percentage of infected cells was determined using flow cytometry. A 
representative experiment of two performed is shown, with each experiment 
conducted in duplicate. Error bars indicate range of data for the duplicates.                
**, P < 0.005. 
B A 
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SA and JAM-A are required for reovirus infection of polarized endothelial cells. To 
determine whether differences in infectivity of polarized HBMECs after apical or 
basolateral adsorption are attributable to differences in receptor engagement, I used  
mutant reovirus strains impaired in the capacity to bind either sialic acid or JAM-A. 
Single amino acid mutations in the σ1 attachment protein can dramatically diminish 
binding to these receptors (11, 102). Polarized HBMECs were adsorbed apically or 
basolaterally with wild-type or mutant reovirus strains, and the percentage of infected 
cells was quantified 24 h post-infection. There were significantly more infected cells 
following apical adsorption with wild-type strain type 3 Dearing (rsT3D) compared with 
mutant strain rsT3D-σ1R202W, which is deficient in SA-binding (11, 120), or mutant 
strain rsT3D-σ1G381A, which is deficient in JAM-A-binding (Figure III-4A) (26). 
Treatment of polarized HBMECs with neuraminidase (to remove cell-surface SA) and 
JAM-A-specific antibody prior to apical virus adsorption significantly decreased 
infection by rsT3D. Similarly, neuraminidase and JAM-A-specific antibody pretreatment 
substantially decreased infection of polarized HBMECs by rsT3D-σ1G381A and rsT3D-
σ1R202W, respectively (Figure III-4A). Concordantly, rsT3D bound more efficiently to 
the apical surface of polarized HBMECs compared with the mutant virus strains, and 
virtually all virus binding was abolished with neuraminidase or JAM-A-specific antibody 
pretreatment (Figure III-4C).  I observed a similar trend after basolateral adsorption in 
that diminished receptor engagement by mutant viruses or blockade of receptor 
engagement using inhibitors significantly decreased the percentage of virus-infected and 
virus-bound cells (Figure III-4B and D). However, the overall percentage of infected cells 
and levels of virus binding after basolateral adsorption were substantially less than those 
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following apical adsorption, which diminishes the magnitude of the observed differences 
(note the different y-axis scales in Figure III-4). Reovirus mutant rsT3D-σ1R202W 
bound to the basolateral surface of HBMECs equivalently to wild-type rsT3D but 
infected significantly fewer cells, suggesting that SA engagement may enhance reovirus 
replication at a post-attachment step following basolateral adsorption of polarized 
endothelial cells. These data suggest that infection of polarized endothelial cells is 
dependent on virus binding to sialylated glycans and JAM-A on the apical and basolateral 
surfaces of polarized endothelial cells, but binding to the apical surface is more efficient. 
To determine whether increased binding of reovirus to the apical surface of 
polarized HBMECs is attributable to enhanced receptor expression, I examined the 
distribution of JAM-A on polarized HBMECs by confocal microscopy. Polarized 
HBMEC monolayers were stained using antibodies specific for TJ protein claudin-1 as 
well as JAM-A (Figure III-5A). Substantially more JAM-A staining was detected at the 
apical surface of the polarized cell monolayer (Figure III-5B), including non-junction 
sites that lack detectable claudin-1 staining (Figure III-5A). Confocal micrographs of 
apical portions of cells showed a stippled pattern of JAM-A expression. In equatorial 
sections of cells, JAM-A was distributed at the cell periphery, presumably in contact with 
JAM-A on adjacent cells. In these images, TJ puncta marked by claudin-1 and JAM-A 
colocalization are clearly visible (Figure III-5A, white asterisks). At the basolateral 
surface, the JAM-A signal was diminished in intensity and diffusely localized compared 
with JAM-A staining at the apical surface (Figure III-5). Increased distribution of JAM-A 
to the apical surface of polarized HBMECs may allow reovirus to bind and infect these 
cells more efficiently from this route.  
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Figure III-4. JAM-A and sialic acid are required for reovirus infection of 
polarized HBMECs. Polarized HBMECs were adsorbed either apically (A,C) or 
basolaterally (B,D) at an MOI of 10 PFU per cell with reovirus strains rsT3D, rsT3D-
σ1R202W, or rsT3D-σ1G381A in the presence or absence of anti-JAM-A antibody 
(20 µg/ml) or A. ureafaciens neuraminidase (80 mU/ml). (A,B) Cells were incubated 
for 20-24 h, removed from Transwells using trypsin, permeabilized, and incubated 
with Alexa Fluor-conjugated reovirus-specific antiserum. The percentage of infected 
cells was determined using flow cytometry. A representative experiment of two 
performed is shown, with each experiment conducted in duplicate. Error bars indicate 
range of data for the duplicates. (C,D) Cells were harvested from Transwells 
immediately after adsorption and stained with Alexa Fluor-conjugated reovirus-
specific antiserum. MFI was quantified using flow cytometry. Note that different y-
axis scales are used for apical and basolateral adsorption. A representative experiment 
of two performed is shown, with each experiment conducted in duplicate. Error bars 
indicate range of data for the duplicates. *, P < 0.05; **, P < 0.005 
A C 
B D 
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Figure III-5. Polarized HBMECs express JAM-A predominantly at the apical 
surface.  (A) Polarized HBMECs were stained for JAM-A (green), claudin-1 (red), 
and nuclei (blue) and imaged by confocal microscopy. Shown are images of the apical, 
equatorial, and basolateral regions of a single, representative z-stack. Colocalization of 
TJ proteins is indicated by white asterisks. Scale bar indicates 10 µm. Enlarged images 
of the white boxed areas are shown in the bottom panels. Cell images were captured 
using a Zeiss LSM 510 Meta laser-scanning confocal microscope using a 63×/1.40 
Plan-Apochromat objective lens. (B) JAM-A channel MFI of apical and basolateral 
sections of individual cells (n = 5) was quantified. Error bars indicate standard 
deviation. *, P < 0.05 
A 
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Reovirus infection does not alter endothelial cell TJ integrity. To determine whether 
reovirus infection alters the integrity of TJs in the polarized monolayer, I quantified the 
TEER at both early and late times post-adsorption. After adsorption with an MOI of 1000 
PFU per cell, no significant alteration in TEER was observed in an interval from 0 to 2 h 
post-infection (Figure III-6). I conclude from these data that reovirus does not alter the 
function of endothelial TJs at early time points during infection.  
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Figure III-6. Reovirus infection of polarized HBMECs does not disrupt TJs at 
early times post-infection. Polarized HBMECs were mock-infected (closed symbol, 
solid line) or adsorbed either apically (closed symbol, dashed line) or basolaterally 
(open symbol, dotted line) with reovirus T3SA+ at an MOI of 1000 PFU per cell. 
Cells were washed, fresh medium was added to the apical and basolateral 
compartments, and TEER was determined at the times shown. A representative 
experiment of two performed is shown, with each experiment conducted in duplicate. 
Error bars indicate range of data for the duplicates. TEER from the various samples 
was compared using one-way ANOVA. Student’s t test was used to evaluate 
differences between mock- and apical-infected or mock- and basolateral-infected 
samples. No differences were statistically significant. 	  
	   68 
Discussion 
 
Disease caused by many viruses in an infected host occurs after bloodstream spread from  
an initial site of infection to distant target sites. Reoviruses are neurotropic viruses that 
first replicate within the small intestine and disseminate systemically via the blood, 
nerves, and lymphatics. Reovirus penetration of the endothelium to invade the 
bloodstream may occur within the intestine or lymph nodes to allow establishment of 
primary viremia. To investigate reovirus infection of the endothelium, I cultured 
HBMECs on Transwell membranes until polarization was achieved (Figure III-1). 
Although reoviruses use TJ protein JAM-A as a receptor, TEER was not altered 
immediately following reovirus adsorption (Figure III-6), suggesting that TJ integrity 
remains intact after infection. Adsorption of polarized endothelial cells either apically or 
basolaterally with reovirus resulted in productive infection (Figures III-2 and III-3). 
Interestingly, reovirus strain T3D replicated more efficiently than strain T1L in polarized 
endothelial cells (compare Figures III-2 and III-3). This difference might be due to 
differences in cell-surface expression of the sialylated glycans used by the different 
reovirus serotypes or cell-intrinsic properties of endothelial cells that confer serotype-
dependent differences in reovirus susceptibility. Regardless of the serotype, replication 
was more efficient when reovirus was adsorbed to the endothelial cell apical surface 
(Figures III-2 and III-3), and significantly more reovirus antigen-positive cells were 
detected following adsorption by this route (Figures III-2B and III-3B). The observed 
increase in infectivity and replication after apical adsorption is most likely due to 
increased virus binding to the apical surface (Figure III-2C). The number of cells bound 
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by virus was actually higher than the number of cells productively infected. This finding 
suggests that not all viral particles bound to the cell surface complete an infectious cycle, 
a phenomenon observed in other cell lines (121-123). Reovirus infection of polarized 
endothelial cells by either the apical or basolateral route requires engagement of 
sialylated glycans and JAM-A (Figure III-4). Consistent with these findings, substantially  
more JAM-A is distributed to the apical than the basolateral surface of polarized 
HBMECs (Figure III-5). Subconfluent, non-polarized HBMECs are substantially more 
susceptible to reovirus infection than are polarized HBMECs (Figure III-7), presumably 
due to higher levels of JAM-A on the cell surface and absence of a restriction of JAM-A 
expression to TJs. 
Although bloodstream spread is an important step in the pathogenesis of many 
viral diseases, mechanisms used by viruses to gain entry into the blood are not well 
understood. My work describes how viral infection of endothelial cells may allow access 
into the circulation. I show that reovirus productively infects polarized endothelial cells 
by both apical and basolateral routes. Infection after apical adsorption is more efficient 
compared with basolateral adsorption due to increased utilization of SA and JAM-A at 
the apical surface. And although reovirus infection of polarized endothelial cells requires 
engagement of JAM-A, TJ function remains intact at early time points of infection. Since 
TJ proteins are used as receptors by a diverse array of viruses, including adenovirus (55), 
feline calicivirus (56), hepatitis C virus (124, 125), and several picornaviruses (55, 126), 
my findings may provide a more general understanding of how viruses establish viremia 
for bloodstream spread.  
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Figure III-7. Subconfluent endothelial cells are more permissive for reovirus 
infection than confluent endothelial cells. HBMECs were plated at a density of 105 
cells per well and cultured for 1, 4, or 7 d prior to adsorption with reovirus strain 
T3SA+. Cells were incubated in OptiMEM alone (mock), OptiMEM containing JAM-
A-specific antibody (J10.4), or OptiMEM containing A. ureafaciens neuraminidase 
(NM) for 1 h at room temperature prior to the addition of virus. HBMECs were 
adsorbed with reovirus at an MOI of 10 PFU per cell for 1 h at room temperature, and 
the amount of virus was adjusted according to the number of cells on the day of 
adsorption. After incubation at 37C for 20-24 h, cells were collected, permeabilized, 
and stained using Alexa Fluor-conjugated reovirus-specific antiserum. The percentage 
of infected cells was quantified using flow cytometry. Shown is a representative graph 
of duplicate samples, with the experiment repeated twice. Error bars indicate range of 
data for the duplicates. **, P < 0.005 
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CHAPTER IV 
 
REOVIRUS IS RELEASED NONCYTOLYTICALLY FROM THE APICAL 
SURFACE OF POLARIZED HUMAN BRAIN MICROVASCULAR 
ENDOTHELIAL CELLS 
 
  Viral access to the bloodstream requires traversal of the endothelium. Invasion of 
the bloodstream by viruses can occur by direct inoculation of the virus via an insect 
vector, dismantling TJs that connect endothelial cells, productive infection of endothelial 
cells, or hijacking of hematopoietic cells that normally exist within the circulation. 
Reoviruses invade the bloodstream of a host shortly after inoculation of the 
gastrointestinal tract and establish viremia, however, mechanisms used by reoviruses to 
gain access to the bloodstream are not known. In the previous chapter, I showed that 
reoviruses productively infect polarized endothelial cells in a receptor-dependent manner. 
If productive infection of endothelial cells serves as a means to direct reovirus into the 
bloodstream, infected endothelial cells should route virions directionally into the 
bloodstream or undergo cell lysis to release virus nonspecifically into the circulatory 
system. Because many viruses disseminate hematogenously, understanding mechanisms 
used by reovirus to gain entry into the vascular compartment may shed light on how other 
viruses establish viremia and aid in the development of inhibitors of this key step in viral 
pathogenesis.  
 In this study, I determined how reoviruses are released from infected polarized 
endothelial cells to better understand mechanisms of viral entry into the bloodstream. I 
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found that regardless of the route of adsorption, reovirus release occurs exclusively from 
the apical surface of polarized endothelial cells. Interestingly, I found that despite the 
high titers of reovirus released into the supernatant, infected polarized cells do not 
undergo cell death. These studies suggest that infection via the tissue (basolateral) side of 
the endothelium results in release of progeny virions apically into the blood vessel lumen. 
Furthermore, these findings highlight a new route of reovirus egress from infected cells 
that is independent of cell lysis.  
 
Reovirus is released apically from infected polarized endothelial cells. To determine 
whether reovirus release from infected polarized endothelial cells was directional, 
polarized HBMECs were adsorbed apically or basolaterally with reovirus strain T3SA+, 
and titers within the apical and basolateral compartments were quantified at various 
intervals by plaque assay. After apical adsorption, viral titer in the apical compartment 
increased more than 30-fold at 24 h and more than 3000-fold at 48 h (Figure IV-1A). 
Interestingly, no virus was detected in the basolateral compartment at any time point 
tested (Figure IV-1A). After basolateral adsorption, virus was detected in the basolateral 
compartment at all intervals tested (Figure IV-1B). However, titers did not increase over 
time, suggesting that infectious virus in this compartment is most likely residual virus 
from the inoculum. Viral titer in the apical compartment was detected at 24 h post-
infection and increased approximately 100,000-fold by 48 h post-infection (Figure IV-
1B). I found that reovirus strain T1L exhibited a similar pattern of release from infected 
polarized endothelial cells (Figure IV-1C, D). TEER of polarized endothelial cells 
adsorbed either apically or basolaterally did not significantly decrease over the course of 
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infection, suggesting that endothelial TJs remained intact (Figure IV-2). Therefore, 
regardless of the route of adsorption, reovirus egress from polarized endothelial cells 
occurs from the apical surface.  
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Figure IV-1. Reovirus release from polarized HBMECs occurs from the apical 
surface. Polarized HBMECs were adsorbed either apically (A,C) or basolaterally 
(B,D) with reovirus T3SA+ (A,B) or T1L (C,D) at an MOI of 10 PFU per cell. Cells 
were washed, fresh medium was added to the apical and basolateral compartments, 
and cells were incubated for the times shown. Viral titers in the medium from the 
apical (white bars) or basolateral (black bars) compartments were determined by 
plaque assay. A representative experiment of three performed is shown, with each 
experiment conducted in duplicate. Error bars indicate range of data for the duplicates. 	  
A B 
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Figure IV-2. Reovirus infection of polarized HBMECs does not disrupt TJs at 
late times post-infection. Polarized HBMECs were mock-infected (closed symbol, 
solid line) or adsorbed either apically (closed symbol, dashed line) or basolaterally 
(open symbol, dotted line) with reovirus T3SA+ at an MOI 10 PFU per cell. Cells 
were washed, fresh medium was added to the apical and basolateral compartments, 
and TEER was determined at the times shown. A representative experiment of three 
performed is shown, with each experiment conducted in duplicate. Error bars indicate 
range of data for the duplicates. TEER from the various samples was compared using 
one-way ANOVA. Student’s t test was used to evaluate differences between mock- 
and apical-infected or mock- and basolateral-infected samples. No differences were 
statistically significant. 	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Reovirus egress from polarized HBMECs occurs noncytolytically. To determine 
whether reovirus egress from infected polarized HMBECs is associated with cell lysis, I 
assessed cell viability using trypan blue staining. Polarized HBMECs or confluent L929 
cells cultured on Transwells were adsorbed apically or basolaterally at an MOI of 10 PFU 
per cell, and cell viability was quantified 24 h post-infection. Levels of HBMEC lysis 
were less than background levels of lysis in mock-treated HBMECs after either apical or 
basolateral virus adsorption (Figure IV-3). In contrast, more than half the population of 
infected L929 cells were lysed at 24 h post-infection (Figure IV-3). These data suggest 
that reovirus infection of polarized HBMECs does not compromise cell viability.  
Reovirus is capable of inducing apoptosis in many types of cultured cells (35-38) 
and in the CNS of infected mice (87, 127-129). Although polarized HBMECs remain 
intact after reovirus infection, I wondered whether reovirus egress from polarized 
HBMEC monolayers might occur via apoptosis. To test this hypothesis, polarized 
HBMECs were adsorbed apically or basolaterally at an MOI of 100 PFU per cell, and 
levels of apoptosis were quantified at 24 and 48 h post-infection using terminal 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining. At 24 h post-
infection, 17.7% of cells were infected after apical adsorption, but apoptosis was 
detectable in only 0.9% of those cells (Figure IV-4A). At 24 h after basolateral 
adsorption, 3.0% of cells were infected, but apoptosis was not detected in those cells 
(Figure IV-4A). At 48 h post-apical adsorption, 29.5% of cells were infected with 
reovirus, with only 3.0% showing evidence of apoptosis (Figure IV-4A). After 
basolateral adsorption, 6.6% of cells were infected with reovirus, yet only 1.4% of those 
cells were apoptotic (Figure IV-4A). As a positive control for apoptosis, treatment of 
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polarized HBMECs with staurosporine resulted in ~ 50% of cells displaying evidence of 
apoptosis with a concomitant decrease in TEER (Figure IV-4), suggesting that the low 
levels of apoptosis in reovirus-infected cells are not attributable to an inherent block to 
apoptosis in HBMECs. Additionally, levels of apoptosis in reovirus-infected HBMECs 
were lower than in mock-infected cells using the complementary acridine orange and 
annexinV staining assays (Figure IV-5).   These data suggest that reovirus egress from 
polarized HBMECs occurs without inducing apoptosis. 
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Figure IV-3. Reovirus infection of polarized HBMECs does not induce cell lysis. 
Polarized HBMECs or confluent L929 cells cultured on Transwells were mock-
infected (M) or adsorbed either apically (AP) or basolaterally (BL) with reovirus 
T3SA+ at an MOI of 10 PFU per cell. Cells were washed, fresh medium was added to 
the apical and basolateral compartments, and cells were incubated at 37⁰C for 20-24 h. 
Cells were harvested and incubated with trypan blue or permeabilized and stained for 
reovirus antigen using Alexa Fluor-conjugated reovirus-specific antiserum. The 
percentage of infected cells (white bars) and the percentage of lysed cells (black bars) 
are shown in a stacked column graph. A representative experiment of two performed 
is shown, with each experiment conducted in duplicate. Error bars indicate range of 
data for the duplicates. 	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Figure IV-4. Reovirus infection of polarized HBMECs is noncytolytic. Polarized 
HBMECs were mock-infected (M) or adsorbed either apically (AP) or basolaterally 
(BL) with reovirus T3SA+ at an MOI of 100 PFU per cell. Cells were incubated at 
37⁰C and harvested at 24 or 48 h post-infection. As a control for apoptosis, 
staurosporine (ST, 10 μM) was added to the medium in the apical and basolateral 
compartments of uninfected cells, which were incubated for 18 h. (A) Cells were 
stained for reovirus antigen using Alexa Fluor-conjugated reovirus-specific antiserum 
and apoptosis using the TUNEL technique. The percentage of infected cells (white 
bars) and percentage of TUNEL-positive cells (black bars) within the population of 
infected cells are shown in a stacked column graph. A representative experiment of 
three performed is shown, with each experiment conducted in duplicate. Error bars 
indicate range of data for the duplicates. (B) TEER was recorded for each sample at 
the time of cell harvest. A representative experiment of three performed is shown, with 
each experiment conducted in duplicate. Error bars indicate range of data for the 
duplicates. 	  
A 
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Figure IV-5. Reovirus infection of polarized HBMECs does not induce cell death. 
Polarized HBMECs were mock-infected (M) or adsorbed either apically (AP) or 
basolaterally (BL) with reovirus T3SA+ at an MOI of 100 PFU per cell. Cells were 
incubated at 37⁰C and harvested at 24 h post-infection. As a control for apoptosis, 
staurosporine (ST, 10 µM) was added to the medium in the apical and basolateral 
compartments of uninfected cells, which were incubated for 18 h. (A) Cells were 
harvested, washed, and stained with acridine orange dye. The number of apoptotic 
cells was enumerated under brightfield microscopy. A representative experiment of 
three performed is shown, with each experiment conducted in duplicate. Error bars 
indicate range of data for the duplicates. (B) Cells were harvested and stained either 
for apoptosis using Alexa Fluor-conjugated antibody specific for AnnexinV or 
reovirus antigen using Alexa Fluor-conjugated reovirus-specific antiserum. The 
percentage of infected cells (within parentheses above the respective bars) and 
percentage of AnnexinV-positive cells are shown. A representative experiment of 
three performed is shown, with each experiment conducted in duplicate. Error bars 
indicate range of data for the duplicates. 
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Discussion 
 
Productive infections are characterized by successful viral entry into, replication and 
assembly within, and exit from a host cell. Because nonenveloped viruses do not require 
the incorporation of host cell membranes into progeny virions, these viruses are thought 
to exit infected cells mainly by the induction of apoptosis and cell lysis. Interestingly, 
hepatitis A virus, a nonenveloped member of the Picornaviridae, exits infected cells in 
exosome-like vesicles as a possible mechanism to evade humoral immunity (130).  Until 
now, reoviruses have not been shown to egress from infected cells in a noncytolytic 
manner.  
Infection of endothelial cells is a possible mechanism for reovirus entry into the 
bloodstream. In this chapter, I show that reovirus strains T1 and T3 are directionally 
released apically from infected polarized endothelial cells (Figure IV-1) in a manner that 
maintains TJ function (Figure IV-2).  Furthermore, I found that reovirus release from 
infected polarized endothelial cells does not induce cell death and lysis (Figures IV-3, 4, 
and 5).  
Regardless of the route of adsorption, reovirus egress from infected polarized 
HBMECs occurs solely from the apical surface (Figure IV-1). Similarly, reovirus 
infection of polarized human airway epithelial cells results in apical release of progeny 
virions (107). Although TEER did not change appreciably over a timecourse of reovirus 
infection of HBMECs (Figure IV-2), I questioned whether infected cells are extruded 
from the monolayer in a manner analogous to epithelial cell turnover (131). If so, I would 
expect TEER to be maintained despite detection of an increased number of nonviable 
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cells over time. To test this hypothesis, I used trypan blue staining to determine whether 
polarized HBMECs infected with reovirus are lysed. Compared with infected L929 cells, 
which display substantial cytopathic effect after reovirus infection (Figure III-2) (38), 
polarized HBMECs infected with reovirus apically or basolaterally do not undergo cell 
lysis (Figure  IV-3), despite the presence of  high viral titers in cells and supernatants 
(Figures III-1 and IV-1). Apical or basolateral adsorption of polarized HBMECs with 
reovirus led to an increase in reovirus antigen-positive cells, but the number of apoptotic 
cells did not increase above those in mock-treated samples (Figure IV-4). I conclude from 
these data that regardless of the route of entry, reovirus release occurs from the apical 
surface in a manner that maintains cell viability. Because infection of polarized 
endothelial cells is noncytolytic, clearance of reovirus from an infected host may require 
cytotoxic T lymphocyte-mediated immunity in addition to neutralizing antibodies (132-
136).  
Virus infection of endothelial cells may serve as an additional mechanism to 
produce and maintain high levels of viremia. For example, DENV infection of 
endothelial cells leads to high-titer viremia by inducing endothelial cell apoptosis, 
resulting in endothelial barrier dysfunction and vascular leak (118). Murine 
cytomegalovirus primarily infects hepatocytes, but virus produced from infected hepatic 
endothelial cells is responsible for dissemination to other organs (137, 138). Similarly, 
reovirus may use the endothelium as a means to amplify to high titers in the bloodstream. 
Reovirus infection from the basolateral route is not efficient (Figures III-2, III-3), but 
progeny viral particles are efficiently transported to and released from the apical surface 
of polarized endothelial cells (Figure IV-1). Once released, progeny virions have access 
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to the apical surface of adjacent endothelial cells and can enter those cells efficiently. 
This cycle may serve as a mechanism to generate high titers of virus in the bloodstream, 
which are observed during reovirus infection (51, 64, 120). Sialylated glycans and JAM-
A are required for infection of endothelial cells by both apical and basolateral routes, 
which may account for the absence of viremia in reovirus-infected JAM-AKO mice (51).  
How reovirus exits the bloodstream is not clear from my studies. Because JAM-A 
is present on the surface of hematopoietic cells, it is possible that reovirus-infected 
hematopoietic cells transport the virus from the bloodstream to sites of secondary 
replication including the CNS. It also is possible that cells adjacent to blood vessels 
become infected as a consequence of infection of the endothelium. Epstein-Barr virus 
(EBV) binding to B cells leads to conjugate formation between B cells and epithelial 
cells, resulting in EBV entry into epithelial cells (139, 140). Blood vessels in the brain 
closely appose pericytes and astrocytes, and reovirus infection of endothelial cells may 
induce modifications of these cells resulting in invasion of the CNS.  
 My studies of reovirus infection of polarized endothelial cells have identified a 
new mechanism for reovirus egress. Maintenance of cell viability may ensure that 
reovirus can replicate to high titers to generate viremia and subsequent targeting of 
organs where secondary replication can occur. The findings I have made with my in vivo 
and in vitro systems to study the role of endothelial JAM-A in reovirus bloodstream 
spread suggest that infection of the endothelium and apical release of reovirus from these 
cells serve as a mechanism for reovirus entry into the bloodstream and amplification in 
the circulation.  
 
A 
A 
B 
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Many viruses use the bloodstream as a means to disseminate systemically within 
the infected host. Because viruses capable of bloodstream spread may share similar 
mechanisms of dissemination, understanding how reovirus disseminates by this route 
may aid in the development of therapeutics that target this critical step in viral 
pathogenesis. Prior to the initiation of my work, JAM-A was known to be a proteinaceous 
receptor for reoviruses that mediates hematogenous dissemination. The goal of my 
dissertation work was to determine precisely how JAM-A expression in vivo facilitates 
reovirus bloodstream spread. In this chapter, I will summarize the work I have 
accomplished, discuss potential implications of the findings, and pose future directions 
for this research.  
 
Role of receptors in viremia and systemic viral spread 
 
 Viremia is an important step in the pathogenesis of many viruses. Seeding of the 
bloodstream ensures systemic virus spread. For arboviruses, high titers of virus in the 
blood are required for host-to-host transmission. DENV replicates in endothelial cells to 
generate high bloodstream titers (118). For other viruses that are not transmitted by an 
insect vector, dissemination by the blood allows the virus to reach sites of secondary 
replication. For murine cytomegalovirus, primary viremia allows the virus to infect 
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hepatocytes (137, 138). However, high titers in the blood occur after infection of 
endothelial cells to produce secondary viremia (137, 138). Although viremia is a common 
step in the life cycle of many viruses, little is known about how bloodstream entry and 
egress occurs. Understanding mechanisms by which viruses traverse the endothelium 
may allow for the design of broad-spectrum therapeutics that target the systemic 
dissemination of viruses. Furthermore, elucidating mechanisms by which reovirus 
disseminates by the blood may allow for the design of oncolytic vectors that spread more 
effectively.  
 Interactions with specific receptors initiate the infectious life cycle of viruses. 
Receptors serve to tether virus particles to the cell surface and initiate viral cell entry. 
JAM-A is expressed on a variety of cell types in many different tissues (39-41, 42 , 43, 
44). JAM-AKO mice are protected from reovirus-induced morbidity and mortality after 
peroral virus inoculation but succumb to reovirus-induced encephalitis after intracranial 
virus inoculation (51). This observation suggests that JAM-A is dispensable for reovirus 
neuropathogenesis. Rather, I found that JAM-A must be expressed in endothelial cells for 
dissemination to the CNS (Figure II-8). If JAM-A is absent on the endothelium, as in 
EndoJAM-AKD mice, virus cannot reach sites of secondary replication, and the 
pathogenesis of reovirus virulence is consequently diminished. I present evidence that 
JAM-A, although expressed at various sites, facilitates an exquisitely specific step in the 
reovirus-host encounter by facilitating bloodstream entry into and egress from the 
circulatory system.  
Primary endothelial cells are permissive for reovirus infection (51), which 
suggests that reovirus infects endothelial cells in vivo during systemic spread. Reovirus 
	   86 
infection of endothelial cells may route virions into the circulation, amplify virus within 
the bloodstream, or a combination of both effects (Figure V-1). When examining 
infection of polarized endothelial cells in vitro, reovirus is capable of infecting cells from 
both apical and basolateral routes (Figures III-2 and III-3). The basolateral route of 
adsorption simulates reovirus infection of the endothelium from a tissue (Figure V-1). 
This route of infection is less efficient than apical infection (Figures III-2 and III-3), 
which simulates reovirus infection of polarized endothelial cells from within the blood 
(Figure V-1). Infection by both routes results in replication and efficient release of 
progeny virions from the apical surface (Figure IV-1). These findings suggest that 
reovirus amplification occurs in endothelial cells, which serves to establish viremia in an 
infected host.   
 Several unanswered questions remain. From my work, endothelial JAM-A is 
clearly required for efficient bloodstream entry and exit. However, it is  not clear how 
reovirus uses JAM-A to infect endothelial cells. I found that JAM-A is localized to the 
apical surface and TJs of polarized HBMECs in culture. However, do these cells 
faithfully simulate the endothelial surface in vivo? And if so, does reovirus engage 
junctional JAM-A or JAM-A localized to the luminal surface? Second, it is not known 
how reovirus transits within the vascular compartment. I found that hematopoietic JAM-
A is dispensable for reovirus bloodstream spread. Do virus particles exist freely in the 
plasma? Or are viruses associated with hematopoietic cells or platelets in a JAM-A-
independent manner? Third, it is unclear how reovirus exits the bloodstream. 
Mechanisms of reovirus entry into the bloodstream also may be used for viral egress from 
this compartment. Lastly, I observed noncytolytic reovirus egress from polarized 
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endothelial cells. This type of viral egress has not been described for reoviruses and 
suggests that there exist cell type-specific modes of reovirus release.  
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Figure V-1. Model for reovirus infection of the endothelium. A cross-sectional 
schematic of a blood vessel is shown. The blood vessel is lined with endothelial cells 
that are linked via TJs (black bars). Following reovirus infection of endothelial cells 
from the basolateral surface (1), virus is routed apically (or luminally) into the 
bloodstream (2). Once within the bloodstream, virus is capable of infecting endothelial 
cells from the apical surface (3). Reovirus binding to JAM-A, found mostly within 
tight junctions, and sialic acid at the apical surface may account for the increased 
efficiency of infection. After reovirus infects cells from the apical surface, progeny 
virions are routed apically into the bloodstream. The efficiency of apical infection may 
allow for endothelial amplification of reovirus (4), resulting in higher levels of viremia 
within an infected host. From Boehme et al. (2013). 
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JAM-A-Dependent Reovirus Infection of Endothelial Cells 
 
 Because JAM-A is a TJ protein, the distribution of JAM-A in subconfluent cells 
may differ from that observed in confluent or polarized cells. I found that subconfluent 
HBMECs were more susceptible to reovirus infection than confluent HBMECs (Figure 
III-7). Furthermore, reovirus infection was lessened to a greater extent in subconfluent 
cells than in confluent cells when a JAM-A-specific antibody was administered prior to 
virus adsorption (Figure III-7). These data suggest that reovirus infection of subconfluent 
HBMECs occurs via JAM-A expressed abundantly on the cell surface. In support of this 
idea, this interaction can be blocked by addition of JAM-A-specific antibody. In 
confluent cells, antibody may not be able to access junctional JAM-A, and reovirus 
infection may be inhibited to a lesser extent by JAM-A-specific antibody. Regardless of 
where reovirus interacts with JAM-A, it is unclear how reovirus-JAM-A interactions 
progress to productive infection. In epithelial cells, JAM-A localizes to the TJ and is 
thought to recruit other proteins to the TJ via signaling through its cytoplasmic tail 
domain (141, 142). Through interactions with Afadin and Rap-1, JAM-A regulates the 
levels of β1 integrin (143). This function of JAM-A may be important in facilitating 
reovirus internalization.  
 In non-polarized Chinese hamster ovary (CHO) cells, reovirus infection can occur 
in the absence of the cytoplasmic tail of JAM-A (144). However, different requirements 
for infection may exist in settings where JAM-A functions in TJ maintenance. To 
determine whether reovirus usurps JAM-A signaling functions to facilitate infection of 
polarized endothelial cells, reovirus infection can be assessed in brain microvascular or 
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pulmonary endothelial cells cultured from JAM-AKO mice stably transfected with 
mutant JAM-A constructs (Figure V-2).  A mutant JAM-A construct lacking the 
cytoplasmic domain (JAM-AΔCT) can be expressed in JAM-AKO endothelial cells to 
determine whether the cytoplasmic tail is required for reovirus infection. A mutant JAM-
A construct with the JAM-A ectodomain fused to a glycosylphosphatidylinositol (GPI) 
anchor (JAM-AΔTM) can be expressed in JAM-AKO endothelial cells to determine 
whether the transmembrane domain is required for reovirus infection. If the 
transmembrane domain or cytoplasmic tail is required for reovirus internalization, 
contributions of specific cytoplasmic tail residues to reovirus infection could be defined 
using JAM-A constructs with an altered PDZ-binding motif (JAM-APDZmut) and 
phosphorylation sites (JAM-A Cluster 1-4) (FigureV-2). The JAM-A cytoplasmic tail 
incorporates twelve potential phosphoacceptor sites (serines, threonines, or tyrosines). To 
test the requirement of cytoplasmic tail phosphorylation sites for reovirus infection of 
polarized endothelial cells, the twelve possible phosphoacceptor residues could be 
changed to alanine in clusters of three (Figure V-2). The cluster mutants will collectively 
disrupt all potential phosphorylation sites within the JAM-A cytoplasmic tail. The JAM-
A cluster mutants could be stably introduced into JAM-AKO endothelial cells, followed 
by infection with reovirus.  
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Figure V-2. Mutant JAM-A constructs. Schematic depictions of wild-type and 
mutant JAM-A constructs are shown. Extracellular D1 and D2 Ig-like domains, a 
single transmembrane (TM) domain, and the cytoplasmic tail (CT) are shown. The 
PDZ-binding motif (PDZ) is located within the JAM-A CT and potential 
phosphorylation residues are indicated with residue number. Residues to be altered in 
each mutant are boxed in blue. 
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Reovirus Viremia 
 
 Reoviruses are neurotropic viruses that are transmitted primarily by the fecal-oral 
route(1). Spread within the blood from the gastrointestinal tract to the CNS indicates that 
reovirus stably exists in body compartments that differ dramatically. For example, the 
luminal environment within the intestine differs substantially from the sterile 
environment of the CNS. The blood compartment contains many cellular components, 
including erythrocytes, leukocytes, and platelets, in addition to serum components. It is 
not clear whether reoviruses exist within the cellular or serum compartment within the 
bloodstream. Reovirus binds to erythrocytes by interacting with cell-surface glycophorin, 
a sialoglycoprotein, in hemagglutination assays (25). In Chapter II, I show that 
hematopoietic JAM-A does not facilitate reovirus hematogenous spread, but another cell-
surface molecule may be used by reovirus for binding interactions with or productive 
infection of these cells. JAM-A on the surface of platelets facilitates platelet activation 
and clot formation (44); reovirus may bind to platelets during systemic spread in the 
circulation. To determine how reovirus exists in the circulation, blood from reovirus-
infected mice could be harvested and fractionated into erythrocyte, leukocyte, platelet, 
and serum fractions. Each blood component could be titered by plaque assay to determine 
which compartment contains reovirus particles. Determining how reovirus traffics within 
the blood has implications for generating reovirus oncolytic vectors that exist more stably 
within the blood.  
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Reovirus Bloodstream Egress 
 
I provide evidence in Chapters II and III that infection of endothelial cells in a 
JAM-A-dependent manner facilitates reovirus bloodstream entry and egress. However, it 
is not understood how reovirus egress from the vascular compartment occurs. Reovirus 
infection of polarized endothelial cells in vitro suggests that endothelial cell infection 
does not direct virus particles basolaterally into the surrounding tissue. I envision three 
possibilities for reovirus bloodstream exit. First, reovirus engagement of JAM-A may 
induce TJ dysfunction, resulting in vascular leak. Vascular permeability studies may 
determine whether reovirus engagement of endothelial JAM-A dismantles TJs in vivo. 
Methylene blue and sodium fluorescein are tracers that are commonly used in studies of 
vascular permeability (145-147). These molecules do not normally diffuse through 
endothelial TJs but can be detected and quantified in tissues where TJ function is 
compromised. Mouse adenovirus-1 infection of endothelial cells reduces TJ protein 
expression and decreases barrier function in polarized endothelial cell monolayers (148). 
Coxsackieviruses engage decay-accelerating factor, an apically distributed protein of 
polarized epithelial cells, to disrupt TJs (149). In doing so, coxsackieviruses gain access 
to the basolaterally located CAR (53). HIV-1 gp120 diminishes expression of TJ proteins 
and increases vascular permeability (150). In Chapters III and IV, I found that reovirus 
infection of polarized endothelial cells in culture does not reduce the TEER, suggesting 
that TJs remain intact. However, what happens in vivo may be different from what is 
observed in cell-culture systems, and studies should be performed to determine whether 
reovirus induces vascular leak.  
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 Second, it is possible that reovirus infection of endothelial cells induces local 
changes in the endothelium that result in infection of perivascular cells. EBV binding to 
B cells can result in conjugate formation between B cells and epithelial cells (139, 140). 
This interaction leads ultimately to infection of the epithelium. Reovirus infection of the 
endothelium may lead to infection of cells closely apposed to blood vessels. For example, 
the blood brain barrier (BBB) is composed of endothelial cells and their TJs, pericytes, 
and astrocyte foot processes. In a pilot experiment to determine whether cells of the BBB 
also are susceptible to reovirus infection, I adsorbed a confluent monolayer of human 
brain pericytes with reovirus strains T1L and T3D. I found that these cells are permissive 
for infection by either reovirus strain (Figure V-3). Infection of astrocytes that are closely 
associated with the brain microvasculature may be an alternative route of entry into the 
CNS.  
 Third, it is possible that reovirus uses hematopoietic cells to exit the circulatory 
system. Although I provide evidence in Chapter II that hematopoietic JAM-A is 
dispensable for reovirus dissemination, it is possible that reovirus uses a receptor distinct 
from JAM-A to either bind to or infect hematopoietic cells. Since reoviruses have 
evolved to use different receptors for infection and replication within the gastrointestinal 
tract, bloodstream, and CNS, it is possible that an unknown receptor exists for trafficking 
of virus out of the bloodstream and into target tissues. Furthermore, reovirus is associated 
with leukocytes in the blood of cancer patients receiving intravenous reovirus oncolytic 
therapy (99). To determine whether reovirus binds to or infects hematopoietic cells in 
vivo, splenocytes and peripheral blood leukocytes could be collected from reovirus-
infected animals and assessed for reovirus antigen. Flow cytometric profiles of different 
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hematopoietic cell subsets could be used to identify whether a particular cell type is used 
by reovirus to traffic systemically.   
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Figure V-3. Human brain pericytes are permissive for infection by reovirus 
strains T1L and T3D. Confluent monolayers of human brain pericytes were adsorbed 
with reovirus strains T1L or T3D at an MOI of 100 PFU per cell at room temperature 
for 1 h. After incubation at 37°C for 24 h, cells were fixed and stained with reovirus-
specific antiserum. The percentage of infected cells was determined using indirect 
immunofluorescence.  
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Reovirus Noncytolytic Egress 
 
 When examining reovirus infection of polarized endothelial cells, I found that 
release of virus occurs noncytolytically. Mechanisms of reovirus egress are not well 
understood, but viral release from cells has traditionally been linked to cell lysis (1). I 
wondered whether viral release independent of cell lysis or cell death only occurred in the 
context of a polarized cell monolayer. I found that reovirus infection of subconfluent 
HBMECs induced very little cell death compared to that observed after infection of L929 
murine fibroblasts (Figure V-4). These data suggest that reovirus exhibits cell type-
specific modes of egress. 
 To determine possible pathways used by reovirus to exit infected cells in the 
absence of cell lysis or cell death, I examined electron micrographs of reovirus-infected 
polarized HBMECs. In these images, I found that reovirus cytoplasmic inclusions in 
polarized HBMECs appeared to incorporate membranes (Figure V-5). It is possible that 
reovirus recruits membranes to viral inclusions to enable assembled reovirus particles to 
exit infected cells via exocytosis. Hepatitis A virus, a nonenveloped virus, is capable of 
exiting infected cells using exosomes in an endosomal sorting complexes required for 
transport (ESCRT)-dependent manner (130). Interestingly, in examining infected 
polarized HBMECs by electron microscopy, I observed viral particles exiting an intact 
cell (Figure V-6).  
Because I observed membrane-like structures in reovirus inclusions, I wondered 
how membranes might be recruited or generated. Poliovirus interacts with autophagy 
proteins to egress from cells noncytolytically (151). Porcine reproductive and respiratory 
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syndrome virus (PPRSV) activates autophagy to replicate efficiently (152). Interestingly, 
reovirus infection of multiple myeloma cells upregulates autophagy machinery but 
induces apoptosis in these cells (153). To determine whether autophagy is induced 
following reovirus infection of HBMECs, I assessed cleavage of LC3, a protein found in 
autophagosome membranes (154), in infected polarized HBMECs as an indicator of 
autophagic activity. I found that after apical and basolateral infection there was no 
significant cleavage of LC3-I to LC3-II (Figure V-7), suggesting that autophagy is not 
being induced during reovirus infection. However, these data do exclude the possibility 
that individual proteins in the autophagy pathway are being used independently of the 
formation of autophagosomes. To determine whether other autophagy proteins are 
important for reovirus noncytolytic egress, expression of autophagy proteins could be 
diminished using small-interfering RNA (siRNAs), and virus release could be quantified 
in these cells.  
An alternative possibility for the presence of membranes in reovirus inclusions is 
that membranes are generated de novo. Poliovirus activates fatty acid import and 
upregulates cellular long chain acyl-CoA synthetase activity resulting in genesis of 
phospholipids that are incorporated into replication complexes (155). To determine 
whether reovirus infection increases fatty acid import, infected cells could be labeled 
with boron-dipyrromethene (BODIPY)-labeled fatty acid. Subsequent experiments would 
include downregulating expression of enzymes involved in phospholipid synthesis and 
evaluating viral egress in these cells. These studies would shed light on egress of reovirus 
in the absence of cell lysis.  
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Figure V-4. Reovirus infection does not induce cell death in subconfluent 
HBMECs. Subconfluent HBMECs (A) or L929 murine fibroblasts (B) were either 
mock-treated (white bars) or adsorbed with reovirus strain T3SA+ at an MOI of 10 
(gray bars) or 100 (black bars) PFU per cell. After incubation at 37°C for 24 or 48 h, 
cells were trypsinized and stained with acridine orange dye. The percentage of 
apoptotic cells was determined as the number of apoptotic nuclei divided by the total 
number of nuclei. Cells were incubated in 10 µM staurosporine as a positive control 
for cell death.  
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A 
B C 
Figure V-5. Reovirus cytoplasmic inclusions contain membrane-like structures. 
Polarized HBMECs were adsorbed with reovirus strain T3SA+ at an MOI of 10 PFU 
per cell. After incubation at 37°C for 24 h, cells were fixed in 4% paraformaldehyde 
and 1% electron microscopy (EM)-grade glutaraldehyde. (A) Image of an infected 
cell with a cytoplasmic inclusion. Boxed regions are enlarged in (B) and (C). Scale 
bars: 0.2 µm. (B and C) Enlarged regions of the cytoplasmic inclusion shown in (A). 
Arrows indicate membrane-like structures.  
C 
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Figure V-6. Reovirus egress from an intact cell. Polarized HBMECs were 
adsorbed with reovirus strain T3SA+ at an MOI of 10 PFU per cell. After incubation 
at 37°C for 24 h, cells were fixed in 4% paraformaldehyde and 1% EM-grade 
glutaraldehyde. (A) Image of an infected cell with a cytoplasmic inclusion. Boxed 
regions are enlarged in (B). Scale bars: 100 nm. (B) Enlarged region of the boxed 
region shown in (A). Arrows indicate exiting virus particles.  
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Figure V-7. Reovirus infection of polarized HBMECs does not induce 
autophagic activity. Polarized HBMECs were adsorbed either apically (A) or 
basolaterally (B) with reovirus strain T3SA+ at an MOI of 10 PFU per cell. After 
incubation at 37°C for 24 or 48 h, cell lysates were prepared from each sample and 
subjected to SDS-PAGE. (A) Immunoblots of mock-treated (M), apically-adsorbed 
(A), or basolaterally-adsorbed (B) polarized HBMECs. Rottlerin-treated cells (R) 
were used as positive controls for autophagy. The left panel shows samples collected 
24 h post-adsorption and the right panel shows samples collected 48 h post-
adsorption. (B and C) Quantification of the LC3-I (B) and LC3-II (C) densitometry 
units observed in the immunoblot shown in (A). Densitometry units for each sample 
were normalized against a tubulin control.  The left panel shows samples collected 
24 h post-adsorption and the right panel shows samples collected 48 h post-
adsorption. 
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Conclusions 
 
 Defining factors that govern reovirus dissemination in the blood is essential for 
optimum use of reovirus in clinical applications. Reovirus efficiently replicates in and 
kills cancer cells (99, 156). Phase I-III clinical trials are underway to test the efficacy of 
reovirus as an adjunct to conventional cancer therapies (99, 156) (157). Following 
intravenous administration, reovirus must navigate and exit the bloodstream to infect 
solid organ tumors. Intratumoral injection of reovirus may allow for enhanced replication 
in tumor cells and subsequent spread through the blood to target metastatic tumor foci. 
Thus, determining viral and cellular determinants underlying how reoviruses gain access 
to the blood compartment, spread within the bloodstream, and exit from the circulation 
may aid in oncolytic design.  
 Use of the reverse genetics system may allow engineering of reovirus therapeutics 
with mutations that increase vector potency or safety by manipulating dissemination 
determinants (4). For example, during intratumoral reovirus administration, mutating the 
residues in reovirus attachment protein σ1 that interact with JAM-A may decrease 
bloodstream spread from the tumor and retain higher reovirus titers within the tumor 
microenvironment. Furthermore, this virus may have fewer adverse effects due to 
systemic reovirus spread.  It is possible that mutating residues important for reovirus 
interactions with JAM-A will decrease tumor cell infection, however infectivity could be 
unchanged due to SA engagement (158, 159). The presence of proteases in the tumor 
microenvironment (160) also may result in the formation of ISVPs, which are more 
infectious than virion particles (1, 161).  
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 In this dissertation, I present data showing that endothelial JAM-A facilitates 
reovirus bloodstream spread. Reovirus infection of the endothelium may serve to route 
virions into and amplify titers in the vascular compartment. Understanding mechanisms 
of reovirus dissemination will provide broader insight into events at the pathogen-host 
interface that lead to systemic disease and may aid in the development of therapeutics 
that target this critical step in viral pathogenesis. 
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CHAPTER VI 
 
MATERIALS AND METHODS 
 
Cells, Viruses, Enzymes, and Antibodies 
Spinner-adapted murine L929 fibroblast cells were grown in either suspension or 
monolayer cultures as described (28, 64). Human brain microvascular endothelial cells 
(HBMECs) (162, 163) were grown in RPMI-1640 medium (Mediatech) supplemented to 
contain 10% FBS, 10% NuSerum (BD Biosciences), nonessential amino acids (Sigma), 1 
mM sodium pyruvate, MEM vitamins (Mediatech), 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 25 ng/ml amphotericin B. HBMECs and L929 
cells were cultured on collagen-coated Transwells (6.5 mm diameter, 0.4 µm pores; 
Costar) for 7 d prior to infection or imaging experiments.  
Reovirus strain T1L is a laboratory stock. Strain T3SA+ was generated as 
described (102). Recombinant viruses rsT3D, rsT3D-σ1R202W, and rsT3D-σ1G381A 
were generated using plasmid-based reverse genetics (26, 120). Virus was purified as 
described (164). Viral titers were determined by plaque assay using L929 cells (134). 
The immunoglobulin G (IgG) fraction of a rabbit antiserum raised against strains 
T1L and T3D (122) was purified by protein A-Sepharose as described (102, 103). 
Reovirus-specific IgG was conjugated to Alexa Fluor-647 or Alexa Fluor-488 using 
APEX antibody labeling kits (Invitrogen). Human JAM-A-specific monoclonal antibody 
J10.4 (provided by Charles Parkos, Emory University) and claudin-1-specific antibody 
(ab15098, Abcam) were used in confocal microscopy imaging experiments in HBMECs. 
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Murine JAM-A-specific polyclonal antibody (AF1077; R&D Systems) was used to 
characterize mouse strains. Alexa Fluor-conjugated antibodies (Invitrogen) were used as 
secondary antibodies.  
 
Generation of mouse strains 
EndoJAM-AKD mice, which have decreased endothelial JAM-A and lack hematopoietic 
JAM-A, or HematoJAM-AKO mice, which lack JAM-A only within the hematopoietic 
compartment, were generated using cre-lox technology. Female JAM-A flox/flox mice 
were bred to male Tek-cre transgenic (tg) mice (165) to generate EndoJAM-AKD mice 
(Figure II-1) or male Vav-cre tg mice (166) to generate HematoJAM-AKO mice (Figure 
II-4). Litters from these breeding pairs were used for infection experiments. 
HematoJAM-A mice, which lack native JAM-A but overexpress JAM-A within the 
hematopoietic compartment, were obtained by first generating Vav-JAM tg mice in 
which JAM-A expression is driven by the hematopoietic-specific vav promoter (Figure 
II-4). Vav-JAM tg mice were then bred to JAM-AKO mice to ablate native JAM-A 
expression (Figure II-4). All strains used for these studies were maintained on a C57BL/6 
background. Cell-surface expression of JAM-A in endothelial and hematopoietic cells 
was assessed in the different mouse strains using flow cytometry. JAM-A expression 
profiles of the mouse strains are shown in Table 2.  
Mouse genotypes were confirmed using PCR. Primer sequences used for 
genotyping experiments are shown in Table 1. Mouse ear clippings or aliquots of 
homogenized organ were employed for genomic DNA extraction using the REDExtract-
N-Amp Tissue PCR Kit (Sigma).  
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Mouse infection studies 
Two- to three day-old mice were inoculated perorally or intravenously with purified 
reovirus strain T1L diluted in PBS. Peroral inoculations were performed as described (51, 
64). Intravenous inoculations were performed following anesthesia by hypothermia (88, 
167). The proper depth of anesthesia was assessed visually by lack of response to 
external stimuli. Anesthetized mice were positioned on a Wee Sight transilluminator 
(Phillips) to visualize the superficial temporal vein. A dose of 50 microliters of virus 
inoculum was administered via a 33-gauge 0.25-inch needle (Cadence) attached to a 1-ml 
syringe by a T-connector extension set (Braun). Successful inoculation was assessed by 
blanching of the superficial temporal vein and noting reflux of blood from the injection 
site upon removal of the needle. Pups were placed on a warming pad until consciousness 
was regained. At various times post-inoculation, organs were excised, submerged into 
PBS, subjected to two freeze-thaw cycles, and sonicated until homogenized. Viral titers 
in organ homogenates were determined by plaque assay (134). Blood was collected into 
an equal volume of Alsever’s solution (Sigma), subjected to two freeze-thaw cycles, 
sonicated, and processed for viral titer determination by plaque assay (134). Animal 
husbandry and experimental procedures were performed in accordance with Public 
Health Service policy and approved by the Vanderbilt University School of Medicine 
Institutional Animal Care and Use Committee. 
 
Flow cytometry 
Hematopoietic cells were harvested from peripheral blood or from spleens of 6- to 8-
week-old mice. Erythrocytes were lysed using ACK lysis buffer at room temperature for 
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5 min. Leukocytes were collected by centrifugation at 1000 x g for 5 min, and 
hematopoietic cell subsets were identified using antibodies specific for granulocytes (Gr-
1), B cells (B220), T cells (TCRβ), macrophages (CD11b), and dendritic cells (CD11c). 
Expression of cell-surface JAM-A was assessed using an antibody specific for JAM-A 
(AF1077; R&D Systems).  
Lung endothelial cells were harvested as described (168). Lungs were excised 
from euthanized animals and flushed with 10 ml 2.5 mM EDTA, followed by 5 ml 0.25% 
trypsin in 2.5 mM EDTA. Following incubation at 37⁰C for 30 min, lungs were minced 
with a scalpel and washed with 1 ml complete DMEM. Cells were collected by 
centrifugation at 1000 x g for 10 min, resuspended in 1.5 ml EBM-2 medium 
supplemented to contain EGM-2 MV SingleQuots (hEGF, hydrocortisone, gentamicin, 
amphotericin B, VEGF, hFGF-B, IGF-1, ascorbic acid, and heparin) (Lonza), and 
cultivated in 6-well plates coated with 0.2% gelatin. Lung endothelial cells were cultured 
at 37⁰C for 5-7 d, washed twice with PBS on day 3, and supplemented with fresh EBM-2 
medium. Expression of cell-surface JAM-A was assessed by flow cytometry following 
staining of cells with antibodies specific for hematopoietic cells (CD45), endothelial cells 
(CD31), and JAM-A. To determine whether cell-surface expression of JAM-A correlates 
with reovirus infectivity, lung endothelial cells were infected at a MOI of 100 PFU per 
cell. After incubation at 37⁰C for 20-24 h, cells were collected, and stained with Alexa 
Fluor-conjugated reovirus antiserum. The percentage of infected cells was determined 
using flow cytometry. All cell staining was quantified using FlowJo software (Tree Star). 
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Transwell collagen coating 
Transwell inserts were incubated with 100 µl rat tail collagen I (50 µg/ml; Sigma) in the 
presence of ammonium hydroxide at room temperature for 15 min. Transwell inserts 
were washed three times using Hanks balanced salt solution (Mediatech) and once with 
sterile water (Invitrogen) and allowed to dry at room temperature for 2 h. HBMECs or 
L929 cells were cultured on the apical surface of collagen-treated Transwell inserts for 7 
d (Figure VI-1), with the apical compartment containing 200 µl medium and the 
basolateral compartment containing 1 ml medium. Medium within the apical and 
basolateral compartments was replaced with fresh medium 3 and 6 d post-seeding. TEER 
was quantified 3 and 6 d post-seeding, on the day of infection, and at various intervals 
post-infection using an EndOhm-6 Voltohmmeter (Figure VI-1B). 
 
TEER measurements 
TEER across polarized HBMEC monolayers was quantified at 3 and 6 d post-seeding, on 
the day of infection, and at various intervals post-infection using an EVOM 
Voltohmmeter and EndOhm-6 cup electrode (World Precision Instruments). TEER 
readings for test samples were normalized by subtracting TEER of blank collagen-coated 
Transwells. The data are presented as unit area resistance (Ω·cm2) (169).   
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Figure VI-1. Transwell schematic and infection timeline. (A) A schematic of a 
Transwell insert is shown. Transwell inserts are coated with collagen prior to the 
addition of endothelial cells. Endothelial cells are plated on the apical surface of 
the Transwell insert and media is added to the basolateral surface. (B) A schematic 
depicting a timeline of an infection experiment. Seven days prior to infection, 
Transwell inserts are coated with collagen and cells are plated. Media is changed 3 
and 6 d post-seeding, and TEER measurements are recorded to monitor 
polarization status of the monolayer. On day 7 post-seeding, the endothelial cell 
monolayer is polarized and can be used for an infection experiment.  
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Permeability assay 
On 1, 4, and 7 d post-seeding, FITC-labeled 10 kDa dextrans (FITC-dextrans, 25 µg/ml; 
Sigma) were added to the apical compartment of HBMECs seeded on Transwell 
membranes in 200 µl incomplete RPMI medium and 1 ml medium was added to the 
basolateral compartment. Cells were incubated at 37°C for 4 h, and medium from the 
apical and basolateral compartments was collected. FITC fluorescence in the medium 
obtained from each compartment was assessed using a Plate Chameleon Multilabel 
Detection Platform (Hidex) with 485 nm excitation and 535 nm emission filters. Dextran 
concentration was determined from the FITC fluorescence intensity using a standard 
curve generated with the FITC-dextrans. The degree of permeability was determined 
using the following equation: Permeability (%) = [FITC-dextran]basolateral/([FITC-
dextran]basolateral + [FITC-dextran]apical) x 100. On day 7, permeability also were assessed 
for a sample in which 2.5 mM EDTA (Mediatech) was added to the apical and basolateral 
compartments to disrupt TJs. 
 
Virus assays 
Polarized HBMECs cultivated on Transwell inserts were adsorbed with virus apically or 
basolaterally at a MOI of 10 PFU per cell. For apical adsorption, 30 µl of virus inoculum 
was added to the apical compartment. For basolateral adsorption, the Transwell insert 
was inverted in a sterile dish, and 30 µl of virus inoculum was added to the basolateral 
surface. In some experiments, cells were treated with medium, anti-JAM-A antibody (20 
µg/ml), or Arthrobacter ureafaciens neuraminidase (80 mU/ml; MP Biomedicals) prior to 
virus adsorption. After adsorption of virus at room temperature for 1 h, cells were washed 
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twice with PBS, and 200 µl medium was added to the apical compartment and 1 ml 
medium was added to the basolateral compartment. For viral release assays, medium 
from the apical or basolateral compartments was collected at various intervals, and viral 
titers in medium from each compartment were determined by plaque assay using L929 
cells (134). For viral replication assays, Transwell membrane inserts were removed from 
Transwells using a scalpel, submerged in 500 µl medium, and subjected to two cycles of 
freezing and thawing. Viral titers in cell lysates were determined by plaque assay using 
L929 cells (134).  
For infectivity studies, cells were incubated at 37°C for 20-24 h, harvested with 
0.05% trypsin-EDTA (Invitrogen) at room temperature, and quenched with medium 
collected from the apical compartment of the respective sample. Cells were stained with 
Alexa Fluor-conjugated reovirus-specific antiserum as described (28). The percentage of 
reovirus antigen-positive cells was determined using flow cytometry. For binding studies, 
cells were detached from the Transwell insert immediately after adsorption with 
Cellstripper (Mediatech) at 37°C for 5 min and stained using Alexa Fluor-conjugated 
reovirus-specific antiserum as described (28). The MFI of each sample was determined 
using flow cytometry. All cell staining was quantified using FlowJo software (Tree Star). 
Human brain microvascular pericytes were cultured until confluent. Cells were 
adsorbed at an MOI of 100 PFU per cell at room temperature for 1 h, washed twice, 
replaced with fresh medium, and incubated at 37°C for 24 h. Cells were fixed and stained 
with reovirus-specific antiserum and 4',6-diamidino-2-phenylindole (DAPI). Reovirus 
infectivity was assessed by indirect immunofluorescence.  
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Cell imaging 
Polarized HBMECs were fixed in 100% methanol at -20⁰C for 5 min. Cells were blocked 
in PBS containing 5% bovine serum albumin (BSA) at room temperature for 30 min. 
Cells were stained with antibodies specific for JAM-A (1:1000) and claudin-1 (1:100) as 
described (28, 170). After staining, Transwell membranes containing cells were excised 
using a scalpel. Membranes were placed onto glass slides, and glass coverslips (#1.5; 
Thermo Scientific) were mounted using Aqua-Poly/Mount mounting medium 
(Polysciences, Inc.). Cell images were captured using a Zeiss LSM 510 Meta laser-
scanning confocal microscope using a 63×/1.40 Plan-Apochromat objective lens. A 
standard threshold pixel intensity was employed for all images, and the pinhole size used 
was identical for all fluorophores. Images represent a single or series of sections from 
within a z-stack and were adjusted for brightness and contrast to the same extent. MFI of 
pixels from apical and basolateral sections of cells (n = 5) was quantified using ImageJ 
software (NIH).  
 
Trypan blue exclusion assay 
HBMECs and L929 cells were cultured on Transwell inserts until polarized and 
confluent, respectively. Virus was adsorbed apically or basolaterally at an MOI of 10 
PFU per cell, and cells were incubated at 37°C for 20-24 h. After incubation, cells were 
harvested using trypsin-EDTA, quenched with medium collected from the apical 
compartment, and washed once with PBS. A small aliquot (20 µl) of cells was removed 
for analysis of cell lysis. An equal volume of trypan blue (0.4% w/v din PBS; Mediatech) 
was added to cells, followed by incubation at room temperature for 3 min. Lysed and 
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intact cells were enumerated using a hemocytometer with brightfield microscopy. The 
percentage of reovirus-infected cells was quantified from the remainder of each sample 
using flow cytometry. 
 
TUNEL assay 
Polarized HBMECs were adsorbed with virus at an MOI of 100 PFU per cell, washed 
twice with PBS, and incubated at 37°C for 24 or 48 h. Cells were removed from the 
Transwell using trypsin-EDTA, quenched with medium collected from the apical 
compartment, washed once with PBS, and assayed for the percentage of apoptotic cells 
using the TUNEL technique (APO-BrdU TUNEL assay kit; Invitrogen) according to the 
manufacturer’s instructions. After TUNEL staining, cells were stained with Alexa Fluor-
conjugated reovirus-specific antiserum (1:1000) at 4°C for 30 min, washed, and pelleted. 
The samples were resuspended in 0.5 ml propidium iodide-containing buffer. Stained 
cells were analyzed for apoptosis and reovirus antigen-positive cells using flow 
cytometry. 
 
Acridine Orange assay 
Polarized HBMECs were adsorbed with virus at an MOI of 100 PFU per cell, washed 
twice with PBS, and incubated at 37°C for 24 h. Cells were removed from the Transwell 
using trypsin-EDTA, quenched with medium collected from the apical compartment, 
washed once with PBS, and resuspended in a volume to obtain a final concentration of 1 
x 106 cells/mL. Acridine orange dye (50 µl per 1 mL cells; PBS containing 100 µg/ml 
acridine orange and 100 µg/ml ethidium bromide [Bio-Rad]) was added and the 
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percentage of apoptotic cells was determined by enumerating the number of acridine 
orange-stained nuclei versus unstained nuclei under brightfield microscopy.  
  
AnnexinV/Dead Cell Apoptosis assay 
Polarized HBMECs were adsorbed with virus at an MOI of 100 PFU per cell, washed 
twice with PBS, and incubated at 37°C for 24 h. Cells were removed from the Transwell 
using Cellstripper, quenched with FACS buffer, washed once with PBS, and assayed for 
the percentage of apoptotic cells using AnnexinV staining (Alexa Fluor 488 
annexinV/Dead Cell Apoptosis Kit; Invitrogen) according to the manufacturer’s 
instructions. A portion of each cell sample was stained with Alexa Fluor-conjugated 
reovirus-specific antiserum. Stained cells were analyzed for apoptosis or reovirus-
positive antigen using flow cytometry. 
 
Transmission electron microscopy 
Apically-infected and basolaterally-infected HBMEC Transwell samples were fixed in 
4% paraformaldehyde and 1% glutaraldehyde. Samples were washed with PBS four 
times, and incubated in 1% osmium and 0.8% potassium ferricyanide in the dark at 4°C 
for 1 h. Transwell membranes were washed with PBS four times and incubated in 
solutions containing increasing concentrations of acetone (50%, 70%, 90%, 100%, in 
water) on ice for 10 min. After the last incubation in 100% acetone, new 100% acetone 
was replaced and cells were incubated on ice for 10 min. Samples were then incubated 
overnight in a solution containing equal volumes of acetone and epoxy resin. Transwell 
samples were placed in 100% epoxy resin for 10 h, moved to new 100% epoxy resin, 
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placed in in plastic embedding capsules, and polymerized at 60°C for 48 h. Consecutive, 
ultrathin (50 nm) sections were collected on parallel-bar copper grids (with 300 mesh) 
using an Ultramicrotome UC6 (Leica). Copper grids containing samples were stained in a 
solution containing saturated uranyl acetate in the dark at room temperature for 20 min. 
After incubation, grids were washed in four drops of distilled water, incubated in lead 
citrate for 2 min, and washed with four drops of distilled water (170). Grids were dried at 
room temperature and images were acquired using an electron microscope (JEOL 1011 
100 KV).  
 
Immunoblotting 
Immunoblot analysis of cell lysates was performed as described (170). Total cell lysates 
of HBMECs adsorbed apically or basolaterally with reovirus strain T3SA+, or treated 
with rottlerin (10 µM) were resolved by SDS-PAGE and immunoblotted with primary 
antibodies specific for tubulin, LC3, or reovirus-specific antiserum. Membranes were 
scanned using an Odyssey imaging system, and band intensity was quantified using the 
Odyssey software suite.  
 
Statistical analysis 
Experiments were performed in duplicate and repeated at least twice. Representative 
results of single experiments are shown. Mean values were compared using an unpaired 
Student's t test or one-way ANOVA (GraphPad Prism). Error bars denote the range of 
data or standard deviation. P values of < 0.05 were considered to be statistically 
significant. 
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Directional Release of Reovirus from the Apical Surface of Polarized
Endothelial Cells
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ABSTRACT Bloodstream spread is a critical step in the pathogenesis of many viruses. However, mechanisms that promote
viremia are not well understood. Reoviruses are neurotropic viruses that disseminate hematogenously to the central nervous
system. Junctional adhesionmolecule A (JAM-A) is a tight junction protein that serves as a receptor for reovirus. JAM-A is re-
quired for establishment of viremia in infected newbornmice and viral spread to sites of secondary replication. To determine
how viruses gain access to the circulatory system, we examined reovirus infection of polarized human brain microvascular endo-
thelial cells (HBMECs). Reovirus productively infects polarized HBMECs, but infection does not alter tight junction integrity.
Apical infection of polarized HBMECs is more efficient than basolateral infection, which is attributable to viral engagement of
sialic acid and JAM-A. Viral release occurs exclusively from the apical surface via a mechanism that is not associated with lysis or
apoptosis of infected cells. These data suggest that infection of endothelial cells routes reovirus apically into the bloodstream for
systemic dissemination in the host. Understanding how viruses invade the bloodstreammay aid in the development of therapeu-
tics that block this step in viral pathogenesis.
IMPORTANCE Bloodstream spread of viruses within infected hosts is a critical but poorly understood step in viral disease. Reovi-
ruses first enter the host through the oral or respiratory route and infect cells in the central nervous system. Spread of reoviruses
to the brain occurs by blood or nerves, which makes reoviruses useful models for studies of systemic viral dissemination. In this
study, we examined how reoviruses infect endothelial cells, which form the walls of blood vessels. We found that reovirus infec-
tion of endothelial cells allows the virus to enter blood vessels and serves as a means for the virus to reach high titers in the circu-
lation. Understanding how reovirus is routed through endothelial cells may aid in the design of antiviral drugs that target this
important step in systemic viral infections.
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Bloodstream dissemination within an infected host is requiredfor the pathogenesis ofmany viruses. In particular,many neu-
rotropic viruses use the circulation to invade the central nervous
system (CNS) from a distant site of primary replication. Regard-
less of the site of entry into the host, viruses that disseminate
hematogenously must first traverse an endothelial barrier and
egress from the circulation. Although viremia is a well-established
dissemination process, precise mechanisms of viral entry into or
exit from the bloodstream are not well understood.
Mammalian orthoreoviruses (reoviruses) are neurotropic vi-
ruses that disseminate hematogenously to the CNS, where they
display serotype-specific patterns of tropism for neural cells. Se-
rotype 1 reoviruses spread strictly by the bloodstream and infect
ependymal cells within theCNS, causing nonlethal hydrocephalus
(1–3). In contrast, serotype 3 reoviruses spread neurally and he-
matogenously, infect neurons within the CNS, and cause fatal
encephalitis (1, 4, 5). These serotype-specific differences in neu-
ropathogenesis segregate with the viral S1 gene (2, 3), which en-
codes attachment protein1 andnonstructural protein1s (6–8).
Both S1 gene products play key roles in reovirus pathogenesis (4,
5, 9–11), with 1 targeting reovirus to specific host cells (12–14)
and 1s contributing to lymphatic and bloodstream spread (5,
10).
Reoviruses engage two known cellular receptors, oligosaccha-
rides terminating in sialic acid and junctional adhesion molecule
A (JAM-A), via attachment protein 1 by using an adhesion-
strengthening mechanism (15). Virions are first tethered to the
cell surface by low-affinity binding to the relatively more abun-
dant sialic acid, followed by high-affinity interactions with JAM-A
(15). JAM-A is amember of the immunoglobulin superfamily and
is expressed in epithelial and endothelial cells, where it functions
in the formation and maintenance of tight junctions (TJs) (16–
18). JAM-A also is expressed on the surface of hematopoietic cells
and platelets, where it facilitates leukocyte extravasation and
platelet activation, respectively (16, 19, 20). In mice, the capacity
of reovirus to bind sialic acid enhances neurovirulence (9, 21) and
allows infection of bile duct epithelial cells, producing a disease
that mimics biliary atresia in human infants (9). In contrast, the
capacity of reovirus to bind JAM-A is required for the establish-
ment of viremia and dissemination to sites of secondary replica-
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tion through the blood (4). The function of sialic acid and JAM-A
in reovirus infection of polarized endothelial cells is not known.
In this study, we examined reovirus infection of polarized en-
dothelial cells to better understandmechanisms of viral entry into
and egress from the bloodstream.We found that reovirus produc-
tively infects polarized endothelial cells from both apical and ba-
solateral routes of adsorption. Infection was more efficient after
adsorption from the apical surface, a property attributable to the
binding of sialic acid and JAM-A. Interestingly, reovirus was re-
leased exclusively from the apical surface in a noncytolytic man-
ner. These studies provide a new understanding of how viruses
infect polarized endothelial cells and identify the endothelium as
an important mediator of viral pathogenesis.
RESULTS
Reovirus infection of polarized endothelial cells is more effi-
cient from the apical surface. To determine whether reovirus
productively infects polarized endothelial cells (see Fig. S1 in the
supplemental material), we adsorbed either the apical or the ba-
solateral surface of polarized human brain microvascular endo-
thelial cells (HBMECs) with strain T3SA, a virus that efficiently
binds sialic acid and JAM-A (15, 22). The viral titer in cell lysates
increased over time, regardless of the route of adsorption
(Fig. 1A). Following apical adsorption, the viral titer peaked at
24 h postinfection, with the yield reaching approximately 1,000-
fold over the input. In contrast, following basolateral adsorption,
viral replication was delayed, with yields of 5-fold at 24 h and
100-fold at 48 h postinfection. These data indicate that reovirus
infection of polarized HBMECs by either the apical or the baso-
lateral entry route is productive, but apical adsorption results in
more efficient replication and increased viral yields.
Because we observed higher peak titers in polarized HBMECs
after apical adsorption, we sought to determine whether initiation
of reovirus infection is more efficient when cells are infected api-
cally than when they are infected basolaterally. Polarized
HBMECs were adsorbed with virus by the apical or basolateral
route, and the percentage of reovirus antigen-positive cells was
quantified by flow cytometry. Apical adsorption resulted in ap-
proximately 10-fold more infected cells than did basolateral ad-
sorption (Fig. 1B). As a control, apical or basolateral adsorption of
nonpolarized L929 fibroblast cells cultivated on Transwell inserts
yielded equivalent numbers of infected cells (Fig. 1B).
To determinewhether differences in infectivity are attributable
to differences in virus binding, we assessed virus attachment to
polarized HBMECs following apical or basolateral adsorption. In
concordance with the infectivity data, approximately 10-fold
more virus was bound to HBMECs following apical adsorption
than following basolateral adsorption (Fig. 1C). As anticipated,
virus bound equivalently to L929 fibroblasts following adsorption
either apically or basolaterally (Fig. 1C). Together, these data sug-
gest that reovirus binds more efficiently to the apical surface of
polarizedHBMECs, which results in increased infectivity and rep-
lication.
Sialic acid and JAM-A are required for reovirus infection of
polarized endothelial cells. To determine whether differences in
the infectivity of polarized HBMECs after apical or basolateral
adsorption are attributable to differences in receptor engagement,
we used mutant reovirus strains impaired in the capacity to bind
either sialic acid or JAM-A. Single amino acidmutations in the 1
attachment protein can dramatically diminish binding to these
FIG 1 Reovirus infection of polarized HBMECs is more efficient following
adsorption from the apical surface. Polarized HBMECs were adsorbed either
apically (white bars) or basolaterally (black bars) with reovirus T3SA at an
MOI of 10 PFU per cell. (A) Transwell inserts were excised at 0, 24, and 48 h
postinfection, and viral titers in cell lysates were determined by plaque assay. A
representative experiment of three performed, with each experiment con-
ducted in duplicate, is shown. Error bars indicate the range of data for the
duplicates. (B) HBMECs were incubated for 20 to 24 h and harvested by
trypsinization. Cells were permeabilized and stained with Alexa Fluor-
conjugated, reovirus-specific antiserum. The percentage of infected cells was
determined by flow cytometry. A representative experiment of three per-
formed, with each experiment conducted in duplicate, is shown. Error bars
indicate the range of data for the duplicates. (C) HBMECs were removed
immediately after adsorption and stained with Alexa Fluor-conjugated,
reovirus-specific antiserum. MFI was determined by flow cytometry. A repre-
sentative experiment of three performed, with each experiment conducted in
duplicate, is shown. Error bars indicate the range of data for the duplicates. **,
P 0.005.
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receptors (15, 23). Polarized HBMECs were adsorbed apically or
basolaterally with wild-type or mutant reovirus strains, and the
percentage of infected cells was quantified at 24 h postinfection.
There were significantly more infected cells following apical ad-
sorption with wild-type strain type 3 Dearing (rsT3D) than after
apical adsorption with mutant strain rsT3D-1R202W, which is
deficient in sialic acid binding (21, 23), or mutant strain rsT3D-
1G381A, which is deficient in JAM-A binding (24) (Fig. 2A).
Treatment of polarized HBMECs with neuraminidase (to remove
cell surface sialic acid) and JAM-A-specific antibody prior to api-
cal virus adsorption significantly decreased infection by rsT3D.
Similarly, neuraminidase and JAM-A-specific antibody pretreat-
ment substantially decreased infection of polarized HBMECs by
rsT3D-1G381A and rsT3D-1R202W, respectively (Fig. 2A).
Concordantly, rsT3D bound more efficiently to the apical surface
of polarized HBMECs than did the mutant virus strains, and vir-
tually all virus binding was abolished by neuraminidase or JAM-
A-specific antibody pretreatment (Fig. 2C).We observed a similar
trend after basolateral adsorption in that diminished receptor en-
gagement by mutant viruses or blockade of receptor engagement
with inhibitors significantly decreased the percentages of virus-
infected and virus-bound cells (Fig. 2B and D). However, the
overall percentage of infected cells and levels of virus binding after
basolateral adsorption were substantially lower than those follow-
ing apical adsorption, which diminishes the magnitude of the ob-
served differences (note the different y axis scales in Fig. 2C and
D). Reovirus mutant rsT3D-1R202W bound to the basolateral
surface of HBMECs equivalently to wild-type rsT3D but infected
significantly fewer cells, suggesting that sialic acid engagement
may enhance reovirus replication at a postattachment step follow-
ing basolateral adsorption of polarized endothelial cells. These
data suggest that infection of polarized endothelial cells is depen-
dent on virus binding to sialylated glycans and JAM-A on the
apical and basolateral surfaces of polarized endothelial cells, but
binding to the apical surface is more efficient.
To determine whether increased binding of reovirus to the
apical surface of polarized HBMECs is attributable to enhanced
receptor expression, we examined the distribution of JAM-A on
polarized HBMECs by confocal microscopy. Polarized HBMEC
monolayers were stained with antibodies specific for TJ protein
claudin-1, as well as JAM-A (Fig. 3A). Substantially more JAM-A
staining was detected at the apical surface of the polarized cell
monolayer (Fig. 3B), including nonjunction sites that lack detect-
able claudin-1 staining (Fig. 3A). Confocal micrographs of apical
portions of cells showed a stippled pattern of JAM-A expression.
In equatorial sections of cells, JAM-A was distributed at the cell
periphery, presumably in contact with JAM-Aon adjacent cells. In
these images, TJ puncta marked by claudin-1 and JAM-A colocal-
ization are clearly visible (Fig. 3A, white asterisks). At the basolat-
eral surface, the JAM-A signal was diminished in intensity and
diffusely localized compared with JAM-A staining at the apical
surface (Fig. 3A and B). Increased distribution of JAM-A to the
apical surface of polarized HBMECs may allow reovirus to bind
and infect these cells more efficiently by this route.
Reovirus is released apically from infected polarized endo-
thelial cells. We next determined whether progeny virus is re-
leased apically or basolaterally from infected polarized endothelial
cells. Polarized HBMECs were adsorbed apically or basolaterally
with virus, and titers within the apical and basolateral compart-
ments were quantified at various intervals by plaque assay. After
FIG 2 JAM-A and sialic acid are required for reovirus infection of polarized
HBMECs. Polarized HBMECs were adsorbed either apically (A, C) or basolat-
erally (B, D) at an MOI of 10 PFU per cell with reovirus strain rsT3D, rsT3D-
1R202W, or rsT3D-1G381A in the presence or absence of anti-JAM-A an-
tibody (Ab; 20 g/ml) or A. ureafaciens neuraminidase (80 mU/ml). (A, B)
Cells were incubated for 20 to 24 h, removed from Transwell inserts with
trypsin, permeabilized, and incubated with Alexa Fluor-conjugated, reovirus-
specific antiserum. The percentage of infected cells was determined by flow
cytometry. A representative experiment of two performed, with each experi-
ment conducted in duplicate, is shown. Error bars indicate the range of data for
the duplicates. (C, D)Cells were harvested fromTranswell inserts immediately
after adsorption and stained with Alexa Fluor-conjugated, reovirus-specific anti-
serum.MFI was quantified by flow cytometry. Note that different y axis scales are
used for apical and basolateral adsorption. A representative experiment of two
performed, with each experiment conducted in duplicate, is shown. Error bars
indicate the range of data for the duplicates. *, P 0.05; **, P 0.005.
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apical adsorption, the viral titer in the apical compartment in-
creasedmore than 30-fold at 24 h andmore than 3,000-fold at 48 h
(Fig. 4A). Interestingly, no virus was detected in the basolateral
compartment at any time point tested (Fig. 4A). After basolateral
adsorption, virus was detected in the basolateral compartment at
all of the intervals tested (Fig. 4B).However, titers did not increase
over time, suggesting that infectious virus in this compartment is
most likely residual virus from the inoculum. The viral titer within
the apical compartment was detected at 24 h postinfection and
increased approximately 100,000-fold by 48 h postinfection
(Fig. 4B). Therefore, regardless of the route of adsorption, reovi-
rus egress from polarized endothelial cells occurs from the apical
surface.
Reovirus infectiondoesnot alter endothelial cellTJ integrity.
To determine whether reovirus infection alters the integrity of TJs
in the polarized monolayer, we quantified the transendothelial
electrical resistance (TEER) at both early and late times postad-
sorption. After adsorption with a multiplicity of infection (MOI)
of 1,000 PFU per cell, no significant alteration in TEER was ob-
FIG 3 Polarized HBMECs express JAM-A predominantly at the apical sur-
face. (A) Polarized HBMECs were stained for JAM-A (green), claudin-1 (red),
andnuclei (blue) and imaged by confocalmicroscopy. Shown are images of the
apical, equatorial, and basolateral regions of a single representative z stack.
Colocalization of TJ proteins is indicated by white asterisks. The scale bar
indicates 10 m. Enlarged images of the white-boxed areas are shown in the
bottom panels. Cell images were captured with a Zeiss LSM 510 Meta laser-
scanning confocal microscope with a 63/1.40 Plan-Apochromat objective lens.
(B) JAM-A channelMFI of apical and basolateral sections of individual cells (n
5) was quantified. Error bars indicate standard deviations. *, P 0.05.
FIG 4 Reovirus release from polarized HBMECs occurs from the apical
surface. Polarized HBMECs were adsorbed either apically (A) or basolaterally
(B) with reovirus T3SA at an MOI of 10 PFU per cell. Cells were washed,
freshmediumwas added to the apical and basolateral compartments, and cells
were incubated for the times shown. Viral titers in themedium from the apical
(white bars) and basolateral (black bars) compartments were determined by
plaque assay. A representative experiment of three performed, with each ex-
periment conducted in duplicate, is shown. Error bars indicate the range of
data for the duplicates.
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served in the 2-h postinfection interval (Fig. 5A). Similarly, after
adsorption with an MOI of 10 PFU per cell, no significant altera-
tion in TEER was observed at 1 or 2 days postinfection (Fig. 5B).
We conclude from these data that reovirus does not alter the func-
tion of endothelial TJs during infection.
Reovirus egress from polarized HBMECs occurs noncyto-
lytically. To determine whether reovirus egress from infected po-
larized HMBECs is associated with cell lysis, we assessed cell via-
bility with trypan blue. PolarizedHBMECs or confluent L929 cells
cultured on Transwell inserts were adsorbed apically or basolater-
ally at an MOI of 10 PFU per cell, and cell viability was quantified
at 24 h postinfection. Levels of HBMEC lysis were lower than the
background levels of lysis in mock-treated HBMECs after either
apical or basolateral virus adsorption (Fig. 6A). In contrast, more
than half of the population of infected L929 cells was lysed at 24 h
postinfection. These data suggest that reovirus infection of polar-
ized HBMECs does not compromise cell viability.
FIG 5 Reovirus infection of polarized HBMECs does not disrupt TJs. Polar-
ized HBMECs were mock infected (closed circle, solid line) or adsorbed either
apically (closed circle, dashed line) or basolaterally (open circle, dotted line)
with reovirus T3SA at an MOI of 1,000 PFU per cell (A) or 10 PFU per cell
(B). Cells were washed, fresh medium was added to the apical and basolateral
compartments, and TEER was determined at the times shown. A representa-
tive experiment of two (A) or three (B) performed, with each experiment
conducted in duplicate, is shown. Error bars indicate the range of data for the
duplicates. TEER from the various samples was compared by one-way
ANOVA. Student’s t test was used to evaluate differences between mock-
infected and apically infected (A) or mock-infected and basolaterally infected
(B) samples. No differences were statistically significant.
FIG 6 Reovirus infection of polarizedHBMECs is noncytolytic. (A) Polarized
HBMECs or confluent L929 cells cultured on Transwell inserts were mock
infected (M) or adsorbed either apically (AP) or basolaterally (BL) with reovi-
rus T3SA at anMOI of 10 PFUper cell. Cells werewashed, freshmediumwas
added to the apical and basolateral compartments, and cells were incubated at
37°C for 20 to 24 h. Cells were harvested and incubated with trypan blue or
permeabilized and stained for reovirus antigen with Alexa Fluor-conjugated,
reovirus-specific antiserum. The percentage of infected cells (white bars) and
the percentage of lysed cells (black bars) are shown in a stacked-column graph.
A representative experiment of two performed, with each experiment con-
ducted in duplicate, is shown. Error bars indicate the range of data for the
duplicates. (B, C) Polarized HBMECs were mock infected (M) or adsorbed
either apically (AP) or basolaterally (BL) with reovirus T3SA at an MOI of
100 PFU per cell. Cells were incubated at 37°C and harvested at 24 or 48 h
postinfection. As a control for apoptosis, staurosporine (ST, 10 M) was
added to the medium in the apical and basolateral compartments of unin-
fected cells, which were incubated for 18 h. (B) Cells were stained for reovirus
antigen with Alexa Fluor-conjugated, reovirus-specific antiserum and for ap-
optosis by the TUNEL technique. The percentage of infected cells (white bars)
and the percentage of TUNEL-positive cells (black bars) within the population
of infected cells are shown in a stacked-column graph. A representative exper-
iment of three performed, with each experiment conducted in duplicate, is
shown. Error bars indicate the range of data for the duplicates. (C) TEER was
recorded for each sample at the time of cell harvest. A representative experi-
ment of three performed, with each experiment conducted in duplicate, is
shown. Error bars indicate the range of data for the duplicates.
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Reovirus is capable of inducing apoptosis in many types of
cultured cells (25–28) and in the CNS of infected mice (1–3, 29).
Although polarized HBMECs remain intact after reovirus infec-
tion, we wondered whether reovirus egress from polarized
HBMEC monolayers might occur via apoptosis. To test this hy-
pothesis, we adsorbed polarizedHBMECs apically or basolaterally
at an MOI of 100 PFU per cell and quantified levels of apoptosis
at 24 and 48 h postinfection by using terminal deoxy-
nucleotidyltransferase-mediated dUTP-biotin nick end labeling
(TUNEL) staining. At 24 h postinfection, 17.7% of the cells were
infected after apical adsorption but apoptosis was detectable in
only 0.9% of those cells (Fig. 6B). At 24 h after basolateral adsorp-
tion, 3.0%of the cells were infected but apoptosis was not detected
in those cells (Fig. 6B). At 48 h after apical adsorption, 29.5% of
the cells were infected with reovirus, with only 3.0% showing ev-
idence of apoptosis (Fig. 6B). After basolateral adsorption, 6.6%
of the cells were infected with reovirus, yet only 1.4% of those cells
were apoptotic (Fig. 6B). As a positive control, treatment of po-
larized HBMECs with staurosporine resulted in ~50% of the cells
displaying evidence of apoptosis with a concomitant decrease in
TEER (Fig. 6B andC), suggesting that the low levels of apoptosis in
reovirus-infected cells are not attributable to an inherent block to
apoptosis in HBMECs. These data suggest that reovirus egress
from polarized HBMECs occurs without inducing apoptosis.
DISCUSSION
Many viruses cause disease in infected hosts after bloodstream
spread from an initial site of infection to a distant target site.
Reoviruses are neurotropic viruses that first replicate within the
small intestine and disseminate systemically via the blood, nerves,
and lymphatics. Reovirus penetration of the endothelium to in-
vade the bloodstream may occur within the intestine or lymph
nodes to allow the establishment of primary viremia. To investi-
gate reovirus infection of the endothelium, we cultured HBMECs
on Transwell membranes until polarization was achieved (see
Fig. S1 in the supplemental material). Although reoviruses use TJ
protein JAM-A as a receptor, TEER was not altered immediately
following reovirus adsorption (Fig. 5), suggesting that TJ integrity
remains intact after infection. Adsorption of polarized endothelial
cells either apically or basolaterally with reovirus resulted in pro-
ductive infection (Fig. 1; see Fig. S2 in the supplemental material).
Interestingly, reovirus strain T3D replicated more efficiently than
strain type 1 Lang (T1L) in polarized endothelial cells (compare
Fig. 1; see Fig. S2). This discrepancymight be due to differences in
the cell surface expression of the sialylated glycans used by the
different reovirus serotypes or cell-intrinsic properties of endo-
thelial cells that confer serotype-dependent differences in reovirus
susceptibility. Regardless of the serotype, replication was more
efficient when reovirus was adsorbed to the endothelial cell apical
surface (Fig. 1; see Fig. S2), and significantly more reovirus
antigen-positive cells were detected following adsorption by this
route (Fig. 1B; see Fig. S2). The observed increase in infectivity and
replication after apical adsorptionwasmost likely due to increased
virus binding to the apical surface (Fig. 1C). The number of cells
bound by virus was actually higher than the number of cells pro-
ductively infected. This finding suggests that not all viral particles
bound to the cell surface complete an infectious cycle, a phenom-
enon observed in other cell lines (30–32). Reovirus infection of
polarized endothelial cells by either the apical or the basolateral
route requires the engagement of sialylated glycans and JAM-A
(Fig. 2). Consistent with these findings, substantiallymore JAM-A
is distributed to the apical than to the basolateral surface of polar-
ized HBMECs (Fig. 3). Subconfluent, nonpolarized HBMECs are
substantially more susceptible to reovirus infection than are po-
larized HBMECs (data not shown), presumably because of higher
levels of JAM-A on the cell surface and the absence of a restriction
of JAM-A expression to TJs.
Regardless of the route of adsorption, reovirus egress from
infected polarized HBMECs occurs solely from the apical surface
(Fig. 4; see Fig. S2 in the supplemental material). Similarly, reovi-
rus infection of polarized human airway epithelial cells results in
apical release of progeny virions (33). Although TEER did not
change appreciably over a time course of reovirus infection of
HBMECs (Fig. 5), we questioned whether infected cells are ex-
truded from the monolayer in a manner analogous to epithelial
cell turnover (34). If they are, we would expect TEER to be main-
tained despite the detection of an increased number of nonviable
cells over time. To test this hypothesis, we used trypan blue stain-
ing to determine whether polarized HBMECs infected with reovi-
rus are lysed. Compared with infected L929 cells, which display
substantial cytopathic effect after reovirus infection (28) (Fig. 6A),
polarizedHBMECs infectedwith reovirus apically or basolaterally
do not undergo cell lysis (Fig. 6A), despite the presence of high
viral titers in cells and supernatants (Fig. 1 and 4). Sonication of
supernatants harvested from the apical surface of polarized
HBMECs did not lead to an increased viral titer, suggesting that
released virus was not trapped within extruded cells or
membrane-bound vesicles (data not shown). Apical or basolateral
adsorption of polarized HBMECs with reovirus led to an increase
in reovirus antigen-positive cells, but the number of apoptotic
cells did not increase above that in mock-treated samples
(Fig. 6B). Additionally, levels of apoptosis in reovirus-infected
HBMECs were lower than in mock-infected cells by the comple-
mentary acridine orange and annexinV staining assays (see Fig. S3
in the supplemental material). We conclude from these data that
regardless of the route of entry, reovirus release occurs from the
apical surface in a manner that maintains cell viability. Because
infection of polarized endothelial cells is noncytolytic, clearance of
reovirus from an infected host may require cytotoxic T
lymphocyte-mediated immunity in addition to neutralizing anti-
bodies (35–39).
Virus infection of endothelial cells may serve as an additional
mechanism to produce and maintain high levels of viremia. For
example, dengue virus infection of endothelial cells leads to high-
titer viremia by inducing endothelial cell apoptosis, resulting in
endothelial barrier dysfunction and vascular leakage (40).Murine
cytomegalovirus primarily infects hepatocytes, but virus pro-
duced from infected hepatic endothelial cells is responsible for
dissemination to other organs (41, 42). Similarly, reovirus may
use the endothelium as a means to amplify to high titers in the
bloodstream (Fig. 7). Reovirus infection from the basolateral
route is not efficient, but progeny viral particles are efficiently
transported to and released from the apical surface of polarized
endothelial cells. Once released, progeny virions have access to the
apical surface of adjacent endothelial cells and can enter those cells
efficiently. This cycle may serve as a mechanism to generate high
titers of virus in the bloodstream, which are observed during reo-
virus infection (4, 10, 21). Sialylated glycans and JAM-A are re-
quired for the infection of endothelial cells by both the apical and
Lai et al.
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basolateral routes, which may account for the markedly dimin-
ished viremia in reovirus-infected JAM-A-deficient mice (4).
How reovirus exits the bloodstream is not clear fromour study.
Because JAM-A is present on the surface of hematopoietic cells, it
is possible that reovirus-infected hematopoietic cells transport the
virus from the bloodstream to sites of secondary replication, in-
cluding the CNS. It also is possible that cells adjacent to blood
vessels become infected as a consequence of infection of the endo-
thelium. Epstein-Barr virus (EBV) binding to B cells leads to con-
jugate formation between B cells and epithelial cells, resulting in
EBV entry into epithelial cells (43, 44). Blood vessels in the brain
closely appose pericytes and astrocytes, and reovirus infection of
endothelial cells may inducemodifications of these cells, resulting
in invasion of the CNS.
Bloodstream spread is an important step in the pathogenesis of
many viral diseases, but the mechanisms used by viruses to gain
entry into the bloodstream are not well understood. Our work
describes how viral infection of endothelial cells may allow access
to and amplificationwithin the circulation.We show that reovirus
productively infects polarized endothelial cells by both the apical
and basolateral routes. Infection after apical adsorption is more
efficient than basolateral adsorption because of increased utiliza-
tion of sialic acid and JAM-A at the apical surface. Reovirus release
from polarized endothelial cells occurs exclusively from the apical
surface in a manner that maintains TJ integrity and cell viability.
Since TJ proteins are used as receptors by a diverse array of viruses,
including adenovirus (45), feline calicivirus (46), hepatitis C virus
(47, 48), and several picornaviruses (45, 49), our findings may
provide a more general understanding of how viruses establish
viremia for bloodstream spread. Moreover, the apical release
mechanism employed by reovirus may be similarly generalizable,
providing a potential new target for a host-specific, broad-
spectrum antiviral therapeutic.
MATERIALS AND METHODS
Cells, viruses, enzymes, and antibodies. Spinner-adapted murine L929
fibroblast cells were grown in either suspension or monolayer cultures as
previously described (10, 50). HBMECs (51, 52) were grown in RPMI
1640 medium (Mediatech) supplemented to contain 10% fetal bovine
serum, 10% NuSerum (BD Biosciences), nonessential amino acids
(Sigma), 1 mM sodium pyruvate, MEM Vitamins (Mediatech), 2 mM
L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 25 ng/ml
amphotericin B. HBMECs and L929 cells were cultured on collagen-
coated Transwell inserts (6.5-mm diameter, 0.4-m pores; Costar) for
7 days prior to infection or imaging experiments.
Reovirus strain T1L is a laboratory stock. Strain T3SAwas generated
as previously described (15). Recombinant viruses rsT3D, rsT3D-
1R202W, and rsT3D-1G381A were generated by plasmid-based re-
verse genetics (21, 24). Virus was purified as previously described (53).
Viral titers were determined by plaque assay with L929 cells (37).
The immunoglobulin G (IgG) fraction of a rabbit antiserum raised
against strains T1L and T3D (31) was purified by protein A-Sepharose as
previously described (9, 15). Reovirus-specific IgG was conjugated to
Alexa Fluor 647 with an APEX antibody labeling kit (Invitrogen). JAM-
A-specific monoclonal antibody J10.4 (provided by Charles Parkos, Em-
ory University) and claudin-1-specific antibody ab15098 (Abcam) were
used in confocal microscopy imaging experiments. Alexa Fluor-
conjugated antibodies (Invitrogen) were used as secondary antibodies.
TEER measurements. TEER across polarized HBMEC monolayers
was quantified at 3 and 6 days postseeding, on the day of infection, and at
various intervals postinfection with an EVOM voltohmmeter and an
EndOhm-6 cup electrode (World Precision Instruments). TEER readings
for test samples were normalized by subtracting the TEER of blank
collagen-coated Transwell inserts. The data are presented as unit area
resistance (·cm2) (54).
Virus assays. PolarizedHBMECs cultivated on Transwell inserts were
adsorbed with virus apically or basolaterally at anMOI of 10 PFU per cell.
For apical adsorption, 30 l of virus inoculum was added to the apical
compartment. For basolateral adsorption, the Transwell insert was in-
verted in a sterile dish and 30 l of virus inoculum was added to the
basolateral surface. In some experiments, cells were treated withmedium,
anti-JAM-A antibody (20 g/ml), or Arthrobacter ureafaciens neuramin-
idase (80 mU/ml; MP Biomedicals) prior to virus adsorption. After ad-
sorption of virus at room temperature for 1 h, cells werewashed twicewith
phosphate-buffered saline (PBS) and 200 l of medium was added to the
apical compartment and 1 ml of medium was added to the basolateral
compartment. For viral release assays, medium from the apical or baso-
Tight junction
Reovirus
Endothelium
Bloodstream
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2 3 4
FIG 7 Model of reovirus infection of the endothelium. A cross-sectional schematic of a blood vessel is shown. The blood vessel is lined with endothelial cells that
are linked via TJs (black bars). Following reovirus infection of endothelial cells from the basolateral surface (step 1), virus is routed apically (or luminally) into
the bloodstream (step 2). Once within the bloodstream, virus is capable of infecting endothelial cells from the apical surface (step 3). Reovirus binding to JAM-A,
found mostly within TJs, and sialic acid at the apical surface may account for the increased efficiency of infection. After reovirus infects cells from the apical
surface, progeny virions are routed apically into the bloodstream. The efficiency of apical infection may allow for endothelial amplification of reovirus (step 4),
resulting in higher levels of viremia within an infected host.
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lateral compartment was collected at various intervals and viral titers in
medium from each compartment were determined by plaque assay with
L929 cells (37). For viral replication assays, Transwell membrane inserts
were removed from Transwell inserts with a scalpel, submerged in 500 l
of medium, and subjected to two cycles of freezing and thawing. Viral
titers in cell lysates were determined by plaque assay with L929 cells (37).
For infectivity studies, cells were incubated at 37°C for 20 to 24 h,
harvested with 0.05% trypsin-EDTA (Invitrogen) at room temperature,
and quenchedwithmedium collected from the apical compartment of the
respective sample. Cells were stained with Alexa Fluor-conjugated,
reovirus-specific antiserum as previously described (50). The percentage
of reovirus antigen-positive cells was determined by flow cytometry. For
binding studies, cells were detached from the Transwell insert immedi-
ately after adsorptionwith Cellstripper (Mediatech) at 37°C for 5min and
stained with Alexa Fluor-conjugated, reovirus-specific antiserum as pre-
viously described (50). The mean fluorescence intensity (MFI) of each
sample was determined by flow cytometry. All cell staining was quantified
with FlowJo software (Tree Star).
Cell imaging. Polarized HBMECs were fixed in 100% methanol at
20°C for 5 min. Cells were blocked in PBS containing 5% bovine serum
albumin at room temperature for 30 min. Cells were stained with anti-
bodies specific for JAM-A (1:1,000) and claudin-1 (1:100) as previously
described (50, 55). After staining, Transwell membranes containing cells
were excised with a scalpel. Membranes were placed onto glass slides, and
glass coverslips (#1.5; Thermo Scientific) were mounted with Aqua-Poly/
Mountmountingmedium (Polysciences, Inc.). Cell imageswere captured
with a Zeiss LSM 510 Meta laser-scanning confocal microscope with a
63/1.40 Plan-Apochromat objective lens. A standard threshold pixel
intensity was used for all images, and the pinhole size used was the same
for all fluorophores. Images represent a single section or a series of sec-
tions from within a z stack and were adjusted for brightness and contrast
to the same extent. TheMFI of pixels from apical and basolateral sections
of cells (n 5) was quantified with ImageJ software (NIH).
Trypan blue exclusion assay.HBMECs and L929 cells were cultured
on Transwell inserts until polarized and confluent, respectively. Virus was
adsorbed apically or basolaterally at an MOI of 10 PFU per cell, and cells
were incubated at 37°C for 20 to 24 h. After incubation, cells were har-
vested with trypsin-EDTA, quenched with medium collected from the
apical compartment, andwashed oncewith PBS. A small aliquot (20l) of
cells was removed for analysis of cell lysis. An equal volume of trypan blue
(0.4% [wt/vol] in PBS; Mediatech) was added to cells, which were then
incubated at room temperature for 3 min. Lysed and intact cells were
enumerated using a hemocytometer with bright-field microscopy. The
percentage of reovirus-infected cells in the remainder of each sample was
quantified by flow cytometry.
TUNEL assay. Polarized HBMECs were adsorbed with virus at an
MOI of 100 PFU per cell, washed twice with PBS, and incubated at 37°C
for 24 or 48 h. Cells were removed from the Transwell insert with trypsin-
EDTA, quenched with medium collected from the apical compartment,
washed once with PBS, and assayed for the percentage of apoptotic cells
by the TUNEL technique (APO-BrdU TUNEL assay kit; Invitrogen)
according to themanufacturer’s instructions. After TUNEL staining, cells
were stained with Alexa Fluor-conjugated, reovirus-specific antiserum
(1:1,000) at 4°C for 30 min, washed, and pelleted. The samples were re-
suspended in 0.5 ml propidium iodide-containing buffer. Stained cells
were analyzed for apoptosis and the presence of reovirus antigen by flow
cytometry. See Text S1 in the supplemental material for the additional
methods used.
Statistical analysis. Experiments were performed in duplicate and re-
peated at least twice. Representative results of single experiments are
shown. Mean values were compared with an unpaired Student’s t test or
one-way analysis of variance (ANOVA) (GraphPad Prism). Error bars
denote the range of data or standard deviation. P values of 0.05 were
considered statistically significant.
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Abstract
Many viruses cause disease within an infected host after spread from an initial portal of
entry to sites of secondary replication. Viruses can disseminate via the bloodstream or
through nerves. Mammalian orthoreoviruses (reoviruses) are neurotropic viruses that
use both bloodborne and neural pathways to spread systemically within their hosts
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to cause disease. Using a robust mouse model and a dynamic reverse genetics system,
we have identified a viral receptor and a viral nonstructural protein that are essential for
hematogenous reovirus dissemination. Junctional adhesion molecule-A (JAM-A) is a
member of the immunoglobulin superfamily expressed in tight junctions and on hema-
topoietic cells that serves as a receptor for all reovirus serotypes. Expression of JAM-A is
required for infection of endothelial cells and development of viremia in mice,
suggesting that release of virus into the bloodstream from infected endothelial cells
requires JAM-A. Nonstructural proteins1s is implicated in cell cycle arrest and apoptosis
in reovirus-infected cells but is completely dispensable for reovirus replication in
cultured cells. Surprisingly, a recombinant s1s-null reovirus strain fails to spread hema-
togenously in infected mice, suggesting that s1s facilitates apoptosis of reovirus-
infected intestinal epithelial cells. It is possible that apoptotic bodies formed as a
consequence ofs1s expression lead to reovirus uptake by dendritic cells for subsequent
delivery to the mesenteric lymph node and the blood. Thus, both host and viral factors
are required for efficient hematogenous dissemination of reovirus. Understanding
mechanisms of reovirus bloodborne spread may shed light on how microbial
pathogens invade the bloodstream to disseminate and cause disease in infected hosts.
1. INTRODUCTION
Many pathogenic human and animal viruses disseminate frommucosal
sites to peripheral tissues where they cause organ-specific disease
(Nathanson & Tyler, 1997). The capacity of a virus to spread systemically
can correlate with increased virulence (de Jong et al., 2006; Gu et al.,
2007; Kuiken et al., 2003; Pallansch & Roos, 2001). Systemic dissemination
requires that the virus effectively navigate diverse intracellular and extracel-
lular environments to infect, replicate, and evade immune detection in
multiple cell types and tissues (Adair et al., 2012; Antar et al., 2009;
Boehme, Frierson, Konopka, Kobayashi, & Dermody, 2011; Boehme,
Guglielmi, & Dermody, 2009). Although some general principles of virus
dissemination are understood, little is known about the precise viral and cel-
lular determinants that govern virus spread. Defining mechanisms by which
viruses disseminate within their hosts is of fundamental importance to an
understanding of viral pathogenesis.
Mammalian orthoreoviruses (reoviruses) are highly tractable models for
studies of viral pathogenesis. Studies of reovirus neural spread have provided
important information about mechanisms by which neurotropic viruses cause
disease in the central nervous system (CNS). The recent identification of new
viral and host determinants that govern reovirus spread by the blood provides
new insights intohowhematogenousdisseminationcontributes toviral disease.
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1.1. Reoviruses
Viruses of the Reoviridae family infect a wide range of host organisms, includ-
ing mammals, birds, insects, and plants (Dermody, Parker, & Sherry, 2013).
The Reoviridae includes rotaviruses, the most common diarrheal pathogen
among children (Parashar, Bresee, Gentsch, & Glass, 1998), orbiviruses,
which are economically important pathogens of sheep, cattle, and horses
(Coetzee et al., 2012), and reoviruses. Three reovirus serotypes (T1, T2,
and T3) currently circulate in humans and other mammals. The serotypes
are distinguished on the basis of antibody-mediated neutralization of infectiv-
ity and inhibition of hemagglutination. Each serotype is represented by a
prototype strain isolated from a human host: type 1 Lang (T1L), type 2
Jones (T2J), and type 3 Dearing (T3D). These strains differ dramatically in
host cell tropism, mechanisms of cell killing, modes of dissemination, and
CNS disease. In particular, studies of T1 and T3 reoviruses have generated
foundational knowledge about strategies used by viruses to replicate and cause
neural injury. Development of a plasmid-based reverse genetics system
allows introduction of mutations into the viral genome to test specific hypo-
theses about the structure and function of viral proteins andRNAs (Kobayashi
et al., 2007; Kobayashi, Ooms, Ikizler, Chappell, & Dermody, 2010).
In concert with an experimentally facile mouse model of infection
(Fields, 1992; Parashar, Tarlow, & McCrae, 1992), reovirus is an ideal
experimental platform for studies of virus–host interactions.
Reoviruses are nonenveloped, icosahedral viruses that contain a genome
consisting of 10 segments of double-stranded (ds) RNA (Fig. 1.1; Dermody
et al., 2013). There are three large (L1, L2, L3), three medium (M1, M2,
M3), and four small (S1, S2, S3, S4) dsRNA segments that are packaged
in an equimolar stoichiometric relationship with one copy of each per
virion. With the exception of the M3 and S1 gene segments, each of the
reovirus gene segments is monocistronic. Reovirus virions are composed
of two concentric protein shells, the outer capsid and core (Fig. 1.1;
Dryden et al., 1993). The outer capsid consists of heterohexameric com-
plexes of the m1 (encoded by M2) and s3 (encoded by S4) proteins. At each
of the icosahedral fivefold symmetry axes, the attachment protein s1
(encoded by S1) extends from turret-like structures formed by pentamers
of l2 (encoded by L2) protein. The inner core shell is formed by parallel
asymmetric dimers of l1 (encoded by L3) protein that are stabilized by
s2 (encoded by S2) protein. The l3 (encoded by L1) and m2 (encoded
byM1) proteins are anchored to the inner surface of the core via interactions
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with l1. Lastly, the M3 gene segment encodes nonstructural protein mNS,
the S3 gene segment encodes nonstructural protein sNS, and the S1 gene
segment encodes nonstructural protein s1s.
Viral attachment protein s1 is a long filamentous molecule with
head-and-tail morphology (Fig. 1.2A; Chappell, Prota, Dermody, & Stehle,
2002; Fraser et al., 1990;Mercier et al., 2004;Reiter et al., 2011). Thes1 pro-
tein is comprised of three distinct structural domains: an N-terminal a-helical
coiled-coil tail, a central b-spiral body, and a C-terminal globular head
(Chappell et al., 2002;Reiter et al., 2011). Short regions of undefined structure
partition each domain and are hypothesized to permit molecular flexibility
required to engage cellular receptors during viral entry (Bokiej et al., 2012;
Chappell et al., 2002; Fraser et al., 1990; Reiter et al., 2011). Attachment
of thes1 protein to cell-surface receptors initiates reovirus infection of suscep-
tible host cells (Lee, Hayes, & Joklik, 1981; Weiner, Ault, & Fields, 1980;
Weiner, Powers, & Fields, 1980). The s1 protein of T3 reovirus targets
two different receptors, a-linked sialic acid (SA) (Armstrong, Paul, & Lee,
1984; Dermody, Nibert, Bassel-Duby, & Fields, 1990a; Pacitti & Gentsch,
1987; Paul, Choi, & Lee, 1989; Paul & Lee, 1987) and junctional adhesion
molecule-A (JAM-A) (Barton, Forrest, et al., 2001; Campbell et al., 2005;
Prota et al., 2003). Residues in the T3 s1 b-spiral body domain bind SA
Outer capsid
Core
L1
L2
L3
M1
M2
M3
S1
S2
S3
S4
(σ3 and µ1) 
σ1
λ2
µNS
σNS
σ1s
λ3
m2
(σ2 and λ1) 
A B
Figure 1.1 The reovirus virion. (A) Cryoelectron micrograph image reconstruction of a
reovirus virion. Outer-capsid protein s3 (blue) is the initial target for virion disassembly
in infected cells. Pentameric l2 protein (yellow) forms an insertion pedestal for s1,
which is the viral attachment protein. (B) Schematic of a reovirus virion. Reovirus par-
ticles are formed from two concentric protein shells, the outer capsid and core. The core
contains the viral genome, which consists of 10 dsRNA segments. Reovirus also encodes
nonstructural proteins, sNS, mNS, and s1s. Copyright © American Society for Microbiol-
ogy, Nason et al. (2001).
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(Chappell, Duong, Wright, & Dermody, 2000; Reiter et al., 2011), whereas
sequences in the s1 globular head domain engage JAM-A (Barton, Forrest,
et al., 2001; Kirchner et al., 2008).
After receptor binding, virions are internalized into endosomes via a pro-
cess dependent on b1 integrin (Maginnis et al., 2006) and distributed to
organelles marked by Rab7 and Rab9 where viral disassembly takes place
(Mainou &Dermody, 2012). During viral disassembly, outer-capsid protein
s3 is degraded by cathepsin proteases, attachment protein s1 undergoes a
conformational change, and outer-capsid protein m1 is cleaved to form
infectious subvirion particles (ISVPs) (Danthi et al., 2010). The m1 cleavage
fragments undergo conformational rearrangement to facilitate endosome
penetration and delivery of transcriptionally active core particles into the
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Figure 1.2 Structure of s1 and JAM-A. (A) Full-length model of attachment protein s1
bound to JAM-A. A model of full-length s1 extending from the virion is shown as a rib-
bon drawing, with the known structure of the C-terminus (Reiter et al., 2011) in tricolor
and the predicted structure of the N-terminus in gray. Arrows indicate predicted regions
of flexibility. A model of full-length JAM-A is shown in green as a ribbon drawing of the
known structure of the extracellular domain (Prota et al., 2003) and a schematic repre-
sentation of the transmembrane and intracellular domains. For clarity, only two JAM-A
monomers are shown bound to s1. (B) Structure of human JAM-A D1 and D2 domains.
Ribbon drawings of a JAM-A homodimer, with one monomer shown in yellow and the
other in green. Two orthogonal views are displayed. (A) Adapted from Kirchner, Guglielmi,
Strauss, Dermody, and Stehle (2008, Fig. 1). (B) Adapted from Prota et al. (2003). Copyright
(2003) National Academy of Sciences, USA.
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cytoplasm (Nibert, Odegard, Agosto, Chandran, & Schiff, 2005; Odegard
et al., 2004). Primary transcription occurs within the viral core, and nascent
RNAs are translated or encapsidated into new viral cores, where they serve
as templates for negative-strand synthesis. Within new viral cores, secondary
rounds of transcription occur. Outer-capsid proteins are added to nascent
cores, which silences viral transcription and yields progeny viral particles.
Reovirus release from host cells is hypothesized to occur via a lytic mech-
anism, but the egress pathway is not understood (Dermody et al., 2013).
1.2. Junctional adhesion molecule-A
JAM-A is the only known proteinaceous receptor for reovirus. It mediates
entry of prototype and field-isolated strains of all three reovirus serotypes
(Barton, Forrest, et al., 2001; Campbell et al., 2005). JAM-A is a member
of the immunoglobulin (Ig) superfamily of proteins that functions in cell–
cell adhesion (Bazzoni, 2003). It is expressed on the surface of endothelial
and epithelial cells as a component of tight junctions that maintain the integ-
rity of barriers formed between polarized cells (Martin-Padura et al., 1998;
Woodfin et al., 2007). JAM-A also is expressed on hematopoietic cells,
where it mediates leukocyte extravasation (Corada et al., 2005; Ghislin
et al., 2011), and on platelets, where it functions in platelet activation during
blood clot formation (Bazzoni, 2003; Sobocka et al., 2004). JAM-A contains
three distinct structural domains: an N-terminal ectodomain, a single-span
transmembrane anchor, and a C-terminal cytoplasmic tail (Fig. 1.2B; Prota
et al., 2003). The ectodomain consists of two Ig-like domains, a membrane-
distal D1 domain and a membrane-proximal D2 domain. The cytoplasmic
tail terminates in a PDZ-binding domain that interacts with intracellular
tight junction components (Bazzoni et al., 2005; Nomme et al., 2011).
JAM-A participates in homotypic interactions between D1 domains on
opposing monomers (Prota et al., 2003). An interaction between two
JAM-A monomers on adjacent cells promotes cell adhesion (Iden et al.,
2012; Mandell, Babbin, Nusrat, & Parkos, 2005; Ostermann et al., 2005).
The s1 protein interacts with the JAM-A D1 domain to adhere reovirus
virions to the surface of target cells (Kirchner et al., 2008). Interestingly, the
s1–JAM-A interaction is substantially stronger (approximately 1000-fold)
than the interaction between JAM-A monomers (Kirchner et al., 2008).
Consequently, s1 binding to JAM-A likely disrupts JAM-A homodimers.
Studies using JAM-A-deficient mice indicate that JAM-A is required for
the establishment of viremia, which is essential for dissemination and disease
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in newborn mice following peroral inoculation of reovirus (Antar et al.,
2009). JAM-A is not required for reovirus replication in the murine CNS
or development of encephalitis (Antar et al., 2009). These findings suggest
that reovirus utilizes other cell-surface receptors to mediate entry into spe-
cific cell types.
1.3. Reovirus pathogenesis
Reoviruses are highly virulent in newborn mice and cause injury to a variety
of host organs, including the CNS, heart, and liver (Dermody et al., 2013).
T1 and T3 reovirus strains invade the CNS but use different routes and pro-
duce distinct pathologic consequences following peroral or intramuscular
inoculation. T1 reoviruses spread by hematogenous routes and infect
ependymal cells, causing nonlethal hydrocephalus (Tyler, McPhee, &
Fields, 1986; Weiner, Drayna, Averill, & Fields, 1977; Weiner, Powers,
et al., 1980). T3 reoviruses spread to the CNS by both hematogenous
and neural routes, and infect neurons (Antar et al., 2009; Boehme et al.,
2011; Tyler et al., 1986). In the brain, T3 reoviruses induce neuronal apo-
ptosis, which results in fatal encephalitis (Morrison, Sidman, & Fields, 1991;
Tyler et al., 1986;Weiner et al., 1977;Weiner, Powers, et al., 1980). Studies
using T1L!T3D reassortant viruses mapped the major determinant of CNS
pathology to the viral S1 gene (Dichter &Weiner, 1984; Tardieu &Weiner,
1982), which encodes attachment protein s1 and nonstructural protein s1s
(Sarkar et al., 1985; Weiner, Ault, et al., 1980). Because of its role in viral
attachment and entry, these serotype-specific differences in dissemination
and disease have largely been ascribed to thes1 protein. However,s1s plays
a critical role in promoting reovirus spread by the bloodstream (Boehme
et al., 2011, 2009).
1.4. Nonstructural protein s1s
Protein s1s is a 14 kDa nonstructural protein encoded by the viral S1 gene
segment (Cashdollar, Chmelo, Wiener, & Joklik, 1985; Ernst & Shatkin,
1985; Sarkar et al., 1985). The s1s open-reading frame (ORF) completely
overlaps the s1 coding sequence; however, s1s lies in a different reading
frame (Cashdollar et al., 1985; Cenatiempo et al., 1984; Dermody,
Nibert, Bassel-Duby, & Fields, 1990b; Ernst & Shatkin, 1985; Sarkar
et al., 1985). Although every reovirus strain sequenced to date contains
a s1s ORF, little amino acid sequence identity exists between the s1s
proteins from the different reovirus serotypes (Cashdollar et al., 1985;
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Dermody et al., 1990b). The only conserved sequence among s1s proteins
is a cluster of basic amino acids near the amino terminus (Cashdollar et al.,
1985; Dermody et al., 1990b). The basic cluster from T3 s1s functions as
an autonomous nuclear localization signal that can redirect an appended
heterologous protein to the nucleus (Hoyt, Bouchard, & Tyler, 2004).
While the majority of native s1s localizes to the nucleus (Rodgers,
Connolly, Chappell, & Dermody, 1998), it is not known whether the basic
cluster mediates nuclear translocation in the context of reovirus infection.
Functionally, the s1s protein is implicated in reovirus-induced cell cycle
arrest at the G2/M boundary (Poggioli, Dermody, & Tyler, 2001;
Poggioli, Keefer, Connolly, Dermody, & Tyler, 2000) and may influence
reovirus neurovirulence by promoting reovirus-induced apoptosis in the
murine CNS (Hoyt et al., 2005). Initial studies to define the function of
s1s in reovirus pathogenesis were complicated by the use of nonisogenic
s1s-null mutant and parental virus strains (Rodgers et al., 1998).
Development of a plasmid-based reverse genetics system for mammalian
reovirus (Kobayashi et al., 2007, 2010) made it possible to elucidate the
function of s1s in reovirus replication and pathogenesis. Recombinant
reoviruses deficient in s1s expression were engineered by incorporating a
single nucleotide change (AUG to ACG) to disrupt the s1s translational
start site into the plasmid containing the cDNA encoding the S1 gene
segment. Importantly, the mutation does not affect the coding sequence
of the overlapping s1 ORF. Thus, except for s1s expression, the resultant
viruses are isogenic with the parental strain. Viruses deficient in s1s expres-
sion have been generated in the T1 and T3 S1 gene backgrounds. In both
cases, the s1s-null viruses are viable and replicate with equivalent kinetics
and produce yields of progeny virus comparable to the corresponding
wild-type viruses, indicating that the s1s protein is dispensable for reovirus
replication in cultured cells (Boehme et al., 2011, 2009). These viruses were
used to uncover a role for s1s in promoting hematogenous reovirus
dissemination.
2. DYNAMICS OF REOVIRUS INFECTION IN THE
INTESTINE AND LUNG
Reoviruses infect their hosts by the fecal-oral and respiratory routes.
Virus enters the host by ingestion of contaminated food or inhalation of
virus-containing aerosols. At both portals of entry, reoviruses infect epithe-
lial cells and disseminate to peripheral sites where they cause disease.
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2.1. Infection via the gastrointestinal tract
Reoviruses have been isolated from the stools of healthy (Ramos-Alvarez &
Sabin, 1954, 1956) and ill (Ramos-Alvarez & Sabin, 1958) children as well as
a variety of animals (Ramos-Alvarez & Sabin, 1958). These findings suggest
that reovirus is ingested into and shed from the gastrointestinal tract. The
dynamics of reovirus infection in vivo have largely been elucidated using
experimental mouse and rat model systems. Following entry into the gastro-
intestinal tract of rodents, intestinal proteases rapidly convert reovirus virions
to ISVPs, suggesting that the form of the reovirus particle that initiates infec-
tion in the intestine is the ISVP (Bass et al., 1990; Bodkin, Nibert, & Fields,
1989; Chappell et al., 1998). In newborn mice, cells at the tips of microvilli
are readily infected, whereas cells in the intestinal crypts are spared (Antar
et al., 2009; Boehme et al., 2009). In contrast, intestinal crypt cells are
infected in adult mice, and cells at the villus tips are uninfected (Rubin,
Kornstein, & Anderson, 1985). Infectious reovirus can be recovered follow-
ing peroral inoculation from the duodenum, jejunum, ileum, and colon
(Rubin, Eaton, & Anderson, 1986; Rubin et al., 1985). However, the vast
majority of virus is produced in the ileum. This differential production of
virus may be due to the capacity of reovirus to infect Peyer patches. Reo-
viruses are thought to penetrate the intestinal barrier via transport across
microfold (M) cells, which are specialized cells of the follicle-associated epi-
thelium (FAE) that overlay the Peyer patches (Amerongen, Wilson,
Fields, & Neutra, 1994; Wolf, Dambrauskas, Sharpe, & Trier, 1987;
Wolf et al., 1983, 1981). M cells transfer antigens from the intestinal lumen
to lymphoid cells of the gut-associated lymphoid tissue (van de Pavert &
Mebius, 2010) and serve to monitor luminal contents by exposing Peyer
patch lymphoid cells to food antigens, the intestinal microbiota, and invad-
ing pathogens. This process is essential for induction of oral tolerance and
activation of immune responses to pathogenic microorganisms (van de
Pavert & Mebius, 2010). The preferential targeting of crypt cells observed
in adult mice is hypothesized to result from transcytosis of virus across
M cells and subsequent infection of crypt cells via the basolateral surface
(Rubin, 1987). However, M cells also take up reovirus in neonatal mice
(Antar et al., 2009; Boehme et al., 2009; Wolf et al., 1981), suggesting that
viral transcytosis across M cells is unlikely to explain the difference in intes-
tinal cell tropism observed in adult and newborn mice. It is possible that
the proliferative status of stem cells in the crypts of adult mice may recapit-
ulate the cellular environment of neonatal intestinal cells, thereby facilitating
reovirus infection of intestinal crypt cells.
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2.2. Infection via the respiratory tract
Reovirus also infects the respiratory tract (Sabin, 1959). In rats, both T1 and
T3 reovirus strains cause a pneumonia that is characterized by destruction of
type 1 alveolar epithelial cells and infiltration of leukocytes into the alveolar
spaces (Morin,Warner, & Fields, 1996). The pathology associated with reo-
virus infection closely mimics disease progression in bronchiolitis obliterans
organizing pneumonia, which is notable for fibrous extensions into alveolar
spaces in the context of an organizing pneumonia (Bellum et al., 1997). Fol-
lowing inoculation into the respiratory tract, lung proteases convert reovirus
virions to ISVPs (Golden & Schiff, 2005; Nygaard, Golden, & Schiff, 2012).
Similar to infection in the intestine, reovirus infects the lung by transcytosis
through M cells that overlie the bronchus-associated lymphoid tissue
(Morin, Warner, & Fields, 1994; Morin et al., 1996).
3. HEMATOGENOUS SPREAD OF REOVIRUS
3.1. Transport of reovirus from the intestine to the
bloodstream
Systemic reovirus infection is thought to originate from infected lymphoid
cells in the Peyer patch. From the Peyer patch, reovirus transits intestinal
lymphatics to the mesenteric lymph node (MLN) and ultimately enters the
bloodstream via the thoracic duct (Antar et al., 2009; Boehme et al., 2009;
Wolf et al., 1981). Many pathogens that cause systemic disease, including
poliovirus (Bodian, 1955; Sabin, 1956) and Salmonella (Carter & Collins,
1974; Galan & Curtiss, 1989; Jones, Ghori, & Falkow, 1994), initiate
extraintestinal infection and access the bloodstream via this route.
Reovirus reaches the Peyer patches early after infection; viral antigen is
detected in Peyer patches within 24 h after peroral inoculation (Antar et al.,
2009; Bass, Trier, Dambrauskas, & Wolf, 1988; Boehme et al., 2009; Wolf
et al., 1987, 1983, 1981). However, the mechanism by which reovirus
infects Peyer patch cells is not known. It is possible that dendritic cells in
the Peyer patches take up reovirus virions immediately following viral trans-
cytosis across M cells. This is the most direct route from the intestinal lumen
to the Peyer patch and the primary pathway used for processing of intestinal
antigens for immune surveillance. A second possibility is that progeny
virions released from the basolateral surface of infected FAE cells are
taken up by lymphoid cells in Peyer patches. Both viral structural and non-
structural proteins are detected in FAE cells (Fleeton et al., 2004), indicating
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that active viral replication occurs in these cells. However, it is not known
whether FAE cells produce virus. A third possibility is that dendritic cells in
Peyer patches take up apoptotic fragments from infected FAE cells, which
undergo apoptosis following reovirus infection (Fleeton et al., 2004). Den-
dritic cells in the underlying Peyer patches immediately adjacent to apopto-
tic FAE cells contain both active caspase-3 and reovirus structural proteins
(Fleeton et al., 2004). These observations suggest that Peyer patch dendritic
cells take up apoptotic bodies from infected FAE cells. Additionally, apopto-
sis induction in the FAEmay signal Peyer patch cells to phagocytose the apo-
ptotic remnants, along with reovirus particles.
Regardless of the mechanism by which reovirus accesses Peyer patches,
reovirus antigen is detected in theMLN 24 h after peroral inoculation. Little
is known about the cell types that support reovirus replication within the
intestine and dissemination to the MLN. In adult mice, CD11cþ dendritic
cells harbor reovirus antigen, but these cells are not thought to be actively
infected (Fleeton et al., 2004). Viral nonstructural proteins are not present in
these cells (Fleeton et al., 2004), suggesting that active replication does not
occur. CD11cþ dendritic cells are present in neonatal animals
(Muthukkumar, Goldstein, & Stein, 2000), but it is not known whether
these cells internalize reovirus following peroral inoculation of newborn
mice. Reovirus productively infects bulk splenocytes isolated from newborn
mice (Tardieu, Powers, & Weiner, 1983), suggesting that reovirus can rep-
licate in primary lymphoid cells. Reovirus cannot productively infect
splenocytes explanted after the mouse reaches 7 days of age (Tardieu
et al., 1983). Thus, the lack of viral replication in Peyer patch cells in older
animals may contribute to the age restriction to reovirus infection.
From Peyer patches, reovirus is hypothesized to traffic via afferent lym-
phatics to theMLN, then through efferent lymphatics to the blood. It is pos-
sible that infected lymphoid cells or lymphoid cells harboring virus mediate
transport from the Peyer patches to the bloodstream. However, migrating
dendritic cells rarely exit lymph nodes once they enter and present antigen
to B and T cells (Iwasaki, 2007). Thus, the cells responsible for transport of
reovirus from the Peyer patch are likely retained in the MLN. Reovirus
titers in the MLN increase rapidly after peroral inoculation (Antar et al.,
2009; Boehme et al., 2009), suggesting that active viral replication occurs
in the MLN. However, it is also possible that the increase in viral load in
the MLN represents migration of infected lymphoid cells from the Peyer
patches. Dissemination from the MLN to the bloodstream may occur as free
virus or within another lymphoid cell subset.
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An alternative mechanism for accessing the blood is direct uptake of viral
particles from the gut. CD18þ phagocytes extend cellular processes between
enterocytes to directly sample luminal contents. Dendritic cells also extend
processes through the epithelial monolayer, while maintaining barrier integ-
rity to sample gut pathogens (Rescigno et al., 2001). A number of pathogens,
including Salmonella (Vazquez-Torres et al., 1999) and Yersinia (Isberg &
Barnes, 2001), use macrophages or dendritic cells to invade the bloodstream
and cause extraintestinal infection. Following uptake of luminal pathogens,
CD18þ phagocytes traffic across the lamina propria and directly into the
blood allowing for rapid entry of the pathogen into the bloodstream.
3.2. Reovirus viremia
Although virus is detected in the blood of infected animals, it is not known
whether reovirus virions within the blood are free in the plasma or associated
with hematopoietic cells. Other Reoviridae family members, including blue-
tongue virus (BTV) and Colorado tick fever virus, produce cell-associated
viremia during infection. BTV infects and replicates in mononuclear cells,
lymphocytes, and endothelial cells (Barratt-Boyes & MacLachlan, 1994;
Ellis et al., 1993; MacLachlan, Jagels, Rossitto, Moore, & Heidner, 1990;
Mahrt & Osburn, 1986; Veronesi et al., 2009). Colorado tick fever virus is
detected in mature erythrocytes (Oshiro, Dondero, Emmons, & Lennette,
1978). However, arthropod vectors transmit BTV and Colorado tick fever
virus, making viremia a necessary part of the viral infectious cycle in nature.
Mammalian reoviruses are not transmitted by arthropod vectors and may
produce a distinctly different type of viremia. Studies in which oncolytic reo-
virus was delivered intravenously to persons with cancer revealed that virus
is largely found in hematopoietic cells, specifically mononuclear cells,
granulocytes, and platelets (Adair et al., 2012). Each of these cell types express
JAM-A (Martin-Padura et al., 1998; Naik, Naik, Eckfeld, Martin-DeLeon,
& Spychala, 2001; Sobocka et al., 2000), suggesting that reovirus associates
with or infects blood cells to disseminate through the blood to target organs.
However, in these studies, virus was delivered directly into the bloodstream
by intravenous inoculation. It is not known how reovirus spreads systemically
following infection from a natural portal, such as the intestine or lung.
3.3. Role of receptors in reovirus dissemination
Interactions between viral attachment proteins and host cell receptors play a
pivotal role in viral pathogenesis. Receptor engagement is a primary
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mechanism to define cells targeted by viruses. Therefore, patterns of receptor
expression are a keydeterminant of viral disease.Reoviruses engage two types
of cellular receptors: cell-surface carbohydrate (Paul et al., 1989) and JAM-A
(Barton, Forrest, et al., 2001). Both T1 and T3 (Dermody et al., 1990a;
Pacitti & Gentsch, 1987; Paul et al., 1989) reoviruses bind cell-surface SA
(Armstrong et al., 1984; Dermody et al., 1990a; Pacitti & Gentsch, 1987;
Paul et al., 1989; Paul& Lee, 1987).However, the domains ofs1 that engage
glycans differ between the serotypes (Dermody et al., 1990a; Chappell et al.,
2000), as do the specific glycans bound (Reiss et al., 2012).
SA engagement enhances reovirus infection through an adhesion-
strengthening mechanism in which viral particles are tethered to the cell sur-
face via a low-affinity interaction with the carbohydrate (Barton, Connolly,
Forrest, Chappell, & Dermody, 2001). This interaction maintains the virus
on the cell surface and increases the opportunity to engage JAM-A.
SA-binding reovirus strains have an increased capacity to infect cells com-
pared with non-SA-binding viruses; pretreatment of cells with neuramini-
dase to remove cell-surface SA eliminates this advantage (Barton, Connolly,
et al., 2001). SA engagement also enhances reovirus tropism for bile duct
epithelial cells in mice following peroral inoculation (Barton et al., 2003).
The resulting disease closely mimics biliary atresia in human infants
(Barton et al., 2003), an illness epidemiologically associated with reovirus
(Richardson, Bishop, & Smith, 1994; Tyler et al., 1998).
Reovirus strains circulating in nature vary in the capacity to bind
SA (Dermody et al., 1990a, 1990b). This finding suggests that SA binding
comes with a fitness cost. Accordingly, SA binding appears to inhibit the
capacity of reovirus to establish infection at mucosal portals of entry.
Non-SA-binding viruses infect primary human airway epithelial cells sub-
stantially more efficiently than SA-binding strains (Excoffon et al., 2008).
Moreover, infection of primary human airway epithelial cells by
SA-binding viruses is enhanced by removal of cell-surface SA with neur-
aminidase. Mucosal surfaces are covered with a glycocalyx consisting of
polysaccharides and glycoproteins that are rich in SA (Excoffon et al.,
2008). SA-binding viruses may be trapped by SA within the glycocalyx
and incapable of reaching the underlying epithelium (Excoffon et al.,
2008). However, once infection is established, SA binding may enhance
the capacity of reovirus to cause disease. In addition to the capacity to
target bile duct epithelium, SA-binding strains are more neurovirulent than
non-SA-binding viruses following intracranial inoculation (Barton et al.,
2003; Frierson et al., 2012). This increase in virulence is likely due to more
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efficient infection of neurons, which results in neuronal apoptosis and
encephalitis. The function of SA binding in reovirus hematogenous spread
remains to be determined.
Although all reoviruses bind JAM-A, T1, and T3 reoviruses infect dis-
tinct cells and cause serotype-specific patterns of pathologic injury within
the CNS. These observations suggest that JAM-A binding does not influ-
ence serotype-specific differences in reovirus neural tropism and CNS dis-
ease. Following peroral inoculation, reovirus produces similar viral titers
in the intestine of wild-type and JAM-A-deficient mice, suggesting that
JAM-A is not required for reovirus replication in the mouse gastrointestinal
tract (Antar et al., 2009). In sharp contrast, viral titers at all sites of secondary
replication are significantly lower in JAM-A-deficient animals compared
with wild-type controls (Fig. 1.3). Viral loads are comparable within the
brains of wild-type and JAM-A-deficient animals after intracranial inocula-
tion, suggesting that JAM-A is not required for viral replication at this site of
secondary replication (Antar et al., 2009). These results suggest that JAM-A
is required for dissemination of the virus from the intestine to replication
sites in target organs.
How might JAM-A promote hematogenous dissemination? Substan-
tially lower reovirus titers are detected in the blood of JAM-A-deficient
mice compared with wild-type mice (Fig. 1.4), suggesting that JAM-A is
involved in the establishment of viremia (Antar et al., 2009). Diminished
viremia is detected in mice inoculated with either T1 or T3 reovirus, indi-
cating that JAM-A functions in promoting bloodborne spread of T1 viruses
that disseminate by strictly hematogenous mechanisms as well as neurotropic
T3 reoviruses. Primary pulmonary endothelial cells isolated from JAM-A-
deficient mice are refractory to reovirus infection compared with
those harvested from wild-type mice (Fig. 1.5). These data suggest that
reovirus engages JAM-A to infect endothelial cells, likely in the lymphatics
or vasculature of the gastrointestinal tract. It is possible that virus released
from endothelial cells invades the bloodstream to disseminate to peri-
pheral target organs either free in the plasma or associated with hematopoi-
etic cells.
3.4. Function of nonstructural protein s1s in reovirus
dissemination
Studies using T1 s1s-null virus uncovered a role for s1s in promoting
bloodborne reovirus spread (Boehme et al., 2009). The s1s protein is not
required for the initial establishment of reovirus infection in the gut.
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Wild-type and s1s-null viruses replicate to comparable levels in the gastro-
intestinal tract following peroral inoculation (Fig. 1.6). Reovirus antigen is
evident in the intestinal epithelium and Peyer patches of mice inoculated
with wild-type or s1s-null virus, indicating that s1s does not influence
* *
*
*
*
*
A
4 8 12
2
Intestine Heart Brain
Time postinoculation (day)
V
ira
l t
ite
r 
(lo
g 1
0 
P
F
U
/o
rg
an
)
4
3
5
6
7
4 8 124 8 124 8 124 8 12
Spleen Liver
JAM-A-/-JAM-A+/+
B
4 8 12
2
Intestine Heart Brain
Time postinoculation (day)
V
ira
l t
ite
r 
(lo
g 1
0 
P
F
U
/o
rg
an
)
4
3
5
6
7
8
*
*
*
4 8 124 8 124 8 124 8 12
Spleen Liver
*
**
JAM-A-/-JAM-A+/+
Figure 1.3 JAM-A is required for hematogenous reovirus dissemination. (A) Newborn
C57/BL6 JAM-Aþ/þ and JAM-A#/# mice were inoculated perorally with 106 PFU of strain
T1L. At days 4, 8, and 12 after inoculation, mice were euthanized, organs were resected,
and viral titers were determined by plaque assay. Results are expressed as mean viral titers
for sixanimals foreach timepoint. Errorbars indicateSD.*P<0.005byStudent’s t-test.When
all values are less than the limit of detection (spleen, liver, heart, andbrain in JAM-A#/#mice),
a Student’s t-test P value cannot be calculated. (B) Newborn JAM-Aþ/þ and JAM-A#/#mice
were inoculatedperorallywith104 PFUof strainT3SA#. Atdays4,8, and12after inoculation,
mice were euthanized, organs were resected, and viral titers were determined by plaque
assay. Results are expressed as mean viral titers for 6–13 animals for each time point. Error
bars indicate SD. *P<0.05 by Student’s t-test in comparison to JAM-A#/# mice. Reprinted
from Antar et al. (2009), Copyright (2009), with permission from Elsevier.
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reovirus tropism in the intestine. In contrast to wild-type virus, the s1s-null
mutant fails to produce substantial titers in the MLN. The s1s-null virus is
detected at low titer in the MLN, but viral titers do not increase over the
course of infection. These findings indicate that s1s either is essential for
transit through lymphatic channels to the MLN or serves to promote
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Figure 1.4 JAM-A is required for reovirus viremia. Newborn C57/BL6 JAM-Aþ/þ and
JAM-A#/# mice were inoculated perorally with 108 PFU of T1L. At days 1, 2, 4, and 6 after
inoculation,micewere euthanized,mesenteric lymphnode (MLN), blood, and spleenwere
collected, and viral titers were determined by plaque assay. Results are expressed as
mean viral titers for three to eight animals for each time point. Error bars indicate SD.
Reprinted from Antar et al. (2009), Copyright (2009), with permission from Elsevier.
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Figure 1.5 JAM-A is required for efficient reovirus infection of endothelial cells.
JAM-Aþ/þ and JAM-A#/# primary endothelial cells were adsorbed with T1L or T3SA#
at MOIs of 1, 10, or 100 PFU/cell and incubated for 20 h. The percentage of infected cells
was quantified by dividing the number of cells exhibiting reovirus staining by the total
number of cell nuclei exhibiting DAPI staining in whole 96 wells for triplicate experi-
ments. Wells contained between 200 and 1600 nuclei. Error bars indicate SD.
*P<0.05 as determined by Student’s t-test in comparison to JAM-A#/# endothelial cells
inoculated at the same MOI. Reprinted from Antar et al. (2009), with permission from
Elsevier.
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replication inMLN cells.Wild-type virus is detected in the blood and sites of
secondary viral replication, including the brain, heart, liver, and spleen
(Fig. 1.6). Thes1s-null virus is not detected in the blood or any of the target
organs examined. This difference is probably not due to a requirement for
s1s in mediating replication at these sites, as wild-type and s1s-null viruses
produce comparable titers in the brain following intracranial inoculation.
Together, these findings suggest that the s1s protein performs a function
that is essential for reovirus to spread from the gut through intestinal lym-
phatics and ultimately to the blood where it gains access peripheral organs.
In contrast to T1 reoviruses that spread by strictly hematogenous mech-
anisms, T3 reoviruses disseminate by both hematogenous and neural path-
ways. The amino acid sequences of the s1s proteins from the different
reovirus serotypes differ markedly (Dermody et al., 1990b). Therefore, it
is possible that the s1s proteins perform serotype-specific functions. In
nature, reovirus infects by the peroral route and spreads to the CNS in infant
animals resulting in neuropathology. However, infectivity of T3 prototype
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Figure 1.6 The s1s protein is required for systemic reovirus dissemination following
peroral inoculation. Newborn C57/BL6 mice were inoculated perorally with 104 PFU
of wild-type or s1s-null reovirus. At days 4, 8, and 12 postinoculation, viral titers in
the organs shown were determined by plaque assay. Error bars indicate SEM.
*P<0.05 as determined by Mann–Whitney test in comparison to wild-type virus. When
all values are less than the limit of detection, a Mann–Whitney test P value cannot
be calculated. Adapted from Boehme et al. (2009). Copyright (2009) National Academy
of Sciences, USA.
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strain T3D is diminished significantly within the gastrointestinal tract
(Bodkin & Fields, 1989; Bodkin et al., 1989) due to cleavage of itss1 protein
by intestinal proteases (Bodkin & Fields, 1989; Bodkin et al., 1989; Nibert,
Chappell, &Dermody, 1995). Consequently, intramuscular inoculation into
the hindlimb is used to assess mechanisms of T3D dissemination. Inoculation
of Type 3 reoviruses intramuscularly leads to invasion of the brain by neural
routes (Tyler et al., 1986). Following intramuscular inoculation, wild-type
T3D produces substantially higher titers than thes1s-null virus in peripheral
organs including the heart, liver, intestine, and spleen, similar to results
obtained using wild-type and s1s-null T1 viruses (Boehme et al., 2011).
Moreover,wild-typeT3Dbut not theT3Ds1s-nullmutant virus is detected
in the blood. Together, these data suggest that s1s functions to promote
the establishment of reovirus viremia in a serotype-independent manner,
which ultimately leads to infection of peripheral target tissues.
In contrast to its function in hematogenous spread, thes1s protein is dis-
pensable for reovirus spread to the CNS by neural routes. Both wild-type
and s1s-null viruses produce comparable titers in the spinal cord following
inoculation into the hindlimb muscle (Boehme et al., 2011). Both viruses
also produce comparable titers in the brain following direct intracranial
inoculation and in cultured primary neurons. Together, these findings indi-
cate that s1s is not required for reovirus neural spread or replication in the
murine CNS. Thus, although T3 viruses spread via neural and hematoge-
nous mechanisms, the T3 s1s protein only influences the efficiency of
hematogenous dissemination.
4. NEURAL DISSEMINATION OF REOVIRUS
In addition to bloodborne spread, T3 reoviruses use neural circuits to
disseminate to the CNS (Boehme et al., 2011; Tyler et al., 1986). Spread via
neural routes is a fundamental mechanism of reovirus pathogenesis that is
essential for development of reovirus-induced encephalitis (Boehme
et al., 2011; Tyler et al., 1986). Direct infection of neurons at peripheral sites
provides the virus with access to the CNS and serves as a conduit to the
brain. Although the importance of neural spread in reovirus pathogenesis
is well appreciated, the cellular and molecular mechanisms that underlie
neuronal reovirus trafficking are not well understood.
In contrast to hematogenous spread, JAM-A is dispensable for neural dis-
semination. Although JAM-A is expressed in the brain, the cell types on
which it is present have not been defined. JAM-A is found on NG2-glia
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cells, which are a subset of stem cells that give rise to oligodendrocytes
(Nomme et al., 2011). It is unclear whether JAM-A is expressed on periph-
eral or CNS neurons. Viral titers in the brains of wild-type and JAM-A-
deficient mice are comparable after intracranial inoculation (Antar et al.,
2009). Viral tropism in the brain for hippocampal, thalamic, and cortical
regions also does not differ between wild-type and JAM-A-deficient mice.
Concordantly, primary cortical neurons isolated from wild-type and JAM-
A-deficient mice are equally susceptible to reovirus infection and produce
equivalent yields of viral progeny (Antar et al., 2009). Together, these data
indicate JAM-A is not required for reovirus infection of neural tissue
and suggest that JAM-A is dispensable for reovirus spread by neural routes.
These findings further suggest that a cellular receptor distinct from JAM-A
mediates reovirus infection of neurons.
Some evidence exists about the means by which reovirus traverses neural
pathways. Treatment of animals with colchicine to inhibit fast axonal trans-
port impairs reovirus spread to the spinal cord following hindlimb inocula-
tion (Sjostrand & Karlsson, 1969; Tyler et al., 1986). However, treatment
with b-b0-iminodipropionitrile to inhibit slow axonal transport does not
affect reovirus dissemination to the spinal cord (Hansson, Kristensson,
Olsson, & Sjostrand, 1971; Mahrt & Osburn, 1986). These findings suggest
that reovirus traffics in neurons by fast axonal transport. However, these
inhibitors may act nonspecifically to impair other aspects of viral replication.
It also is not known whether reovirus uses afferent or efferent neurons to
traffic to the CNS or whether virions can travel using both retrograde
and anterograde pathways within neurons. Finally, it is not known where
or how progeny virions exit neurons. Much work is required to fully elu-
cidate how reoviruses replicate and traffic in neurons.
5. FUNCTION OF HEMATOGENOUS AND NEURAL
SPREAD IN REOVIRUS PATHOGENESIS
T1 reoviruses disseminate to sites of secondary viral replication solely
by hematogenous pathways. Following peroral inoculation of JAM-A-
deficient mice, T1 reovirus does not reach the blood or peripheral organs
(Antar et al., 2009). Similarly, T1 s1s-null virus fails to disseminate from
the intestine to sites of secondary replication (Boehme et al., 2009). Because
T1 reoviruses utilize a single mechanism to spread within its host, inhibiting
that mode of dissemination prevents virus-induced systemic disease.
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T3 reoviruses, in contrast, disseminate to peripheral organs using a
combination of hematogenous and neuralmechanisms.Neural spread is essen-
tial for maximal neural injury induced by T3 reovirus (Tyler et al., 1986).
Following peroral inoculation or inoculation into the hindlimb muscle, T3
reovirus infects peripheral neurons and travels along nerve fibers to infect
the CNS and cause disease (Morrison et al., 1991; Tyler et al., 1986).
Inhibiting neural spread by sectioning the sciatic nerve prior to hindlimb inoc-
ulation prevents virus spread to the spinal cord (Tyler et al., 1986). This finding
indicates that T3 reovirus spreads along neural routes to the CNS and suggests
that neural dissemination is essential for reovirus neuropathogenesis.
The importance of hematogenous spread in reovirus neuropathogenesis is
evident from studies that identified host and viral factors that mediate reovirus
transport through the blood. JAM-A-deficient mice are completely resistant
to reovirus-induced disease following peroral inoculation with T3 reovirus,
whereas wild-type mice succumb to infection (Antar et al., 2009). Viral titers
in the brains of JAM-A-deficientmice are substantially reduced in comparison
to those in wild-type controls. Concordantly, viral loads in the blood of
JAM-A-deficient mice are lower than those detected in wild-type mice
(Antar et al., 2009). However, following intracranial inoculation, wild-type
and JAM-A-deficient mice are equally susceptible to reovirus disease, and
equivalent viral yields are produced in the brains of wild-type and JAM-A-
deficient mice (Antar et al., 2009). These results indicate that reduced reovirus
virulence in JAM-A-deficient mice following peroral inoculation is not the
result of differences in reovirus replication in the brain.
Studies of T3 s1s-null viruses also highlight the requirement of hematog-
enous dissemination for reovirus neuropathogenesis. Wild-type T3 reovirus is
substantially more virulent than the T3 s1s-null virus following hindlimb
inoculation (Fig. 1.7). Approximately 75% of animals inoculated with
wild-type virus succumb to infection compared with 25% of mice inoculated
with the s1s-null virus (Boehme et al., 2011). Wild-type and s1s-null T3
reoviruses induced 100% mortality following intracranial inoculation,
although animals inoculated with wild-type virus succumbed to CNS disease
with slightly faster kinetics than those inoculated with the s1s-null virus.
Wild-type and s1s-null viruses also produce equivalent titers in the brain
following intracranial inoculation, indicating that s1s is dispensable for viral
replication in themurineCNS.Thus, the disparity in virulence betweenwild-
type and s1s-null viruses following intramuscular inoculation does not result
from differences in replication in the CNS between the two viral strains.
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Figure 1.7 The s1s protein enhances reovirus virulence following intramuscular inoc-
ulation. (A) Newborn C57/BL6 mice were inoculated in the left hindlimb with 106 PFU of
wild-type or s1s-null T3 reovirus. Mice (n¼19 for each virus strain) were monitored for
survival for 25 days. *P<0.001 as determined by log-rank test in comparison to wild-
type T3 reovirus. (B) Thes1s protein is not required for reovirus spread by neural routes.
Newborn C57/BL6 mice were inoculated in the left hindlimb with 106 PFU of wild-type
or s1s-null T3 reovirus. At days 1, 2, 4, 8, and 12 postinoculation, mice were euthanized,
hindlimb muscle, spinal cord, and brain were resected, and viral titers were determined
by plaque assay. Results are expressed asmean viral titers for six to nine animals for each
time point. Error bars indicate SEM. *P<0.05 as determined by Mann–Whitney test in
comparison to wild-type T3 reovirus. Copyright © American Society for Microbiology,
Boehme et al. (2011).
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Following hindlimb inoculation, wild-type virus is detected in the brain
1 day after infection (Fig. 1.7). In contrast, the s1s-null virus is not found in
the brain until 2 days after inoculation. At days 2 and 4 postinoculation, viral
titers in the brains of animals inoculated with wild-type virus are markedly
higher than those observed in mice inoculated with the s1s-null mutant.
This finding correlates with significantly higher loads of wild-type virus
in the blood of infected animals at early times postinoculation compared
with the s1s-null virus (Boehme et al., 2011). Comparable titers of wild-
type ands1s-null viruses are found in the spinal cord at days 1, 2, and 4 post-
inoculation. This observation suggests that transport of the s1s-null virus to
the CNS by neural pathways is not impaired. At day 8 postinoculation, titers
of wild-type and s1s-null viruses in the brain are equivalent, possibly
reflecting delivery of virus to the brain via neural routes. Collectively, these
findings suggest that hematogenous spread is required for reovirus transport
to the brain at early times after infection. These results also suggest that the
timing of reovirus delivery to the brain is critical for neuropathogenesis.
Viral transport by neural routes does not differ between wild-type and
s1s-null viruses, and both virus strains produce equivalent peak titers in
the brain. However, peak titers of the s1s-null virus appear to be achieved
after the mice reach the age-imposed limit to reovirus infection, and these
animals are no longer susceptible to reovirus-induced CNS disease (Mann,
Knipe, Fischbach, & Fields, 2002). Thus, reovirus transport to the brain by
the blood at early times after infection is critical for neuropathogenesis.
Reovirus spreads to the spinal cord via the sciatic nerve following intra-
muscular inoculation into the hindlimb (Tyler et al., 1986). Transection of
the sciatic nerve prior to inoculation inhibits neural transmission of the virus
to the spinal cord; however, viral dissemination by the blood is unaffected
(Tyler et al., 1986). T3 reovirus retains the capacity to spread to the brain
after sciatic nerve section (Boehme et al., 2011), suggesting that reovirus
can access the brain even in the absence of neural spread, likely via the
bloodstream (Fig. 1.8). In addition, almost no virus is detected in the brain
following hindlimb inoculation with the s1s-null virus when the sciatic
nerve is sectioned. Thus, virus cannot access the brain when both hematog-
enous and neural pathways of spread are inhibited.
Together, these findings suggest that (i) spread by neural routes alone is
not sufficient to cause reovirus CNS disease, (ii) bloodborne spread is
required for delivery of reovirus to the brain at early times postinfection,
(iii) hematogenous viral dissemination to the brain is an essential mechanism
of reovirus neuropathogenesis, and (iv) virus must be delivered to the brain
by the blood early after inoculation for full reovirus neurovirulence.
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Figure 1.8 Reovirus disseminates to the CNS by hematogenous and neural routes.
The left sciatic nerve of newborn C57/BL6 mice was sectioned prior to inoculation in
the left hindlimb with 106 PFU of wild-type or s1s-null T3 reovirus. In parallel, mice
in which the left sciatic nerve was not sectioned were inoculated in the left hindlimb
with 106 PFU of wild-type or s1s-null T3 reovirus. At days 2 and 4 postinoculation, mice
were euthanized: (A) hindlimb muscle, spinal cord, and brain and (B) heart, intestine,
liver, and spleen were resected, and viral titers were determined by plaque assay.
Results are expressed as mean viral titers for six animals for each time point. Error
bars indicate SEM. *P<0.05 as determined by Mann–Whitney test in comparison to
animals in which the sciatic nerve was not sectioned. Copyright © American Society
for Microbiology, Boehme et al. (2011).
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6. UNANSWERED QUESTIONS AND FUTURE DIRECTIONS
We have identified host and viral factors essential for the hematoge-
nous dissemination of reovirus. However, many unanswered questions
remain. Because viruses capable of bloodstream spread may share similar
mechanisms of dissemination, understanding how reovirus spreads in the
infected host may aid in the development of therapeutics that target this crit-
ical step in viral pathogenesis.
6.1. How does reovirus enter and exit the bloodstream?
To spread to peripheral organs by hematogenous pathways, reovirus must
first enter the bloodstream. Studies of reovirus pathogenesis suggest that fol-
lowing peroral inoculation, reovirus infects Peyer patch lymphoid cells that
transport virus to the bloodstream (Fig. 1.9). However, reovirus also
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Endothelial cell
1
2
3
5
4
Figure 1.9 Model of reovirus hematogenous spread from the intestine. (1) Following
peroral inoculation, reovirus infects intestinal epithelial cells (2) and is taken up by lym-
phoid cells in the Peyer patch. (3) Infected dendritic cells or lymphocytes carry reovirus
from the Peyer patch through the lymphatics and finally to the blood. (4) Phagocytic
cells that extend processes into the lumen of the intestine also might be infected for
subsequent transport of virus through the lymphatics. (5) Reovirus may enter directly
into the blood by passing between endothelial cells or via release into the bloodstream
from infected cells.
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disseminates hematogenously following intracranial inoculation (Boehme
et al., 2011, 2009). This observation suggests that reovirus has the capacity
to cross endothelial barriers to enter the blood. Little is known about how
reovirus infects polarized cells, such as those that constitute the endothelium.
JAM-A localizes to tight junctions linking endothelial cells and functions in
maintaining the barrier between the tissue and blood compartments. JAM-A
is required for hematogenous spread of reovirus and infection of primary
cultures of pulmonary vascular endothelial cells (Antar et al., 2009). We
envision several possible mechanisms to explain how reovirus uses
JAM-A to facilitate entry into the blood. First, JAM-A may function as
a gatekeeper for reovirus entry into the bloodstream (Fig. 1.9). Although
reovirus infection does not change the barrier function of primary human
airway epithelial cells (Excoffon et al., 2008), it is unclear whether the
same phenomenon occurs during reovirus infection of the endothelium.
Free reovirus virions may interact with JAM-A in endothelial cell tight
junctions, transiently disrupt these structures, and cause focal breaches
of the endothelial barrier to allow viral invasion of the bloodstream. Other
viruses are known to disrupt polarized cell barriers during infection. Mouse
adenovirus-1 infection of endothelial cells reduces tight junction protein
expression and decreases barrier function in polarized endothelial cell mono-
layers (Gralinski et al., 2009). Coxsackieviruses engage decay-accelerating
factor, an apically distributed protein of polarized epithelial cells, to disrupt
tight junctions (Coyne, Shen, Turner, & Bergelson, 2007). In doing so,
coxsackieviruses gain access to the basolaterally located coxsackievirus
and adenovirus receptor (Coyne et al., 2007). HIV-1 gp120 diminishes
expression of tight junction proteins and increases vascular permeability
(Kanmogne et al., 2005).
Second, it is possible that reovirus infects endothelial cells to allow
progeny virus to be released directly into the blood (Fig. 1.9). Endothelial
cells function as sites of amplification for many viruses that spread via the
bloodstream. Murine cytomegalovirus dissemination occurs after an episode
of secondary viremia that requires viral replication in endothelial cells
(Sacher et al., 2008). It is possible that reovirus productively infects endo-
thelium from the basolateral surface on the abluminal side of the endothe-
lium and is released from the apical surface into the blood. Many viruses
that infect polarized cells egress apically (Roberts, 1995). This mechanism
is common for respiratory viruses, in which release from the apical
surface of infected respiratory epithelial cells ensures that the virus will be
shed into the respiratory tract to facilitate transmission to susceptible hosts
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(Brock et al., 2003; Gerl et al., 2012; Rodriguez & Sabatini, 1978). Studies of
reovirus infection of polarized endothelial cells will shed light on mecha-
nisms used by the virus to traverse endothelial monolayers.
Third, reovirus spread may involve infection or association with hema-
topoietic cells (Fig. 1.9). Hematopoietic cells express JAM-A as an adhesin to
allow monocyte extravasation across endothelial barriers (Martin-Padura
et al., 1998; Williams, Martin-Padura, Dejana, Hogg, & Simmons, 1999).
It is not knownwhether hematopoietic cells are infected or whether infected
blood cells transport reovirus systemically following infection by a natural
route of inoculation. However, in cancer patients treated with an intrave-
nous infusion of reovirus, virions associate with mononuclear cells,
granulocytes, and platelets to allow dissemination to tumors localized in
the viscera (Adair et al., 2012). If hematopoietic cells are responsible for
hematogenous reovirus dissemination, age-dependent restriction of reovirus
replication in these cells may be one mechanism to explain the limitation of
reovirus disease to newborn animals (Tardieu et al., 1983).
Reovirus exit from the bloodstream is required for infection and repli-
cation in target tissues and development of organ-specific disease. After per-
oral inoculation of reovirus, high viral titers are found in virtually all organs
(Antar et al., 2009; Boehme et al., 2011, 2009). Mechanisms similar to those
that facilitate reovirus entry into the vasculature maymediate reovirus escape
from the blood. Reovirus interactions with JAM-A may induce localized
perturbations of tight junction integrity that permit virus escape into tissues.
Reovirus virions in the blood may infect endothelial cells from the apical
surface and progeny virions may be released basolaterally. Finally, infected
hematopoietic cells may transport virus from the blood into target organs.
None of these possibilities is mutually exclusive; reovirus may use multiple
strategies to enter and exit the bloodstream. Studies using mice with tissue-
specific expression of JAM-A may help to elucidate mechanisms by which
JAM-A facilitates reovirus spread through the bloodstream.
6.2. How does s1s promote hematogenous spread?
Mechanisms by which s1s promotes dissemination have not been deter-
mined. The s1s protein is required for reovirus-induced cell cycle arrest
at the G2/M boundary (Poggioli et al., 2002, 2001) and has been implicated
in apoptosis in vivo (Hoyt et al., 2005). It not known whether inhibition of
cell cycle progression is related to the induction of apoptosis following reo-
virus infection. Cells respond to replication stress or DNA damage by
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activating checkpoints that arrest the cell cycle. For cells in which genomic
damage cannot be repaired, apoptosis is induced to ensure that only faithfully
replicated DNA is passed to daughter cells. The relationship between cell
cycle arrest and apoptosis in the context of reovirus infection has not been
examined. It is possible that s1s-mediated cell cycle arrest contributes to
reovirus-induced apoptosis. Interaction of s1s with components of the host
cell cycle machinery that inhibit normal cell cycle progression could cause
the cell to undergo apoptosis.
It is not known whether s1s-dependent cell cycle arrest and apoptosis
are responsible for s1s-mediated reovirus dissemination. It is possible that
s1s-dependent apoptosis in intestinal epithelial cells promotes reovirus
uptake by phagocytic cells at the site of inoculation, and these cells in turn
traffic virus to the bloodstream where the virus has access to JAM-A.
Although s1s is not required for reovirus replication in cultured cells
(Boehme et al., 2011, 2009; Rodgers et al., 1998), it is possible that s1s
is necessary for efficient reovirus replication in specific cell types that are
required for viral dissemination. Defining the cell types used by reovirus
to spread through the blood may help uncover hows1s promotes hematog-
enous spread. Finally, s1s may mediate evasion of the host immune
response, thereby allowing viral spread. Differences in viral dissemination
between wild-type and s1s are evident at early times postinoculation. This
suggests that s1s would dampen host innate immune mechanisms, as
opposed to adaptive responses that develop at later times after infection.
Determining how s1s promotes hematogenous reovirus spread is essential
to understand how an enteric, neurotropic virus transits from the intestine to
the CNS.
6.3. Clinical implications
Defining factors that govern reovirus dissemination in the blood is essential
for optimum use of reovirus in clinical applications. Reovirus efficiently rep-
licates in and kills cancer cells (Adair et al., 2012; Karapanagiotou et al.,
2012). Phase II and III clinical trials are underway to test the efficacy of reo-
virus as an adjunct to conventional cancer therapies (Adair et al., 2012;
Karapanagiotou et al., 2012; Kottke et al., 2011). Following intravenous
administration, reovirus must navigate and exit the bloodstream to infect
solid organ tumors. Intratumoral injection of reovirus may allow for
enhanced replication in tumor cells and subsequent spread through the
blood to target metastatic tumor foci. Thus, defining viral and cellular
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determinants underlying how reoviruses gain access to the blood compart-
ment, spread within the bloodstream, and exit from the circulation may aid
in oncolytic design. Use of the reverse genetics system may allow engineer-
ing of reovirus therapeutics with mutations that increase vector potency or
safety by manipulating dissemination determinants (Kobayashi et al., 2007).
We have uncovered a central role for hematogenous dissemination in
reovirus neuropathogenesis and elucidated molecular mechanisms that gov-
ern reovirus spread by the blood. However, we have much more to learn.
Understanding mechanisms of reovirus dissemination will provide broader
insight into events at the pathogen–host interface that lead to systemic dis-
ease and may aid in the development of therapeutics that target this critical
step in viral pathogenesis.
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